Compounds with Anti-KRAS mutant tumor activity
Patent Information
- Application Number
- MYPI2025002001
- Authority / Receiving Office
- MY · MY
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-09-26
- Filing Date
- 2023-09-27
- Publication Date
- 2024-03-30
AI Technical Summary
The existing KRas inhibitors are not satisfactory in terms of anti-tumor activity, and suffer from toxic side effects, poor drug resistance, insufficient pharmacokinetic properties, and drug interaction risks, making it difficult to provide better clinical treatment options.
By modifying the substituents at specific positions on the benzopyrimidine ring of the KRas inhibitor structure and combining specific types of substituent combinations, new compounds with improved inhibitory activity, safety and pharmacokinetic properties are developed.
Significantly improved inhibitory activity against the KRas-G12D mutant protein, reducing the risk of drug interactions, improving drug resistance and safety, and providing better pharmacokinetic properties, allowing the compound to be administered in a convenient manner.
Abstract
Description
Compounds with activity against KRAS-mutant tumors
[0001] Cross-references
[0002] This application claims priority to Chinese patent application No. 202211208795.6 filed on September 30, 2022, Chinese patent application No. 202211583282.3 filed on December 9, 2022, Chinese patent application No. 2023100802872 filed on January 17, 2023, Chinese patent application No. 2023102587885 filed on March 16, 2023, Chinese patent application No. 2023107213489 filed on June 16, 2023, and Chinese patent application No. 2023112477769 filed on September 26, 2023. Technical Field
[0003] The present invention relates to the field of medicinal chemistry. More specifically, the present invention relates to a class of compounds with novel structures that can be used as KRAS inhibitors, pharmaceutical compositions containing such compounds, methods for preparing such compounds, and uses of these compounds in treating cancer or tumors. Background Art
[0004] Ras, also known as the rat sarcoma oncogene homolog, represents a group of closely related monomeric globular proteins that belong to the GTPase family of proteins. Specifically, under normal physiological conditions, Ras is activated by growth factors and various other extracellular signals and is responsible for regulating functions such as cell growth, survival, migration, and differentiation. These regulatory functions of Ras are achieved through the conversion between GDP-bound and GTP-bound states, a "molecular switch" (Alamgeer et al., Current Opin Pharmacol. 2013, 13:394-401). Ras bound to GDP is in an inactive form and is in a dormant or closed state. At this time, the signaling system is shut down. It will be activated when exposed to some pro-growth stimuli. For example, it can be induced by guanine nucleotide exchange factors (GEFs) to release GDP and bind to GTP. As a result, Ras is "turned on" and converted into the active form of Ras, which recruits and activates various downstream effectors to carry out signal transduction. It can transmit signals on the cell surface to the cytoplasm, thereby controlling many key cellular processes such as differentiation, survival and proliferation (Zhi Tan et al., Mini-Reviews in Medicinal Chemistry, 2016, 16, 345-357).
[0005] Ras has GTPase activity, which can cleave the terminal phosphate of GTP and convert it to GDP, i.e., converting itself to an inactive state. However, the endogenous GTPase activity of Ras is very low, and the conversion of GTP-Ras to GDP-Ras requires the exogenous protein GAP (GTPase-activating protein). GAP interacts with Ras and promotes the conversion of GTP to GDP. Therefore, any Ras gene mutation that affects the interaction between Ras and GAP or the conversion of GTP to GDP will cause Ras to remain in an activated state for a long time, thereby continuously transmitting growth and division signals to cells, stimulating continuous cell proliferation, and ultimately leading to tumor formation and development.
[0006] Among the genes associated with human tumors, there are three ubiquitously expressed Ras genes, H-RAS, K-RAS, and N-RAS, which encode highly homologous, approximately 21KDa HRas, NRas, and KRas proteins, respectively. In 1982, researchers first discovered that Ras was activated by mutation in cancer cell lines (Chang, EH et al., Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(16), 4848-4852). Subsequent large-scale genome sequencing studies in different cancer types revealed that Ras proteins mutated in more than 30% of cancer types, with the highest mutation rates in pancreatic cancer (>90%), colon cancer (45%), and lung cancer (35%). Transgenic and genetically engineered mouse models have also revealed that mutated Ras proteins are sufficient to drive and induce various types of cancer, and Ras oncogenes are also crucial for the maintenance and progression of tumors in various cancer types. For example, in Ras mutant cancer cell lines and cancer animal models, RNA intervention has been shown to slow tumor growth. These studies have made Ras oncoproteins widely accepted in the pharmaceutical field as very attractive anti-cancer drug targets.
[0007] Studies have shown that Ras mutations are most common in KRas, and KRas mutations can be observed in about 85% of Ras mutation-driven cancers; the vast majority of Ras mutations occur at codons G12, G13, and Q61, of which about 80% of KRas mutations occur at glycine at codon 12, such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation, G13D mutation, etc. KRas mutations are common in pancreatic cancer, lung adenocarcinoma, colorectal cancer, gallbladder cancer, thyroid cancer, and bile duct cancer, and can also be seen in 25% of non-small cell lung cancer patients (McCormick, F. et al., Clinical Cancer Research 21(8), 1797-1801, 2015). Therefore, KRas mutant proteins have become the most important branch in the study of Ras drug targets, and the development of its inhibitors is also considered a very promising research and development direction in the development of anti-cancer / tumor drugs.
[0008] However, decades of drug development targeting Ras have revealed that the smooth surface of the Ras protein, lacking a distinct groove or pocket structure for binding small molecule inhibitors, and its very high affinity for guanine substrates (picomolar), have made the development of small molecule inhibitors difficult to resolve. Consequently, Ras has long been considered an "undruggable" target in the industry. At the same time, there is a significant need for compounds with more structural types or patterns as KRas inhibitors to provide more therapeutic options or to offer improved inhibitory activity compared to existing KRas inhibitors, thereby providing more potent therapeutic drugs for clinical use.
[0009] The present invention addresses these and other needs. The present invention provides novel structural inhibitor compounds with KRas mutant protein inhibitory activity. Due to their improved structural patterns, these compounds have enhanced KRas mutant protein inhibitory activity and tumor-related inhibitory activity compared to existing KRas mutant protein inhibitors in the prior art. They also possess favorable pharmacokinetic properties and, therefore, good drugability. For example, they can be conveniently administered for easier absorption in the body, with reduced toxic side effects, improved drug tolerance and safety, and a reduced risk of drug interactions.
[0010] Summary of the Invention
[0011] The present invention provides a compound having structural formula (I) as defined herein below, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates:
[0012] The definitions of the various groups are as defined in the detailed description of the invention.
[0013] The present invention also provides a pharmaceutical composition comprising a compound of the present invention or a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof, and optionally a pharmaceutically acceptable excipient or carrier.
[0014] The present invention also provides a compound of the present invention or a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof for use as a medicament.
[0015] The present invention also provides compounds of the present invention or stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates thereof, for use as inhibitors of Ras mutant proteins, especially KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), preferably KRas G12D.
[0016] The present invention also provides a compound of the present invention or its stereoisomers, tautomers, stable isotope variants, pharmaceutically acceptable salts or solvates, or a pharmaceutical composition comprising the same, for treating and / or preventing diseases mediated by Ras mutant proteins, especially KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), preferably KRas G12D mutant protein.
[0017] The present invention also provides the use of a compound of the present invention or its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, or a pharmaceutical composition comprising the same, for treating and / or preventing diseases mediated by Ras mutant proteins, especially KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), preferably KRas G12D mutant protein.
[0018] The present invention also provides the use of a compound of the present invention or its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating and / or preventing diseases mediated by Ras mutant proteins, especially KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), preferably KRas G12D mutant protein.
[0019] The present invention also provides a method for treating and / or preventing diseases mediated by Ras mutant proteins, especially KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), preferably KRas G12D mutant protein, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention or its stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate, or a pharmaceutical composition comprising the same.
[0020] The present invention also provides a method for treating tumors or cancers, comprising administering to a patient in need thereof a compound of the present invention or its stereoisomers, tautomers, stable isotope variants, pharmaceutically acceptable salts or solvates, or a pharmaceutical composition comprising the same.
[0021] The present invention also provides use of the compound of the present invention or a pharmaceutically acceptable salt or solvate thereof as a KRas inhibitor in research, particularly as a research tool compound for inhibiting KRas G12D.
[0022] The present invention also provides pharmaceutical combinations comprising a compound of the present invention, a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof, and one or more other pharmaceutically active agents.
[0023] The present invention also provides methods for preparing the compounds of the present invention.
[0024] Detailed Description of the Invention
[0025] definition
[0026] Unless otherwise indicated, the various terms used in the specification and claims have the meanings shown below. In the absence of a specific definition of a particular term or phrase, it should be understood according to its ordinary meaning in the art. In the event of a conflict, the present specification (including definitions) will control.
[0027] In the event of a conflict between the chemical structure and the name of a compound disclosed herein, the chemical structure controls.
[0028] As used herein, the term "Ras mutant" or "Ras mutant protein" refers to a protein encoded and expressed by a Ras gene in which one or more codons are mutated, typically including but not limited to a Ras protein in which a glycine residue at codon 12, a glycine residue at codon 13, or a glutamine residue at codon 61 of Ras is mutated, such as a mutant HRas, NRas, or KRas. These residues are located in the active site of Ras, and their mutations can impair the intrinsic or GAP-catalyzed GTPase activity of Ras, resulting in the persistence of Ras bound to GTP.
[0029] For the purposes of the present invention, "Ras mutation" or "Ras mutant protein" and "Ras" when describing inhibitory activity are used interchangeably and generally refer to mutant HRas, NRas or KRas, such as but not limited to KRas-G12C (glycine to cysteine mutation at codon G12), KRas-G12D (glycine to aspartic acid mutation at codon G12), HRas-G12D, NRas-G12D, KRas-G12V ( Glycine to valine mutation at codon G12), KRas-G13D (glycine to aspartic acid mutation at codon G13); particularly refers to KRas mutant protein, more particularly refers to KRas-G12C mutant protein, KRas-G12D mutant protein, KRas-G12V mutant protein, G12A mutant protein, G12R mutant protein, G12S mutant protein, KRas-G13D mutant protein, most particularly refers to KRas-G12D mutant protein.
[0030] As used herein, the term "treatment" refers to administering one or more compounds of the present invention as described herein, or pharmaceutically acceptable salts or solvates thereof, to a subject, such as a mammal, such as a human, suffering from the disease or symptoms of the disease, to cure, alleviate, lessen or affect the disease or symptoms of the disease. Preferably, the treatment is curative or ameliorative.
[0031] The term "prevention" as used herein is well known in the art and refers to administering one or more compounds described herein, or pharmaceutically acceptable salts or solvates thereof, to a subject, such as a mammal, such as a human, suspected of suffering from or susceptible to a Ras mutation-mediated disease as defined herein, particularly a cancer or tumor, so as to reduce the risk of developing the defined disease or prevent the onset of the disease. The term "prevention" includes the use of the compounds of the present invention before the diagnosis or confirmation of any clinical and / or pathological symptoms.
[0032] As used herein, the terms "inhibit" and "reduce" or any variants of these terms refer to the ability of a bioactive agent to reduce the signaling activity of a target of interest by interacting directly or indirectly with the target, and refer to any measurable reduction or complete inhibition of the activity of the target of interest. For example, compared to normal, the activity (e.g., KRas activity) can be reduced by about, up to about, or at least about 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein.
[0033] As used herein, the term "selective inhibition" refers to the ability of a bioactive agent to preferentially reduce the signaling activity of a target of interest over off-target signaling activity by interacting directly or indirectly with the target. With respect to the compounds of the present invention, the compounds have the ability to selectively inhibit G12 or G13 mutations of KRas, HRas, or NRas proteins relative to various mutations occurring in one or more codons of the Ras protein, such as G12C mutations, G12D mutations, G12V mutations, G12A mutations, G12R mutations, G12S mutations, and G13D mutations, preferably the ability to selectively inhibit the G12D mutation of the KRas protein. For example, the present invention has at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or more, or any range derivable therein, inhibition of better activity against a specific Ras mutation as compared to another specific Ras mutation, or at least 1-, 2-, 3-, 4-, 5-, 10-, 25-, 50-, 100-, 250-, or 500-fold better activity against a specific Ras mutation (e.g., KRas-G12D) as compared to another specific Ras mutation.
[0034] As used herein, the term "Ras mutation-mediated disease" refers to a disease in which Ras mutations contribute to the onset and progression of the disease, or in which inhibition of Ras mutations reduces the incidence, ameliorate, or eliminates disease symptoms. For purposes of the present invention, "Ras mutation-mediated disease" preferably refers to a KRas mutation-mediated disease, most preferably a KRas-G12D-mediated disease, and even more preferably a KRas-G12D-mediated cancer or tumor.
[0035] As used herein, the term "cancer" or "tumor" refers to abnormal cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. For purposes of the various aspects of the present invention, the cancer or tumor includes, but is not limited to, lung adenocarcinoma, lung cancer, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor (CNS), primary CNS lymphoma, spinal tumor, brain stem glioma, or pituitary adenoma.
[0036] For various aspects of the present invention, preferably, the cancer or tumor is associated with a Ras mutation, in particular a KRas mutation, preferably a KRas G12D mutation, including but not limited to the above-mentioned tumor types and their preferred ranges. Particularly preferred tumors of the present invention include lung cancer, lung adenocarcinoma, colon cancer, rectal cancer, pancreatic cancer, endometrial cancer, bile duct cancer, leukemia, and ovarian cancer.
[0037] As used herein, the terms "subject," "individual," or "patient" refer to a vertebrate. In certain embodiments, the vertebrate is a mammal. Mammals include, but are not limited to, farm animals (e.g., cattle), sports animals, pets (e.g., guinea pigs, cats, dogs, rabbits, and horses), primates, mice, and rats. In certain embodiments, the mammal is a human.
[0038] As used herein, the term "therapeutically effective amount" refers to an amount or dosage generally sufficient to produce a beneficial therapeutic effect in a patient with a "Ras mutation-mediated disease," such as a cancer or tumor, requiring treatment. Those skilled in the art can determine the effective amount or dosage of the active ingredient of the present invention by conventional methods and in combination with conventional influencing factors.
[0039] The term "drug combination" as used herein means that the compounds of the present invention can be combined with other active agents to achieve the purpose of the present invention. The other active agents may be one or more additional compounds of the present invention, or may be a second or additional (e.g., a third) compound that is compatible with the compounds of the present invention, i.e., does not adversely affect each other, or has complementary activity, such as these active agents are known to regulate other biologically active pathways, or regulate different components in the biologically active pathways involved in the compounds of the present invention, or even overlap with the biological targets of the compounds of the present invention. Such active agents are suitably combined in an effective amount to achieve the intended purpose. The other active agents may be co-administered with the compounds of the present invention in a single pharmaceutical composition, or administered separately from the compounds of the present invention in different discrete units, and when administered separately, may be performed simultaneously or sequentially. The sequential administration may be close or distant in time.
[0040] As used herein, the term "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce adverse, allergic or other untoward reactions when administered in appropriate amounts to animals, such as humans.
[0041] As used herein, the term "pharmaceutically acceptable salt" refers to salts that retain the biological effectiveness and properties of the parent compound and are not biologically or otherwise undesirable, including acid addition salts and base addition salts. "Pharmaceutically acceptable acid addition salts" can be formed by compounds having a basic group with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, carbonic acid, phosphoric acid, etc., and organic acids selected from aliphatic, alicyclic, aromatic, araliphatic, heterocyclic, carboxylic, and sulfonic organic acids, such as formic acid, acetic acid, propionic acid, glycolic acid, gluconic acid, lactic acid, pyruvic acid, oxalic acid, malic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, aspartic acid, ascorbic acid, glutamic acid, anthranilic acid, benzoic acid, cinnamic acid, mandelic acid, pamoic acid, phenylacetic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like, as well as salts derived from pharmaceutically acceptable organic non-toxic bases including, but not limited to, primary, secondary, and tertiary amines, substituted ammoniums including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, tromethamine, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrazine, choline, betaine, ethylenediamine, glucosamine, methylglucamine, triethanolamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins, and the like.
[0042] The term "isomer" as used herein refers to any stereoisomer, enantiomeric mixture, including racemates, diastereomeric mixtures, geometric isomers, atropisomers and / or tautomers that may exist in the structure of a compound. The determination and separation of the stereochemistry of the isomers are well known to those skilled in the art (SP Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994).
[0043] Certain compounds of the present invention contain at least one asymmetric center and may thus give rise to stereoisomers. The present invention therefore encompasses all possible isomeric forms of the compounds defined herein, and pharmaceutically acceptable salts or solvates thereof, unless otherwise indicated.
[0044] The compound structural formula or structural fragments used herein Indicates the absolute configuration of a stereocenter, i.e., a chiral center. Accordingly, in the names of the compounds or intermediates provided by the present invention, R or S indicates the absolute configuration of the chiral center. Indicates the racemic form where two configurations of the chiral center exist simultaneously, such as express Axial chirality can also be used in the definition of some compounds of the present invention to represent the configuration of the compound. These configurations are determined using the Cahn-Ingold-Prelog rules well known to those skilled in the art. The absolute configurations of the axial chirality in the two example structures shown below are described as follows:
[0045] When the linking axial chiral bond is marked with "*", it means that the compound has a single chiral configuration and is obtained by SFC resolution, but the absolute configuration is uncertain, for example, express or
[0046] The number of groups attached to each atom in a compound definition, compound formula, or structural fragment herein depends on the chemical valence of that atom and need not be shown in full. Generally, only non-hydrogen groups are shown in a group definition, structural formula, or structural fragment. Unshown groups generally represent H. The presence and quantity of unshown groups can be readily determined by one skilled in the art.
[0047] It should be understood that when a person skilled in the art can determine, based on the structure of the compound shown herein, that the compound exists as a pair of chiral isomers and that the compound can be easily separated based on conventional methods in the art, then the disclosure of the racemate of the compound herein (whether in terms of structural formula or chemical name) should be deemed to have disclosed each isomer of the compound separately.
[0048] The structural fragments used in this article The bonds indicated to be cross-linked are the bonds connecting this structural fragment to the rest of the molecule.
[0049] The substituents shown as crossing chemical bonds in the cyclic structure fragments referred to herein are, for example, -(R 12 ) m , refers to the one or more R 12 The substituents may be substituted at any chemically feasible substitution site or sites in the ring, including Z.
[0050] The compounds of the present invention include unlabeled forms of the compounds of the present invention and isotopically labeled forms thereof. Isotopically labeled forms of compounds are compounds that differ only in that one or more atoms are replaced by corresponding isotopically enriched atoms. Examples of isotopes that can be incorporated into the compounds of the present invention include, for example, isotopes of hydrogen, carbon, nitrogen, oxygen, fluorine, chlorine, and iodine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 18 O. 17 O. 35 S. 18 F. 37 Cl and 125 I. Such isotope-labeled compounds can be used as probes, analytical tools or therapeutic agents in, for example, biological assays. In certain embodiments, the compounds of the present invention are provided in an unlabeled form. In other embodiments, the compounds of the present invention are provided in an isotope-labeled form, such as a hydrogen isotope D-labeled form. In particular, R in the compounds of general formula (I) and its various sub-formulas herein is 11 and R 14 One or more H in the group may be replaced by an isotope D, such as R 14 are each independently H or D, R 11 Can be substituted with one or more D, especially -C substituted with one or more D 1-6 alkyl.
[0051] As used herein, the term "solvate" refers to a solvent addition form of a compound containing a stoichiometric or non-stoichiometric amount of a solvent, including any solvated form of a compound of the invention, including, for example, solvates with water, such as hydrates, or solvates with organic solvents, such as methanol, ethanol, or acetonitrile, i.e., as methanolate, ethanolate, or acetonitrile, respectively; or in the form of any polymorph. It should be understood that such solvates of the compounds of the invention also include solvates of pharmaceutically acceptable salts of the compounds of the invention.
[0052] As used herein, the term "metabolite" refers to a product produced by the metabolism of a compound in vivo. Such products may be derived, for example, from oxidation, reduction, hydrolysis, amidation, deamidation, esterification, deesterification, enzymatic cleavage, etc. of the administered compound. Identification and analysis of metabolite products are performed in a manner well known to those skilled in the art.
[0053] The term "pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" as used herein refers to one or more compatible solid or liquid fillers or gel substances that are suitable for human use and have sufficient purity and sufficiently low toxicity. Examples include, but are not limited to, cellulose and its derivatives (such as sodium carboxymethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as magnesium stearate), calcium sulfate, vegetable oils, polyols (such as propylene glycol, glycerol, mannitol, sorbitol, etc.), emulsifiers (such as Tweens), wetting agents (such as sodium lauryl sulfate), colorants, flavorings, stabilizers, antioxidants, preservatives, etc.
[0054] The term "halogen" or "halo" as used herein means F, Cl, Br or I. Furthermore, the term "substituted with halogen" as used herein when defining a group is intended to include mono- or poly-halogenated groups in which one or more identical or different halogens replace one or more hydrogens in the corresponding group.
[0055] The term "alkyl" as used herein means a linear or branched monovalent saturated hydrocarbon group consisting of carbon atoms and hydrogen atoms. Specifically, the alkyl group has 1-10, such as 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3 or 1 to 2 carbon atoms. For example, as used herein, the term "C1-6 alkyl" refers to a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms, examples of which include methyl, ethyl, propyl (including n-propyl and isopropyl), butyl (including n-butyl, isobutyl, sec-butyl or tert-butyl), pentyl (including n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, etc.
[0056] As used herein, the term "-O-alkyl" or "alkoxy" refers to an alkyl group as defined herein that is attached to the rest of the molecule via an oxygen atom. Specifically, the -O-alkyl group has 1-10, such as 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. For example, as used herein, the term "-O-C1-6alkyl" refers to a straight or branched saturated hydrocarbon group having 1 to 6 carbon atoms that is attached to the rest of the molecule via an oxygen atom, examples of which include -O-methyl, -O-ethyl, -O-propyl (including -O-n-propyl and -O-isopropyl), -O-butyl (including -O-n-butyl, -O-isobutyl, -O-sec-butyl, or -O-tert-butyl), -O-pentyl (including -O-n-pentyl, -O-isopentyl, -O-neopentyl), -O-n-hexyl, 2-methylpentyl-O-, and the like.
[0057] As used herein, the term "-S-alkyl" refers to an alkyl group as defined herein that is attached to the rest of the molecule via a sulfur atom. Specifically, an -O-alkyl group has 1-10, such as 1 to 8, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 to 2 carbon atoms. For example, as used herein, the term "-S-C1-6alkyl" refers to a straight or branched saturated hydrocarbon group having 1 to 6 carbon atoms that is attached to the rest of the molecule via a sulfur atom, examples of which include -S-methyl, -S-ethyl, -S-propyl (including -S-n-propyl and -S-isopropyl), -S-butyl (including -S-n-butyl, -S-isobutyl, -S-sec-butyl, or -S-tert-butyl), -S-pentyl (including -S-n-pentyl, -S-isopentyl, -S-neopentyl), -S-n-hexyl, 2-methylpentyl-S-, and the like.
[0058] As used herein, the term "C optionally substituted by halogen" 1-6 "Alkyl" refers to the C1-6 alkyl group as described above, wherein one or more (e.g., 1, 2, 3, 4, or 5) hydrogen atoms are optionally replaced by halogen. It will be understood by those skilled in the art that when there is more than one halogen substituent, the halogens may be the same or different and may be located on the same or different C atoms. Examples of "halogen-substituted C1-6 alkyl" include, for example, -CH2F, -CHF2, -CF3, -CCl3, -C2F5, -C2Cl5, -CH2CF3, -CH2Cl, -CH2CH2CF3, or -CF(CF3)2.
[0059] The term "alkenyl" as used herein refers to a straight or branched unsaturated hydrocarbon group consisting of carbon atoms and hydrogen atoms and containing at least one double bond. Specifically, the alkenyl group has 2-8, such as 2 to 6, 2 to 5, 2 to 4 or 2 to 3 carbon atoms. For example, as used herein, the term "C2-6 alkenyl" refers to a straight or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, propenyl, allyl, butenyl, pentenyl, etc., and the carbon atom in the alkenyl group that is connected to the rest of the molecule can be saturated or an olefinic carbon atom.
[0060] As used herein, the term "alkynyl" refers to a straight or branched unsaturated hydrocarbon group consisting of carbon atoms and hydrogen atoms and containing at least one triple bond. Specifically, the alkynyl group has 2-8, such as 2 to 6, 2 to 5, 2 to 4, or 2 to 3 carbon atoms. For example, as used herein, the term "C2-6 alkynyl" refers to a straight or branched alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, propargyl, butynyl, etc. The carbon atom in the alkynyl group that is connected to the rest of the molecule can be saturated or can be an acetylenic bond carbon atom.
[0061] As used herein, the term "cycloalkyl" refers to a monocyclic, fused polycyclic, bridged polycyclic, or spirocyclic non-aromatic saturated monovalent hydrocarbon ring structure having a specified number of ring carbon atoms. 3-12 cycloalkyl), for example, 3 to 10, 3 to 8, 3 to 7, 3 to 6, 5 to 6 carbon atoms. Examples of suitable cycloalkyls include, but are not limited to, monocyclic structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl; or polycyclic (e.g., bicyclic) structures, including spiro, fused, or bridged systems such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, spiro[3.4]octanyl, bicyclo[3.1.1]hexyl, bicyclo[3.1.1]heptyl, or bicyclo[3.2.1]octanyl. For example, as used herein to define compounds, the term "C 3- "6-cycloalkyl" refers to a monocyclic cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl group.
[0062] As used herein, the term "heterocycloalkyl" refers to a monocyclic, fused polycyclic, spirocyclic, or bridged polycyclic non-aromatic saturated ring structure comprising one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from O, N, and S and the specified number of ring atoms, or an N-oxide thereof, or an S-oxide or S-dioxide thereof. A heterocycloalkyl group may have 3 to 12 ring members (which may be referred to as a 3-12-membered heterocycloalkyl group), for example, 3 to 10 ring members, 3 to 8 ring members, 3 to 7 ring members, 4 to 7 ring members, 4 to 6 ring members, or 5 to 6 ring members. A heterocycloalkyl group typically contains up to 4 (e.g., 1, 2, 3, or 4) heteroatoms, for example, a 4-7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S. Examples of suitable heterocycloalkyl groups include, but are not limited to, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl (e.g., 1-pyrrolidinyl, 2-pyrrolidinyl, and 3-pyrrolidinyl), tetrahydrofuranyl (e.g., 1-tetrahydrofuranyl, 2-tetrahydrofuranyl, and 3-tetrahydrofuranyl), tetrahydrothiophenyl (e.g., 1-tetrahydrothiophenyl, 2-tetrahydrothiophenyl, and 3-tetrahydrothiophenyl), piperidinyl (e.g., 1-piperidinyl), , 2-piperidinyl, 3-piperidinyl and 4-piperidinyl), tetrahydropyranyl (e.g., 4-tetrahydropyranyl), tetrahydrothiopyranyl (e.g., 4-tetrahydrothiopyranyl), morpholinyl (e.g., morpholino), thiomorpholinyl, dioxanyl, piperazinyl or azepanyl, diazepanyl such as 1,4-diazacycloheptyl, 3,6-diaza-bicyclo[3.1.1]heptyl or 3-aza-bicyclo[3.2.1]octyl. The atom in the heterocycloalkyl group that is attached to the rest of the compound can be a carbon atom or a heteroatom, as long as it is chemically feasible.
[0063] Preferred heterocycloalkyl groups are, for example It is understood that structures having asymmetric centers encompass racemic and / or single enantiomeric forms thereof, e.g. Can represent and / or
[0064] As used herein, the term "heteroaryl" means a monocyclic or fused polycyclic aromatic ring structure comprising one or more (e.g., 1, 2, 3, or 4) heteroatoms independently selected from O, N, and S and the specified number of ring atoms, or an N-oxide thereof, or an S-oxide or S-dioxide thereof. Specifically, the aromatic ring structure may have 5 to 12 ring members. The heteroaryl group may be, for example, a 5-6 membered monocyclic ring, or a fused bicyclic structure formed by condensing two 6-membered rings, condensing two 5-membered rings, condensing a 6-membered ring and a 5-membered ring, or condensing a 5-membered ring and a 4-membered ring. The heteroaryl ring typically contains up to 4 heteroatoms, more typically up to 3 heteroatoms, independently selected from O, N, and S, wherein N and S may be in an oxidized state such as N-oxide, S=O, or S(O)2. In one embodiment, the heteroaryl group contains at least one ring nitrogen atom, at least one ring sulfur atom, or at least one ring oxygen atom. For example, the heteroaryl group can be a 5-6 membered heteroaryl group containing 1-3 heteroatoms independently selected from N, O or S. Examples of suitable 5-membered monocyclic heteroaryl groups include, but are not limited to, pyrrolyl, furanyl, thienyl, imidazolyl, furazanyl, oxazolyl, oxadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl, isothiazolyl, pyrazolyl, triazolyl and tetrazolyl; examples of suitable 6-membered monocyclic heteroaryl groups include, but are not limited to, pyridinyl, pyrazinyl, pyridazinyl, pyrimidinyl and triazinyl. For example, heteroaryl can also be a fused ring containing 1, 2, 3 or 4 heteroatoms independently selected from N, O or S, such as benzofuran, benzothiophene, indole, benzimidazole, indazole, benzotriazole, pyrrolo[2,3-b]pyridine, pyrrolo[2,3-c]pyridine, pyrrolo[3,2-c]pyridine, pyrrolo[3,2-b]pyridine, imidazo[4,5-b]pyridine, Pyridine, imidazo[4,5-c]pyridine, pyrazolo[4,3-d]pyridine, pyrazolo[4,3-c]pyridine, pyrazolo[3,4-c]pyridine, pyrazolo[3,4-b]pyridine, isoindole, purine, indolizine, imidazo[1,2-a]pyridine, imidazo[1,5-a]pyridine, pyrazolo[1,5-a]pyridazine, pyrrolo[1,2-b]pyrimidine pyrimidine, imidazo[1,2-c]pyrimidine, 5H-pyrrolo[3,2-b]pyrazine, 1H-pyrazolo[4,3-b]pyrazine, 1H-pyrazolo[3,4-d]pyrimidine, 7H-pyrrolo[2,3-d]pyrimidine, quinoline, isoquinoline, cinnoline, quinazoline, quinoxaline, phthalazine, 1,6-naphthyridine, 1,7-naphthyridine, 1,8-naphthyridine, 1,5-naphthyridine, 2 ,6-naphthyridine, 2,7-naphthyridine, pyrido[3,2-d]pyrimidine, pyrido[4,3-d]pyrimidine, pyrido[3,4-d]pyrimidine, pyrido[2,3-d]pyrimidine, pyrido[2,3-b]pyrazine, pyrido[3,4-b]pyrazine, pyrimido[5,4-d]pyrimidine, pyrazino[2,3-b]pyrazine and pyrimido[4,5-d]pyrimidine.The atom in a heteroaryl group that is attached to the rest of the compound can be a carbon atom or a heteroatom, as long as it is chemically feasible.
[0065] As used herein, the term "hydroxy" refers to an -OH group.
[0066] As used herein, the term "cyano" refers to a -CN group.
[0067] As used herein, the term "optionally substituted" means, unless otherwise indicated, that a group may be unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4, or 5 or more, or any range derivatizable therein) of the substituents listed for that group, wherein the substituents may be the same or different. In one embodiment, the optionally substituted group has 1 substituent. In another embodiment, the optionally substituted group has 2 substituents that are the same or different. In another embodiment, the optionally substituted group has 3 substituents that are the same or different. In another embodiment, the optionally substituted group has 4 substituents that are the same or different. In another embodiment, the optionally substituted group has 5 substituents that are the same or different.
[0068] Many of the groups defined herein are optionally substituted, and the list of substituents given in this definitions section is merely exemplary and is not intended to limit the substituents defined elsewhere in the specification and claims.
[0069] Unless otherwise specified, C in the definition of compounds of the present invention is n-n+m or C n -C m Including various cases from n to n+m carbons, such as C 1-6 Including C1, C2, C3, C4, C5 and C6, and also including any range from n to n+m, such as C 0-6 Including C1, C2, C3, C4, C5, C6, C 0-1 、C 0-2 、C 0-3 、C 0-4 、C 0-5 、C 1-2 、C 1-3 、C 1-4 、C 2-3 etc., C. 1-6 Including C 1-2 、C 1-3 、C 1-4 、C 2-6 、C 3-6 wait.
[0070] It is understood by those skilled in the art of organic synthesis that the various groups carried in the structure of the compounds of the present invention, whether unsubstituted or substituted by various defined substituents, are all based on the premise that the compound molecules are chemically feasible and stable, wherein the type and number of substituents are determined by the number and chemical valence of atoms in the group.
[0071] As used in this specification and the claims that follow, the word "comprise" and variations of the word such as "include" and "comprising" mean "including but not limited to," and are not intended to exclude, for example, other additives, ingredients, integers, or steps. When an element is described as comprising a plurality of ingredients, steps, or conditions, it should be understood that the element may also be described as comprising any combination of the plurality of ingredients, steps, or conditions, or "consisting of" or "consisting essentially of" the plurality or combination of ingredients, steps, or conditions.
[0072] It should be understood that the dosages referred to herein when describing the compounds of the present invention, pharmaceutical compositions, pharmaceutical combinations, kits containing the same, and related uses and methods are based on the weight of the free form and do not include any salts, hydrates or solvates thereof, unless the description indicates that the dosage is based on the weight of the salt, hydrate or solvate.
[0073] Problems to be solved by the present invention
[0074] As described above, compounds that can inhibit Ras mutant proteins, especially KRas mutant proteins (such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), more especially KRas-G12D mutant proteins, can be used to treat or prevent diseases mediated by the mutant proteins (such as cancer or tumors). Therefore, in this field, various structural types of Ras inhibitors have been developed. However, existing KRas inhibitors still have problems that need to be solved, including, for example, many inhibitors have unsatisfactory anti-tumor activity, or have toxic side effects that lead to poor drug resistance, or pharmacokinetic properties that are not sufficient to allow convenient administration, i.e., poor "drugability", or undesirable drug interactions due to inhibition of the cytochrome P450 enzyme system, etc. Furthermore, even for inhibitors with good anti-tumor activity, people still hope to further enhance their selective inhibitory activity against target proteins in vivo, further improve their drug resistance (fewer toxic side effects or better safety) and further improve their pharmacokinetic properties through structural optimization, so as to provide more and better treatment options in clinical practice.
[0075] Solutions to the problem
[0076] Through extensive and in-depth research, the inventors have developed a group of compounds with significant inhibitory activity against Ras mutants, particularly KRas mutants (e.g., G12C, G12D, G12V, G12A, G12R, G12S, and G13D mutants), and more particularly, KRas-G12D mutants. Through structural modification and activity verification, the inventors discovered that specific types of substituents were modified at specific sites on the benzopyrimidine ring of the KRas inhibitor structure. The specific combinations of substitution sites and substituent types achieved further enhanced inhibitory activity against KRas-G12D mutants compared to prior art inhibitors. Furthermore, the resulting compounds exhibited a favorable safety profile, reduced risk of drug interactions, and favorable, and even improved, pharmacokinetic properties, enabling convenient administration.
[0077] Thus, the present invention mainly provides effective Ras inhibitors, specifically KRas inhibitors (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation inhibitors), more specifically KRas-G12D inhibitor compounds; pharmaceutical compositions containing such compounds as active ingredients; and pharmaceutical compositions for treating or preventing diseases caused by Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation inhibitors). 12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D mediated or benefited from Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D inhibition of tumors or cancers; use of the compounds for treating or preventing tumors or cancers caused by Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D inhibition of tumors or cancers; and use of the compounds for treating or preventing tumors or cancers caused by Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D mediated or benefited from Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D inhibition of diseases such as tumors or cancer; and the use of the compound in the preparation of a method for treating or preventing a disease caused by Ras , specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D mediated or benefited from Ras, specifically KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), more specifically KRas-G12D inhibition of diseases such as tumors or cancers.
[0078] The present invention therefore provides the following technical solutions.
[0079] Compounds of the present invention
[0080] The terms "inventive compound" and "compound of the present invention" and the like as used throughout this application, unless otherwise limited, encompass the compounds defined in each embodiment herein and preferred embodiments thereof, or various specific embodiments thereof, including isomers, including atropisomers, enantiomeric mixtures, in particular racemates, diastereomeric mixtures, geometric isomers, tautomers, solvates, metabolites, prodrugs, isotopic variants and salts (e.g., pharmaceutically acceptable salts) thereof.
[0081] Therefore, the above-mentioned various isomers and derivatives of the compounds of the present invention are thus encompassed within the scope of the present invention, and their respective meanings, preparations and specific examples are as defined in the "Definitions" section above, or are well known in the art. However, preferably, it is the compound of the present invention and / or its pharmaceutically acceptable salt or solvate.
[0082] The present invention also encompasses N-oxides of the compounds of this invention, as long as these compounds contain a basic nitrogen atom such as the nitrogen atom present in a nitrogen-containing heterocycle and are chemically and biologically feasible. Some compounds of the present invention can exist in polymorphic or amorphous form, so they also fall within the scope of the present invention.
[0083] The present invention provides the following compound embodiments:
[0084] Embodiment 1: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof,
[0085] in:
[0086] R1 and R1' together form an intracyclic bridge -(CH2) t - or -CH2=CH2-;
[0087] R2 and R3 are each independently selected from H, halogen, -C 1-6 Alkyl, optionally halogen-substituted C 2- 6 alkynyl and -OC optionally substituted by halogen 1-6 alkyl;
[0088] G is selected from CH and N;
[0089] Y is selected from O, S and Se;
[0090] M is selected from N or C-R4;
[0091] Z is selected from N, C, O, S and Se;
[0092] B is selected from
[0093] X is selected from C and S, and p is selected from 0 and 1, provided that when p is 0, X is S, and when p is 1, X is C;
[0094] W is selected from H, halogen, -C 1-6 Alkyl, OH and NH2;
[0095] R4 is selected from H, halogen, CN, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or CN;
[0096] R5 is selected from H, halogen and NH2;
[0097] R6 is selected from H, halogen, CN, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -Se-C 1-6 Alkyl and -C 2-6 Alkynyl, where -C 1-6 Alkyl and -C 2-6 each alkynyl group is independently optionally substituted with halogen;
[0098] R7 and R8 are each independently selected from H, halogen, -NO2, CN, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 replaced;
[0099] R9 is selected from -Si(R b )3, CN, NO2, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -(CH2) n -C 3-6 Cycloalkyl, -(CH2) n -5-6 membered heteroaryl and -(CH2) n -phenyl, where -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 3-6 Cycloalkyl, 5-6 membered heteroaryl and phenyl are each independently optionally selected from halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1- 6 alkyl group substitution;
[0100] R a selected from H and -C optionally substituted by halogen 1-6 alkyl;
[0101] R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl, each optionally substituted with halogen;
[0102] R 10 Selected from H, halogen, CN, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or CN;
[0103] R 11 Selected from H, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl and -(CH2) n -C 3-6 Cycloalkyl, where C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl or C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, CN, -OC 1-6 Alkyl or -O-CON(R a )2 replaced;
[0104] R 12 Selected from H, halogen, -CN, -OH, N(R a )2. -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl and -(CH2) n -C 3-6 Cycloalkyl, where each occurrence of C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl or C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, CN or -OC 1-6 Alkyl substitution,
[0105] or two R attached to the same carbon atom 12 Formation = C (R c )2. Spiral C 3-6 Cycloalkyl or spiro 4-7 membered heterocycloalkyl, wherein R c are each independently selected from H, halogen and -C 1-6 Alkyl, and the spiro C 3-6 Cycloalkyl or spiro 4-7 membered heterocycloalkyl optionally substituted with halogen and -C 1-6 Alkyl substitution,
[0106] or two R attached to adjacent ring carbon atoms 12Together with the carbon atom to which they are attached, they form a C3-4 cycloalkyl group,
[0107] or two R attached to non-adjacent ring carbon atoms 12 together to form a bridged methylene or ethylene group;
[0108] R 13 Selected from H, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or -OC 1-6 Alkyl substitution;
[0109] Or when R 12 and R 13 When attached to adjacent ring carbon atoms, together with the carbon atoms to which they are attached, they form a C3-4 cycloalkyl group;
[0110] R 14 Selected from H, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, where C 1-6 Alkyl and C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or -OC 1-6 Alkyl substituted, or two R attached to the same carbon atom 14 Together with the carbon atom to which they are attached, they form C 3-4 Cycloalkyl;
[0111] k is selected from 0 or 1;
[0112] m and n are each independently selected from integers from 0 to 2; and
[0113] t is selected from an integer of 1 to 2.
[0114] Embodiment 1.1: A compound of formula (I) according to Embodiment 1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein W is selected from OH and NH2; R2 and R3 are each independently selected from H, halogen and -OC optionally substituted by halogen 1-6 Alkyl; R5 is selected from H and halogen; R6 is selected from H, halogen, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -Se-C 1-6 Alkyl and -C 2-6 Alkynyl, where -C 1-6 Alkyl and -C 2-6Each alkynyl group is independently optionally substituted with halogen.
[0115] Embodiment 1.2: A compound of formula (I) according to embodiment 1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 and R3 are each independently selected from H, halogen, -C 1-6 Alkyl and optionally halogen-substituted -OC 1-6 Alkyl, and when two R 12 Formation = C (R c )2. Spiral C 3-6 When cycloalkyl or spiro 4-7 membered heterocycloalkyl, R c are each independently selected from H, halogen and -C 1-6 alkyl.
[0116] Embodiment 1.3: A compound of Formula (I) according to Embodiment 1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein W is selected from H, halogen, OH and NH2.
[0117] Implementation 1.4:
[0118] Embodiment 2.1: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 1.3, wherein B is Where p is 1 and X is C, that is, the fused bicyclic portion where X is located is
[0119] Embodiment 2.1.1: A compound of formula (I) according to Embodiment 2.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R5 is H; or R5 is a halogen selected from F, Cl, Br, I; preferably R5 is a halogen, most preferably F.
[0120] Embodiment 2.1.2: A compound of formula (I) according to Embodiment 2.1 or 2.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R6 is H; or R6 is a halogen selected from F, Cl, Br, I.
[0121] Embodiment 2.1.3: A compound of Formula (I) according to Embodiment 2.1 or 2.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R6 is -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -Se-C1-6 Alkyl, optionally substituted with halogen, for example but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -O-CH3, -O-CH2CH3, -SCH3, -S-CH2CH3, -SeCH3.
[0122] Embodiment 2.1.4: A compound of Formula (I) according to Embodiment 2.1 or 2.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R6 is -C 2-6 Alkynyl, optionally substituted with halogen, such as but not limited to Preferred
[0123] Embodiment 2.1.5: A compound of formula (I) according to any one of Embodiments 2.1 to 2.1.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 and R8 are each H; or R7 and R8 are each halogen, preferably F.
[0124] Embodiment 2.1.6: A compound of formula (I) according to any one of Embodiments 2.1 to 2.1.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is H and the other is selected from halogen, CN and NO2, wherein the halogen is preferably F.
[0125] Embodiment 2.1.7: A compound of formula (I) according to any one of Embodiments 2.1 to 2.1.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is H and the other is selected from -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6Alkyl, non-hydrogen R7 or R8, for example but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3.
[0126] Embodiment 2.1.8: A compound of formula (I) according to any one of Embodiments 2.1 to 2.1.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is selected from H, halogen, -NO2, CN and -C 1-6 alkyl, the other selected from -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1- 6 alkyl is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl groups, as specifically exemplified in Embodiment 2.1.7.
[0127] Embodiment 2.1.9: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.1 to 2.1.8, wherein W is -OH.
[0128] Embodiment 2.1.10: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.1 to 2.1.8, wherein W is -NH2.
[0129] Embodiment 2.1.11: A compound of Formula (I) according to Embodiment 2.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein B is Wherein R5 is H or halogen, preferably halogen, R6 is selected from halogen, -C 2-6 Alkynyl and -C1-6 Alkyl groups, e.g.
[0130] Embodiment 2.2: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 1.3, wherein B is Where p is 0 and X is S, that is, the fused bicyclic portion where X is located is
[0131] Embodiment 2.2.1: A compound of formula (I) according to Embodiment 2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R5 is H; or R5 is a halogen selected from F, Cl, Br, I; preferably R5 is a halogen, most preferably F.
[0132] Embodiment 2.2.1.1: A compound of Formula (I) according to Embodiment 2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R5 is NH2.
[0133] Embodiment 2.2.2: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R6 is H; or R6 is a halogen selected from F, Cl, Br, I.
[0134] Embodiment 2.2.2.1: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to Embodiments 2.2 to 2.2.1.1, wherein R6 is CN.
[0135] Embodiment 2.2.3: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 2.2 to 2.2.1.1, wherein R6 is -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -Se-C 1-6Alkyl, optionally substituted with halogen, for example but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -O-CH3, -O-CH2CH3, -SCH3, -S-CH2CH3, -SeCH3.
[0136] Embodiment 2.2.4: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R6 is -C 2-6 Alkynyl, optionally substituted with halogen, such as but not limited to Preferred
[0137] Embodiment 2.2.5: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 and R8 are each H; or R7 and R8 are each halogen, preferably F.
[0138] Embodiment 2.2.6: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is H and the other is selected from halogen, CN and NO2, wherein the halogen is preferably F; for example, R7 is H and R8 is halogen, preferably F, or R8 is H and R7 is halogen, preferably F.
[0139] Embodiment 2.2.7: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is H and the other is selected from -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6Alkyl, non-hydrogen R7 or R8, for example but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CH2NH2, -CH2NHCH3, -CH2N(CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3.
[0140] Embodiment 2.2.8: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is selected from H, halogen, -NO2, CN and -C 1-6 alkyl, the other selected from -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1- 6 alkyl is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl groups, as specifically exemplified in Embodiment 2.2.7.
[0141] Embodiment 2.2.9: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.2 to 2.2.8, wherein W is -OH.
[0142] Embodiment 2.2.10: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.2 to 2.2.8, wherein W is -NH2.
[0143] Embodiment 2.2.11: A compound of Formula (I) according to Embodiment 2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein B is Wherein R5 is H or halogen, R6 is selected from halogen, -C 2-6 Alkynyl and -C1-6 Alkyl groups, e.g.
[0144] Embodiment 2.2.12: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.2 to 2.2.8, wherein W is -H.
[0145] Embodiment 2.2.13: A compound of formula (I) according to any one of Embodiments 2.2 to 2.2.8, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein W is halogen, preferably F; or W is -C 1-6 Alkyl, such as -CH3 or -CH2CH3.
[0146] Embodiment 2.2.14: A compound of Formula (I) according to Embodiment 2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein B is wherein W is selected from H, -C 1-6 Alkyl and halogen, R7 and R8 are each H, or each is halogen, or one of them is H and the other is halogen or halogen substituted C 1-6 alkyl, or C 1-6 Alkyl, wherein the halogen is preferably F; preferably, W is selected from H, R7 and R8 are each H, or one of them is H and the other is halogen, wherein the halogen is preferably F.
[0147] Embodiment 2.2.15: The compound of formula (I) according to Embodiment 2.2.14, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, wherein examples of B include, but are not limited to:
[0148] Embodiment 2.2.16: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to Embodiments 2.2 to 2.2.15, wherein The asterisks have axial chirality, including or
[0149] Embodiment 2.3: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 1.3, wherein B is
[0150] Embodiment 2.3.1: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 and R8 are each H; or R7 and R8 are each halogen, preferably F.
[0151] Embodiment 2.3.2: The compound of formula (I) of Embodiment 2.3, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, wherein one of R7 and R8 is H and the other is selected from halogen, CN and NO2, wherein the halogen is preferably F, for example, R7 is H and R8 is selected from halogen, CN and NO2, wherein the halogen is preferably F.
[0152] Embodiment 2.3.3: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is H and the other is selected from -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl, for example, R7 is H, R8 is selected from the above groups; non-hydrogen R7 or R8, for example but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CH2NH2, -CH2NHCH3, -CH2N (CH3)2, -NH2, -NHCH3, -N(CH3)2, -C(O)NH2, -C(O)NHCH3, -C(O)N(CH3)2, -C(O)OH, -C(O)OCH3.
[0153] Embodiment 2.3.4: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein one of R7 and R8 is selected from H, halogen, -NO2, CN and -C 1- 6 alkyl, the other selected from -C 1-6 Alkyl, -N(Ra )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl groups, wherein non-hydrogen groups are as specifically exemplified in Embodiment 2.3.3.
[0154] Embodiment 2.3.4.1: A compound of formula (I) according to Embodiment 2.3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 is selected from halogen, preferably F; and R8 is CN.
[0155] Embodiment 2.3.5: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.4, wherein R 10 For H.
[0156] Embodiment 2.3.6: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.4, wherein R 10 is halogen or CN, such as F, Cl, Br, I, CN, preferably F or Cl.
[0157] Embodiment 2.3.7: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 2.3 to 2.3.4, wherein R 10 -C 1-6 Alkyl, preferably -C 1-3 Alkyl, optionally substituted with halogen or CN, such as but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CH2CN, -CH2CH2CN, -CH2CH2CH2CN.
[0158] Embodiment 2.3.8: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 2.3 to 2.3.4, wherein R 10 -(CH2) n -C 3-6 Cycloalkyl, preferably -C 3-6 Cycloalkyl, optionally substituted by halogen or CN; for example but not limited to
[0159] Embodiment 2.3.9: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 is H, R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl, and R 10 Selected from halogen and -C 1-6 Alkyl; each as specifically exemplified in Embodiments 2.3.3, 2.3.6, and 2.3.7.
[0160] Embodiment 2.3.10: A compound of Formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is -Si(R b )3, where R b Selected from -C 1- 6 alkyl and -C 2-6 alkenyl, each optionally substituted with halogen; for example, but not limited to, -Si(CH3)3, -Si(CH3)2(CH2CH3), -Si(CH3)2(CH=CH2).
[0161] Embodiment 2.3.11: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.9, wherein R9 is -C 1-6 Alkyl, optionally substituted with halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6Alkyl substitutions; for example, but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -CH2(Se-CH3), -CH(CH3)(Se-CH3), -C(CH3)2(Se-CH3), -C2F5, -C2Cl5.
[0162] Embodiment 2.3.12: A compound of formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is -C 2-6 Alkenyl, optionally substituted with halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substitution; for example, but not limited to -CH=CH2, -CH2CH=CH2, -CH=CF2, -CF=CF2, -C(CH3)=CH2, -C(CF3)=CH2, -C(CH3)=CF2, -CH=CHCF3, -C(CH3)=CHCF3, -CH2CH=CF2, -CH2CF=CF2, -CH2C(CF3)=CH2, -CH2C(CH3)=CF2, -CH2CH=CHCF3, -CH2C(CH3)=CHCF3, -CH=CH(Se-CH3), -C(Se-CH3)=CH2, -CF=CH(Se-CH3).
[0163] Embodiment 2.3.13: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 2.3 to 2.3.9, wherein R9 is -C 2-6 Alkynyl, optionally substituted with halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substitution; for example, but not limited to -C≡CH, -CH2C≡CH, -C≡CF, -C≡CF, -C≡C(CH3), -C≡C(CF3), -CH2C≡CF, -CH2C≡C(CF3), -C≡C-Se-CH3, -C≡C-Se-CF3.
[0164] Embodiment 2.3.14: A compound of Formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is -OC 1-6 Alkyl or -SC 1-6 Alkyl, optionally substituted with halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substitution; such as but not limited to -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)(CH3), -O-CH2CH2CH2CH3 , -O-CH2CH(CH3)CH3, -OC(CH3)3, -O-CH2Cl, -O-CH2F, -O-CHF2, -O-CF3, -O-CCl3, -O-C H2CH2F, -O-CH2CHF2, -O-CH2CF3, -O-CH2CH2CH2F, -O-CH2CH2CHF2, -O-CH2CH2CF3, -OC (CH3)2CF3, -O-CH2(Se-CH3), -O-CH(CH3)(Se-CH3), -OC(CH3)2(Se-CH3), -O-C2F5, -O- C2Cl5, -S-CH3, -S-CH2CH3, -S-CH2CH2CH3, -S-CH(CH3)(CH3), -S-CH2CH2CH2CH3, -S-C H2CH(CH3)CH3, -SC(CH3)3, -S-CH2Cl, -S-CH2F, -S-CHF2, -S-CF3, -S-CCl3, -S-CH2CH2F , -S-CH2CHF2, -S-CH2CF3, -S-CH2CH2CH2F, -S-CH2CH2CHF2, -S-CH2CH2CF3, -SC(CH3)2 CF3, -S-CH2(Se-CH3), -S-CH(CH3)(Se-CH3), -SC(CH3)2(Se-CH3), -S-C2F5, -S-C2Cl5.
[0165] Embodiment 2.3.15: A compound of Formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is -(CH2) n -C 3-6 Cycloalkyl, preferably -C 3-6 Cycloalkyl, most preferably cyclopropyl, optionally substituted by halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substitution; for example but not limited to
[0166] Embodiment 2.3.16: A compound of Formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is -(CH2) n -5-6 membered heteroaryl, preferably 5-6 membered heteroaryl, optionally substituted by halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substituted; for example, a 5-6 membered heteroaryl containing 1 to 3 heteroatoms independently selected from N, O and S, a 5-6 membered heteroaryl containing 1 to 3 N atoms, a 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from N and O, a 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from N and S; specific examples include, but are not limited to:
[0167] Each optionally substituted by halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl is substituted, for example, by F, Cl, Br, I, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -Se-CH3, -Se-CH2-CH3, -C2F5 and / or -C2Cl5.
[0168] Embodiment 2.3.17: A compound of formula (I) according to any one of Embodiments 2.3 to 2.3.9, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R9 is phenyl, optionally substituted with halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6Alkyl substituted; for example, by F, Cl, Br, I, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -Se-CH3, -Se-CH2-CH3, -C2F5 and / or -C2Cl5.
[0169] Embodiment 2.3.18: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.9 wherein R9 is CN or NO2.
[0170] Embodiment 2.3.19: A compound of Formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 2.3 to 2.3.9, wherein R9 is selected from -Si(R b )3. -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, -Se- 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substituted, and R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl, each optionally substituted by halogen.
[0171] Embodiment 2.3.20: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 is H, R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl, R9 is selected from -Si(R b)3, NO2, CN, -C 1-6 Alkyl, -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 Cycloalkyl groups are each independently optionally selected from halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 The alkyl group is substituted, and R 10 Selected from halogen and -C 1-6 alkyl.
[0172] Embodiment 2.3.20.1: A compound of formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R7 is halogen, preferably F, R8 is selected from CN, R9 is selected from halogen, -C optionally substituted with halogen 3-6 Cycloalkyl and optionally halogen-substituted -C 1-6 Alkyl, and R 10 is selected from halogen and -C optionally substituted by halogen 1-6 alkyl.
[0173] Embodiment 2.3.21: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.20.1 wherein W is -OH.
[0174] Embodiment 2.3.22: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 2.3 to 2.3.20.1 wherein W is -NH2.
[0175] Embodiment 2.3.23: A compound of Formula (I) according to Embodiment 2.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein B is
[0176] Embodiment 3.1: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 2.3.23, wherein G is N.
[0177] Embodiment 3.2: A compound of Formula (I) according to any one of Embodiments 1 to 2.3.23, wherein G is C, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0178] Embodiment 3.3: A compound of formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 3.2, wherein R1 and R1' together form -CH2-, -CH2CH2- or -CH2=CH2-.
[0179] Embodiment 3.4: A compound of formula (I) according to any one of Embodiments 1 to 2.3.23, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein an example of a heterocycle carrying R1 and R1' and containing G is Preferred
[0180] Embodiment 4.1: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 3.4, wherein R2 is H; or R2 is CN.
[0181] Embodiment 4.2: A compound of formula (I) according to any one of Embodiments 1 to 3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 is selected from halogen and -OC optionally substituted by halogen 1-6 Alkyl, such as but not limited to F, Cl, Br, I, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)(CH3), -O-CH2CH2CH2CH3, -O-CH2CH(CH3)CH3, -OC(CH3)3, -O-CH2Cl, -O-CH2F, -O-CHF2, -O-CF3, -O-CCl3, -O-CH2CH2F, -O-CH2CHF2, -O-CH2CF3, -O-CH2CH2CH2F, -O-CH2CH2CHF2, -O-CH2CH2CF3, -OC(CH3)2CF3, -O-C2F5, -O-C2Cl5; preferably -O-CH3; in one embodiment, R2 is selected from -OC 1-6 Alkyl, wherein the alkyl group is optionally substituted by one or more isotopes such as deuterium (D), for example -O-CD3.
[0182] Embodiment 4.2.1: A compound of formula (I) according to any one of Embodiments 1 to 3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 is selected from -C 1-6Alkyl groups, such as but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -C2F5, -C2Cl5; preferably -CH3.
[0183] Embodiment 4.2.2: A compound of formula (I) according to any one of Embodiments 1 to 3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 is selected from -C 2-6 Alkynyl groups, such as but not limited to -C≡CH, -C≡CF, -C≡C-CH3, and -CH2-C≡CH.
[0184] Embodiment 4.3: A compound of formula (I) according to any one of Embodiments 1 to 4.2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R3 is selected from halogen and -OC optionally substituted by halogen 1-6 Alkyl, such as but not limited to F, Cl, Br, I, -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)(CH3), -O-CH2CH2CH2CH3, -O-CH2CH(CH3)CH3, -OC(CH3)3, -O-CH2Cl, -O-CH2F, -O-CHF2, -O-CF3, -O-CCl3, -O-CH2CH2F, -O-CH2CHF2, -O-CH2CF3, -O-CH2CH2CH2F, -O-CH2CH2CHF2, -O-CH2CH2CF3, -OC(CH3)2CF3, -O-C2F5, -O-C2Cl5; preferably R3 is selected from halogen, most preferably F.
[0185] Embodiment 4.3.1: A compound of formula (I) according to any one of Embodiments 1 to 4.2.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R3 is selected from -C 1-6Alkyl groups, such as but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -C2F5, -C2Cl5; preferably -CH3.
[0186] Embodiment 4.4: A compound of formula (I) according to any one of Embodiments 1 to 3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 is H and R3 is halogen, preferably F; or R2 is -C 2-6 Alkynyl, preferably -C≡CH and R3 is halogen, preferably F; or R2 is -OC 1-6 Alkyl, preferably -OCH3, -OCD3, -OCH2CH3 and R3 is halogen, preferably F.
[0187] Embodiment 5.1: A compound of Formula (I) according to any one of Embodiments 1 to 4.4, wherein M is N, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0188] Embodiment 5.2: A compound of formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 4.4, wherein M is C-R4.
[0189] Embodiment 5.2.1: A compound of Formula (I) according to Embodiment 5.2, wherein R4 is H, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0190] Embodiment 5.2.2: A compound of formula (I) according to Embodiment 5.2, wherein R4 is halogen, preferably Cl, F, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0191] Embodiment 5.2.3: A compound of Formula (I) according to Embodiment 5.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R4 is CN.
[0192] Embodiment 5.2.4: A compound of Formula (I) according to Embodiment 5.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R4 is -C1-6 Alkyl, optionally substituted by halogen or CN; for example, but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2Cl, -CH2F, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C(CH3)2CF3, -CH2CN, -CH2CH2CN; preferably -CF3.
[0193] Embodiment 5.2.5: A compound of Formula (I) according to Embodiment 5.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R4 is -(CH2) n -C 3-6 Cycloalkyl, optionally substituted by halogen or CN;
[0194] Embodiment 5.3: A compound of formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 4.4, wherein M is selected from N, CF, C-Cl, C-CN and C-CF3.
[0195] Embodiment 5.4: A compound of formula (I) according to any one of Embodiments 1 to 3.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment wherein M is C-R4, wherein R4 is selected from halogen (preferably F or Cl) or -C 1-6 Alkyl (preferably -CF3), R2 is H and R3 is halogen, preferably F; or M is N, R2 is selected from H, -C 2-6 Alkynyl (preferably -C≡CH) and -OC 1-6 Alkyl (preferably -OCH3, -OCD3, -OCH2CH3), and R3 is halogen, preferably F; specific examples include but are not limited to:
[0196] Embodiment 6.1: A compound of Formula (I) according to Embodiments 1 to 5.4, wherein Y is O, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0197] Embodiment 6.2: A compound of Formula (I) according to any one of Embodiments 1 to 5.4, wherein Y is S, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
[0198] Embodiment 6.3: A compound of Formula (I), stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof according to any one of Embodiments 1 to 5.4, wherein Y is Se.
[0199] Embodiment 7.1: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 6.3, wherein R 14 H; or one or two R 14 It is D.
[0200] Embodiment 7.2: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 6.3, wherein R 14 -C 1-6 Alkyl, optionally substituted with halogen or C 1-6 Alkoxy substitutions; for example, but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2-OCH3, -CH2-O-CH2CH3, -CH2CH2-O-CH3, -CH2CH2-O-CH2CH3, -CH2F, -CH2Cl, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CF(CF3)2.
[0201] Embodiment 7.3: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R 14 -(CH2) n -C 3-6 Cycloalkyl, where C 3- 6 cycloalkyl is optionally substituted with halogen or C 1-6 Alkoxy substitution; for example but not limited to
[0202] Embodiment 7.4: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the two R 14 Together with the carbon atom to which they are attached, they form C 3-4 Cycloalkyl, for example cyclopropyl, cyclobutyl.
[0203] Embodiment 8.1: A compound of formula (I) according to any one of Embodiments 1 to 7.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment In the example, k is 0, then the structural fragment is Wherein Z is selected from N, C, O, S and Se, preferably selected from C, O and Se, such as but not limited to
[0204] Embodiment 8.2: A compound of formula (I) according to any one of Embodiments 1 to 7.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment In the example, k is 1, then the structural fragment is Wherein Z is selected from N, C, O, S and Se, preferably selected from C, O and Se, such as but not limited to
[0205] Embodiment 8.3: A compound of formula (I) according to any one of Embodiments 1 to 8.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R 13 For H.
[0206] Embodiment 8.3.1: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.2, wherein R 13 is halogen, preferably F.
[0207] Embodiment 8.3.2: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.2, wherein R 13 -C 1-6 Alkyl, optionally substituted with halogen or C 1-6 alkoxy substitutions such as, but not limited to, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2-OCH3, -CH2-O-CH2CH3, -CH2CH2-O-CH3, -CH2CH2-O-CH2CH3, -CH2F, -CH2Cl, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CF(CF3)2.
[0208] Embodiment 8.3.3: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.2, wherein R 13 -(CH2) n -C 3-6 Cycloalkyl, where C 3-6 Cycloalkyl is optionally substituted with halogen or C 1-6 Alkoxy substitution; for example but not limited to
[0209] Embodiment 8.3.4: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.2, wherein when R 12 and R 13 When attached to adjacent ring carbon atoms, they form a C3-4 cycloalkyl group together with the carbon atoms to which they are attached, preferably a cyclopropyl group; for example, but not limited to
[0210] Embodiment 8.3.4: A compound of formula (I) according to any one of Embodiments 1 to 8.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl.
[0211] Embodiment 8.4: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.3.4, wherein R 11 For H.
[0212] Embodiment 8.4.1: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.3.4, wherein R 11 -C 1-6 Alkyl, optionally substituted with halogen, CN, -C 1-6 Alkoxy or -O-CON(R a )2 is substituted, preferably optionally by halogen or -C 1-6 Alkoxy substitutions; for example, but not limited to -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2-OCH3, -CH2-O-CH2CH3, -CH2CH2-O-CH3, -CH2CH2-O-CH2CH3, -CH(CH3)CH2-OCH3, -CH2CH(CH3)- OCH3, -CH2F, -CH2Cl, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CHF2, -CH(CH3)F, -CH(CH3)CH2F, -CH2CH(CH3 )F, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CF(CF3)2, -CH2CN, -CH2CH2CN,
[0213] Embodiment 8.4.1.1: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.3.4, wherein R 11 -C 1-6 Alkyl groups in which hydrogen atoms are replaced by one or more isotopes D, such as -CD3.
[0214] Embodiment 8.4.2: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.3.4, wherein R 11 -C 2-6 Alkenyl or -C 2-6 Alkynyl, optionally substituted by halogen, CN, -C 1-6 Alkoxy or -O-CON(R a ) 2 substituted; for example, but not limited to vinyl, propenyl, ethynyl, each optionally substituted with halogen or -C 1-6 Alkoxy substitution.
[0215] Embodiment 8.4.3: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.3.4, wherein R 11 -(CH2) n -C 3-6 Cycloalkyl, the -C 3- 6 cycloalkyl is optionally substituted with halogen, CN, -C 1-6 Alkoxy or -O-CON(R a )2 replaced; for example but not limited to
[0216] Embodiment 8.4.4: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.3.4, wherein R 11 -C 1-6 Alkyl, optionally substituted by halogen or -C 1- 6 alkoxy substituted; for example -CH3, -CH2CH2-O-CH3, -CH2CH2F; or R 11 -C 1-6 Alkyl, wherein one or more hydrogen atoms are replaced by an isotope D, preferably -CD3.
[0217] Embodiment 8.5: A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof according to any one of Embodiments 1 to 8.4.4, wherein R 12 For H.
[0218] Embodiment 8.5.1: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 is halogen, such as F, Cl, Br, I, preferably F.
[0219] Embodiment 8.5.2: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 -N(R a )2, for example -NH2, -NHCH3, -N(CH3)2, N(CH3)(CH2CH3).
[0220] Embodiment 8.5.3: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.4.4, wherein R12 It is -OH.
[0221] Embodiment 8.5.4: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 For-OC 1-6 Alkyl, where C 1-6 The alkyl group is optionally substituted with halogen, CN or C 1-6 Alkoxy substitution; for example, but not limited to -O-CH3, -O-CH2CH3, -O-CH2CH2CH3, -O-CH(CH3)(CH3), -O-CH2CH2CH2CH3, -O-CH2CH(CH3)CH3, -OC(CH3)3, -O-CH2Cl, -O-CH2CN, -O-CH2F, -O-CHF2, -O-CF3, -O-CCl3, -O-CH2CH2F, -O- CH2CH2CN, -O-CH2CHF2, -O-CH2CF3, -O-CH2CH2CH2F, -O-CH2CH2CHF2, -O-CH2CH2CF3, -OC(CH3)2CF 3. -O-C2F5, -O-C2Cl5, -O-CH2-OCH3, -O-CH2-O-CH2CH3, -O-CH2CH2-O-CH3, -O-CH2CH2-O-CH2CH3.
[0222] Embodiment 8.5.5: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.4.4, wherein R 12 -C 1-6 Alkyl, optionally substituted by halogen, CN or C 1-6 Alkoxy substitutions, such as, but not limited to, -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)(CH3), -CH2CH2CH2CH3, -CH2CH(CH3)CH3, -C(CH3)3, -CH2-OCH3, -CH2-O-CH2CH3, -CH2CH2-O-CH3, -CH2CH2-O-CH2CH3, -CH2F, -CH2Cl, -CH2CN, -CHF2, -CF3, -CCl3, -CH2CH2F, -CH2CH2CN, -CH2CHF2, -CH2CF3, -CH2CH2CH2F, -CH2CH2CHF2, -CH2CH2CF3, -C2F5, -C2Cl5, -CF(CF3)2.
[0223] Embodiment 8.5.6: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.4.4, wherein R 12 For-OC 3-6 Cycloalkyl, wherein C 3-6 Cycloalkyl is optionally substituted with halogen, CN or C 1-6 Alkoxy substitution; for example but not limited to
[0224] Embodiment 8.5.7: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 -(CH2) n -C 3-6 Cycloalkyl, optionally substituted by halogen, CN or C 1-6 Alkoxy substitutions, such as but not limited to
[0225] Embodiment 8.5.8: A compound of formula (I) according to any one of Embodiments 1 to 8.4.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the two R 12 Together with the carbon atoms to which they are attached, they form a C3-4 cycloalkyl group, preferably a cyclopropyl group; for example, but not limited to
[0226] Embodiment 8.5.9: A compound of formula (I) according to any one of Embodiments 1 to 8.4.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the two R 12 Together they form a bridged methylene or ethylene group.
[0227] Embodiment 8.5.10: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 For CN.
[0228] Embodiment 8.5.11: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 -C 2-6 Alkenyl or -C 2-6Alkynyl, optionally substituted by halogen, CN or -C 1-6 Alkoxy substituted; for example but not limited to each optionally substituted with halogen, CN or -C 1-6 Alkoxy-substituted vinyl, propenyl, ethynyl.
[0229] Embodiment 8.5.12: A compound of formula (I) according to any one of Embodiments 1 to 8.4.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the two R 12 Formation = C (R c )2, where R c Each independently selected from H, F, Cl, Br, I, -C 1-6 Alkyl; for example, but not limited to, =CH2, =CF2, =CCl2, =C(CH3)2, =C(CF3)2.
[0230] Embodiment 8.5.13: A compound of formula (I) according to any one of Embodiments 1 to 8.4.4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the two R 12 Forming spiral C 3-6 Cycloalkyl or spiro 4-7 membered heterocycloalkyl, such as but not limited to spirocyclopropyl, spirocyclobutyl, spirocyclopentyl, spiroazetidine, spiroazetidine, optionally halogen (preferably F) or C optionally substituted by halogen 1-6 Alkyl (preferably -CF3) substitution.
[0231] Embodiment 8.5.14: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof, according to any one of Embodiments 1 to 8.4.4, wherein R 12 Selected from H, halogen, -OH, N(R a )2. -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, where each occurrence of C 1-6 Alkyl or C 3- 6 cycloalkyl groups are each independently optionally substituted with halogen or -OC 1-6 Alkyl substitution,
[0232] or two R attached to adjacent ring carbon atoms 12 Together with the carbon atom to which they are attached, they form a C3-4 cycloalkyl group,
[0233] or two R attached to non-adjacent ring carbon atoms12 Together they form a bridged methylene or ethylene group.
[0234] Embodiment 8.5.15: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.4.4, wherein R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, such as but not limited to H, F, CN, -C≡CH, -CH2F, -CHF2, -O-CH3; or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 Alkyl groups, such as but not limited to =CH2, =CF2, =CCl2, =C(CH3)2, =C(CF3)2.
[0235] Embodiment 8.5.16: A compound of formula (I), a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt, or solvate thereof according to any one of Embodiments 1 to 8.5.15, wherein R 12 The ring carbon atom connected to R 13 The carbon atoms to which they are attached are adjacent to and 11 Not adjacent, that is Preferred
[0236] Embodiment 9.1: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment wherein Z is selected from C, O and Se; k is 0 or 1; R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl; R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C1-6 Alkyl; R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl; and R 14 is H; or Z is selected from C, O and Se; k is 0 or 1; R 11 -C substituted with one or more hydrogen isotopes such as D 1-6 Alkyl; R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 Alkyl; R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl; and R 14 It is H or a hydrogen isotope such as D.
[0237] Embodiment 9.2: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment Examples include but are not limited to
[0238] Embodiment 9.3: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment for For example where R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (Rc )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; and / or R 14 are each independently selected from H and D; and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; wherein R 12 Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl;
[0239] In one embodiment, the structural fragment is where R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; R 12 Specific examples include fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0240] Embodiment 9.4: A compound of formula (I) according to any one of Embodiments 1 to 6.3, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein the structural fragment for For example where R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; and / or R 14 are each independently selected from H and D; and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; wherein R 12 Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl;
[0241] In one embodiment, the structural fragment is where R 11 For optional -OC 1-6 Alkyl or halogen substituted -C 1-6 Alkyl, -C 2-6 Alkenyl or -C 3-6 Cycloalkyl, examples include methyl, ethyl, cyclopropyl, propenyl, isopropyl, fluoroethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; R 12 Specific examples include fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0242] Embodiment 10.1: A compound of Formula (I) according to Embodiment 1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, having the following sub-formula:
[0243] wherein each substituent has the meaning defined in the above respective embodiments.
[0244] Embodiment 10.1.1: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein:
[0245] Y is O;
[0246] G is CH or N;
[0247] M is C-R4;
[0248] Z is selected from C, Se and O;
[0249] W is -OH or -NH2;
[0250] R1 and R1' together form -(CH2) t -;
[0251] R2 is H;
[0252] R3 is halogen;
[0253] R4 is halogen;
[0254] R5 is selected from H and halogen;
[0255] R6 is selected from halogen, -C 1-6 Alkyl and -C 2-6 Alkynyl;
[0256] R7 and R8 are each independently selected from H, halogen, CN and NO2;
[0257] R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 alkyl;
[0258] R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 alkyl;
[0259] R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl;
[0260] R 14 is H;
[0261] k is selected from 0 or 1;
[0262] m and n are each independently selected from integers from 0 to 2; and
[0263] t is selected from 1 or 2.
[0264] Embodiment 10.1.2: A compound of Formula (I) according to Embodiment 10.1 or 10.1.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein
[0265] in:
[0266] Z is selected from C and O;
[0267] W is -OH or -NH2;
[0268] R5 is selected from H and halogen, preferably halogen, most preferably F;
[0269] R6 is selected from halogen, -C 1-6 Alkyl and -C 2-6 Alkynyl, preferably -C 2-6Alkynyl, most preferably ethynyl;
[0270] R8 is selected from H and halogen, preferably H or F;
[0271] R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl, preferably -CH3, -CH2CH3, -CH2CH2-O-CH3, -CH2CH2-OF;
[0272] R 12 Selected from H, halogen, CN, optionally halogen-substituted -C 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, preferably H, F, CN, -C≡CH, -CH2F, -CHF2, CH3 and -O-CH3, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 Alkyl, preferably =CH2, =CF2, =CCl2, =C(CH3)2, =C(CF3)2;
[0273] R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 Alkyl, preferably H, F and -CH3;
[0274] k is selected from 0 or 1; and
[0275] m is selected from integers of 0 to 2.
[0276] Embodiment 10.1.3: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0277] For example Wherein R5 is halogen, preferably F; and / or R6 is -C 2-6 Alkynyl, preferably ethynyl; and / or R4 is halogen, preferably F; and / or R 14 are each independently selected from H and D; and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C optionally substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; specifically, wherein
[0278] where R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0279] Embodiment 10.1.4: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0280] where R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl, -C 2-6 Alkenyl or -C 3-6 Cycloalkyl, examples include methyl, ethyl, cyclopropyl, propenyl, isopropyl, fluoroethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; R 12 Specific examples include fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; or
[0281] where R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; R 12Specific examples include fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; and / or two R not shown 14 The H is replaced by D.
[0282] Embodiment 10.1.5: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0283] For example Among them, R2, R5, R6, R 13 、R 14 、R 11 and R 12 Each is as generally or specifically defined above for each corresponding embodiment; preferably, R5 is halogen, preferably F; and / or R6 is -C 2-6 Alkynyl, preferably ethynyl; and / or R 14 are each independently selected from H and D; R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R2 is selected from H, -C 2-6 Alkynyl, optionally substituted by halogen or D- 1-6 alkyl and -OC optionally substituted by halogen or D 1-6 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1- 6-alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably -CD3, methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C optionally substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where Rc are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; specifically, wherein
[0284] R2 is selected from H, -C optionally substituted by halogen or D 1-6 Alkyl, -C 2-6 Alkynyl and -OC optionally substituted by halogen or D 1-6 Alkyl, wherein R2 is preferably selected from H, -C 2-6 Alkynyl and -OC optionally substituted by halogen or D 1-6 Alkyl; and / or R 11 is optionally labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0285] Embodiment 10.1.6: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0286] Among them, R2, R 11 and R 12 Each is as generally or specifically defined above for each corresponding embodiment; preferably R2 is selected from H, -C1-6 Alkyl and optionally halogen-substituted -OC 1-6 Alkyl; R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl, -C 2-6 Alkenyl or -C 3-6 Cycloalkyl, examples include methyl, ethyl, cyclopropyl, propenyl, isopropyl, fluoroethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; R 12 Specific examples include fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; or
[0287] Preferably R2 is selected from H, -C 1-6 Alkyl, -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl; R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; R 12 Specific examples include fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; and / or two R not shown 14 The H is replaced by D.
[0288] Embodiment 10.1.7: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0289] For example Among them, W, R4, R7, R8, R 13 、R 14 、R 11 and R 12 Each is as generally or specifically defined in each corresponding embodiment above; preferably, R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 14 are each independently H or D; and / or W is selected from H, -C 1-6 and / or R7 and R8 are both H, or both are halogen (preferably F), or one of them is H and the other is halogen (preferably F), or one of them is H and the other is halogen (preferably F) substituted C 1-6 and / or R4 is selected from halogen (preferably F or Cl), CN and -C substituted by halogen (preferably F) 1-6 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably -CD3, methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C optionally substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; specifically, wherein W is selected from H and halogen; and / or R7 and R8 are both H, or both are halogen (preferably F), or one of them is H and the other is halogen (preferably F), or one of them is H and the other is halogen (preferably F) substituted C 1-6 Alkyl; and / or R 11 is optionally labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F; wherein R 12 Preferably selected from -C substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0290] Embodiment 10.1.8: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0291] Among them, W, R7, R8, R 11 and R 12 Each is as generally or specifically defined above for each corresponding embodiment; preferably W is selected from H and halogen; R7 and R8 are both H, or both are halogen, or one of them is H and the other is halogen, or one of them is H and the other is halogen-substituted C 1-6 Alkyl; R 11 For optional -OC 1-6Alkyl or halogen substituted -C 1-6 Alkyl, preferably -C 1-3 Alkyl, preferably methyl, ethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F; R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; or preferably
[0292] W is selected from H and halogen; R7 and R8 are both H, or both are halogen, or one of them is H and the other is halogen, or one of them is H and the other is halogen-substituted C 1-6 Alkyl; R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2- 6 alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F; R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; and / or two R not shown 14 The H is replaced by D.
[0293] Embodiment 10.1.9: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0294] For example Among them, W, R2, R7, R8, R 13 、R 14 、R 11 and R 12 Each is as generally or specifically defined in each corresponding embodiment above; preferably, R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 14 are each independently H or D; and / or W is selected from H, -C 1-6 and / or R7 and R8 are both H, or both are halogen (preferably F), or one of them is H and the other is halogen (preferably F), or one of them is H and the other is halogen (preferably F) substituted C 1-6 Alkyl; and / or R2 is selected from H, -C 2-6 Alkynyl, optionally substituted by halogen or D 1-6 alkyl and -OC optionally substituted by halogen or D 1-6 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably -CD3, methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C optionally substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; specifically, wherein
[0295] W is selected from H and halogen; and / or R7 and R8 are both H, or both are halogen (preferably F), or one of them is H and the other is halogen (preferably F), or one of them is H and the other is halogen (preferably F) substituted C 1-6 and / or R2 is selected from H, -C optionally substituted by halogen or D 1-6 Alkyl, -C 2-6 Alkynyl and -OC optionally substituted by halogen or D 1-6 Alkyl, wherein R2 is preferably selected from H, -C 2-6 Alkynyl and -OC optionally substituted by halogen or D 1-6 Alkyl; and / or R 11 is optionally labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1- 6-alkyl, optionally substituted by halogen 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C substituted by halogen (preferably F) 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen (preferably F); R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0296] Embodiment 10.1.10: A compound of Formula (I) according to Embodiment 10.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0297] Among them, W, R2, R7, R8, R 11 and R 12Each is as generally or specifically defined above for each corresponding embodiment; preferably W is selected from H and halogen; R7 and R8 are both H, or both are halogen, or one of them is H and the other is halogen, or one of them is H and the other is halogen-substituted C 1-6 Alkyl; R2 is selected from H, optionally substituted by halogen -C 1-6 Alkyl and optionally halogen-substituted -OC 1-6 Alkyl; R 11 For optional -OC 1-6 Alkyl or halogen substituted -C 1-6 Alkyl, preferably -C 1-3 Alkyl, preferably methyl, ethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F; R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; or preferably
[0298] W is selected from H and halogen; R7 and R8 are both H, or both are halogen, or one of them is H and the other is halogen, or one of them is H and the other is halogen-substituted C 1-6 Alkyl; R2 is selected from H, optionally substituted by halogen -C 1-6 Alkyl, -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl; R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3- 6-cycloalkyl, where R care each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F; R 12 Specific examples include, but are not limited to, fluorine, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, dimethyl; and / or two R not shown 14 The H is replaced by D.
[0299] Embodiment 10.2: A compound of Formula (I) according to Embodiment 1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, having the following sub-formula:
[0300] wherein each substituent has the meaning defined in the above respective embodiments.
[0301] Embodiment 10.2.1: A compound of Formula (I) according to Embodiment 10.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein:
[0302] Y is O;
[0303] G is CH or N;
[0304] M is C-R4;
[0305] Z is selected from C, Se and O;
[0306] W is -OH or -NH2;
[0307] R1 and R1' together form -(CH2) t -;
[0308] R2 is H;
[0309] R3 is halogen;
[0310] R4 is halogen;
[0311] R7 is H;
[0312] R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6alkyl;
[0313] R9 is selected from -Si(R b )3. -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, -Se- 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substituted, and R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl, each optionally substituted with halogen;
[0314] R 10 Selected from halogen and -C 1-6 alkyl;
[0315] R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 alkyl;
[0316] R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 alkyl;
[0317] R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl;
[0318] R 14 is H;
[0319] k is selected from 0 or 1;
[0320] m and n are each independently selected from integers from 0 to 2; and
[0321] t is selected from 1 or 2.
[0322] Embodiment 10.2.2: A compound of Formula (I) according to Embodiment 10.2 or 10.2.1, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, having the following sub-formula:
[0323] in:
[0324] Z is selected from C and O;
[0325] W is -OH or -NH2;
[0326] R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 alkyl;
[0327] R9 is selected from -Si(R b )3. -C 1-6 Alkyl and -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or -Se-C 1-6 Alkyl substituted, and R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl;
[0328] R 10 Selected from halogen and -C 1-6 Alkyl, preferably Cl and -CH3;
[0329] R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 Alkyl, preferably -C 1-6 Alkyl, more preferably -CH3;
[0330] R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC 1-6 Alkyl, preferably H, F, CN, -C≡CH, -CH2F, -CHF2, CH3 and -O-CH3, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6Alkyl, preferably =CH2, =CF2, =CCl2, =C(CH3)2, =C(CF3)2;
[0331] R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 Alkyl, preferably H, F and -CH3;
[0332] R 14 is H;
[0333] k is selected from 0 or 1; and
[0334] m is selected from integers of 0 to 2.
[0335] Embodiment 10.2.3: A compound of Formula (I) according to Embodiment 10.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0336] For example Among them, R7, R 10 、R 13 、R 14 、R 11 and R 12 Each is as generally or specifically defined in each corresponding embodiment above; preferably, R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 14 are each independently H or D; and / or R7 is selected from H and halogen; and / or R 10 Selected from -C 1-6 Alkyl and halogen; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably -CD3, methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; wherein the halogen is preferably F or Cl; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0337] Embodiment 10.2.4: A compound of Formula (I) according to Embodiment 10.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0338] Among them, R7, R 10 、R 11 and R 12 Each is as generally or specifically defined above for each corresponding embodiment; preferably R7 is selected from H and halogen; R 10 Selected from -C 1-6 Alkyl and halogen; R 11 For optional -OC 1-6 Alkyl or halogen substituted -C 1-6 Alkyl, preferably -C 1-3 Alkyl, preferably methyl, ethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F or Cl; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0339] Embodiment 10.2.5: A compound of Formula (I) according to Embodiment 10.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0340] For example Among them, R2, R7, R 10 、R 13 、R 14 、R 11 and R 12 Each is as generally or specifically defined in each corresponding embodiment above; preferably, R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 14 are each independently H or D; and / or R2 is selected from H, -C 2- 6 alkynyl, optionally substituted by halogen or D 1-6 alkyl and -OC optionally substituted by halogen or D 1-6 Alkyl; and / or R7 is selected from H and halogen; and / or R 10 Selected from -C 1-6 Alkyl and halogen; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl, preferably -CD3, methyl, ethyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein R 12 Preferably selected from -C 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H and halogen; wherein the halogen is preferably F or Cl; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0341] Embodiment 10.2.6: A compound of Formula (I) according to Embodiment 10.2, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, which is of the following formula:
[0342] Among them, R2, R7, R 10 、R 11 and R 12 Each is as generally or specifically defined above for each corresponding embodiment; preferably R2 is selected from H, -C 1-6 Alkyl and optionally halogen-substituted -OC 1-6 Alkyl; R7 is selected from H and halogen; R 10 Selected from -C 1-6 Alkyl and halogen; R 11 For optional -OC 1- 6-alkyl or halogen-substituted-C 1-6 Alkyl, preferably -C 1-3 Alkyl, preferably methyl, ethyl; R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; wherein the halogen is preferably F or Cl; R 12 Specific examples include, but are not limited to, fluoro, fluoromethyl, difluoromethyl, methyl, methoxy, ethynyl, cyano, fluoromethylene, difluoromethylene, methylene, difluoro, spirocyclopropyl, and dimethyl.
[0343] Embodiment 10.2.7: A compound of Formula (I) according to Embodiment 10.2 or 10.2.6, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R 11 is labeled with one or more hydrogen isotopes such as D-C 1-6 Alkyl, preferably -CD3 alkyl; and / or two R 14 The H is replaced by D.
[0344] Embodiment 11: A compound selected from the following example compounds or pharmaceutically acceptable salts or solvates thereof.
[0345] It should be noted that the compounds of the present invention encompass the above independent embodiments or specific embodiments, and also encompass embodiments consisting of any combination or sub-combination of the above embodiments or specific embodiments, and also encompass embodiments consisting of any combination of any preferred or exemplary embodiments above.
[0346] Advantageous Effects of the Invention
[0347] As mentioned above, Ras mutant proteins, especially KRas mutant proteins, are known to play a role in tumorigenesis and various other diseases. We have surprisingly found that the compounds of the present invention having the above-mentioned structural characteristics can potently inhibit cell proliferation in cell lines carrying KRas mutant proteins (such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), especially KRas-G12D mutant proteins, and thus have potential value as anti-proliferative, pro-apoptotic and / or anti-invasive drugs in preventing, suppressing and / or treating related tumor diseases. In particular, the compounds of the present invention are expected to be useful for preventing or treating diseases or conditions mediated by or that are inhibited by Ras mutants (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), especially KRas-G12D mutants, such as cancer or tumors as defined herein.
[0348] Specifically, it has been found through research that the compounds of the present invention can achieve one or more of the following technical effects:
[0349] ● High mutant protein inhibitory activity: The compounds of the present invention, especially the compounds specifically exemplified herein, show proliferation inhibitory activity against KRas G12D mutant cells in a KRAS G12D mutant cell AGS cell proliferation inhibition assay, with an IC50 value of 10 pM to 10 μM, for example, 10 pM to 5 μM, 100 pM to 5 μM, 500 pM to 1 μM, 0.001 to 10 μM, 100 pM to 1 μM, 100 pM to 0.5 μM, 0.001 to 5 μM, 0.01 to 1 μM, preferably 100 pM to 1 μM, 0.001 to 0.5 μM, more preferably 100 pM to 0.5 μM, 0.001 to 0.1 μM, and most preferably 1 to 50 nM, 100 pM to 0.1 μM, as shown in Activity Example 1;
[0350] The compounds of the present invention, especially the compounds specifically exemplified herein, also show potent proliferation inhibitory activity against KRas G12D mutant cells in the KRAS G12D mutant cell AGS (3D) cell proliferation inhibition assay, with an IC50 value of 0.001 to 5 μM, for example 0.001 to 1 μM, preferably 0.001 to 0.5 μM, more preferably 0.001 to 0.1 μM, and most preferably less than 1 to 50 nM, as shown in Activity Example 5;
[0351] ●Good pharmacokinetic properties, such as a long t 1 / 2 , which can, for example, increase the dosing interval, extend the half-life, and enable better patient compliance; have the best AUC for the safety / activity combination effect 0-t Data, with better drugability and higher bioavailability, as shown in Active Example 2; and
[0352] ● have a significantly satisfactory safety profile, reduced risk of drug interactions, and no significant inhibitory effects on key CYP isoforms of drug metabolism, as shown in Active Example 3; and
[0353] ● It has excellent in vivo pharmacodynamic properties, significantly inhibiting tumor volume while having good safety, such as demonstrating excellent target-related tumor inhibitory activity in the human pancreatic cancer AsPC-1 xenograft mouse model and the human pancreatic cancer cell HPAC subcutaneous xenograft tumor NOD / SCID mouse model, without significant changes in mouse body weight, as shown in Activity Examples 4 and 7.
[0354] Based on the beneficial effects of the above compounds of the present invention, the present invention also provides the following technical solutions in various aspects.
[0355] Compounds of the invention for use in therapy or as medicine
[0356] In one aspect, the present invention provides a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, for use as a medicament.
[0357] In another aspect, the present invention provides a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, for use as an inhibitor of KRas mutant proteins (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), more specifically a RAS G12D inhibitor.
[0358] On the other hand, the present invention provides a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, for use in treating and / or preventing diseases or conditions mediated by or inhibited by Ras mutations, particularly KRas mutants (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), more particularly KRAS G12D mutant proteins.
[0359] In a specific embodiment, the present invention provides a method for treating and / or preventing Ras mutant proteins, specifically KRas mutant proteins (such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), more specifically KRAS G12D mutant proteins, which promote the occurrence and development of the disease or inhibit Ras mutant proteins, specifically KRas mutant proteins (such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutant proteins), more specifically KRAS The G12D mutant protein will reduce the incidence of, reduce or eliminate the symptoms of a disease, such as a tumor or cancer, including but not limited to: lung cancer, lung adenocarcinoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor (CNS), primary CNS lymphoma, spinal tumor, brain stem glioma or pituitary adenoma.
[0360] The present invention particularly provides a compound of formula (I) or its isomers, pharmaceutically acceptable salts or solvates thereof, which can be used to treat patients suffering from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, lung cancer, bile duct cancer, endometrial cancer, ovarian cancer, leukemia; most preferably selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, bile duct cancer.
[0361] Pharmaceutical compositions and their administration
[0362] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of formula (I) as defined above, preferably a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition of the present invention can be used to treat or prevent diseases mediated by Ras mutations, especially KRas mutations, such as KRas G12C, KRas G12D, KRas G12V, G12A, G12R, G12S or KRas G13D mutations, especially KRas G12D mutations, such as tumors or cancers.
[0363] The pharmaceutical compositions of the present invention can be formulated by techniques known to those skilled in the art, such as those disclosed in Remington's Pharmaceutical Sciences, 20th edition. For example, they can be formulated as tablets, powders, capsules, lozenges, granules, solutions, dispersants, suspensions, syrups, sprays, suppositories, gels, emulsions, patches, etc. The compositions can contain conventional components in pharmaceutical preparations, such as diluents (e.g., glucose, lactose, or mannitol), carriers, pH regulators, buffers, sweeteners, fillers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifiers, glidants, processing aids, colorants, flavorings, flavorings, other known additives, and other active agents. Suitable carriers and excipients are well known to those skilled in the art and are described in detail in, for example, Ansel, Howard C., et al., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems. Philadelphia: Lippincott, Williams & Wilkins, 2004.
[0364] The administration and use of the pharmaceutical compositions of the present invention are in accordance with good medical practice. Factors to be considered in this context include the specific disorder being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the location of the agent delivery, the method of administration, the administration schedule, and other factors well known to physician practitioners. The optimal dosage level and frequency of administration of the compounds of the present invention or pharmaceutical compositions can be determined by those skilled in the art through standard tests in the field of pharmaceutical research.
[0365] The compositions of the present invention can be administered in any suitable manner, including oral, topical (including buccal and sublingual), rectal, vaginal, transdermal, parenteral, subcutaneous, intraperitoneal, intrapulmonary, intradermal, intrathecal, inhalation, epidural, and intranasal, and for local treatment, intralesional administration can also be employed. Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. In some embodiments, the pharmaceutical compositions of the present invention are administered orally.
[0366] For a 70 kg human subject, a suitable dosage range of the compound of the present invention can be routinely determined by those skilled in the art, and may be, for example, 1-1000 mg / day.
[0367] When dosages of a drug or a pharmaceutically acceptable salt thereof are described herein, it is understood that the dosage is based on the weight of the free base and does not include any hydrate or solvate thereof unless the specification indicates that the dosage is based on the weight of the salt, hydrate or solvate.
[0368] Treatment methods and uses
[0369] As described above, the compounds of the present invention and the compounds of various specific embodiments thereof, especially the compounds specifically prepared and characterized in the Examples, show an inhibitory effect on Ras mutations, especially KRas mutations, such as KRas G12C, KRas G12D, KRas G12V, G12A, G12R, G12S or KRas G13D mutations, especially KRas G12D.
[0370] Therefore, on the other hand, the present invention provides a method for inhibiting Ras mutations, especially KRas mutations, preferably KRas G12D mutations in cells, comprising contacting the cells with a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, to inhibit the activity of Ras mutations, especially KRas mutations (e.g., G12C mutations, G12D mutations, G12V mutations, G12A mutations, G12R mutations, G12S mutations and G13D mutations), preferably KRas G12D mutations in the cells.
[0371] Based on the same properties, the present invention also provides a method for inhibiting abnormal cell growth in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof.
[0372] On the other hand, the present invention provides a method for treating and / or preventing diseases mediated by Ras mutations, especially KRas mutations (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), preferably KRas G12D mutation, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof.
[0373] On the other hand, the present invention provides the use of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, for inhibiting Ras mutations in cells, especially KRas mutations, preferably KRas G12D mutations, or for inhibiting abnormal cell growth in mammals, or for treating and / or preventing diseases mediated by Ras mutations, especially KRas mutations, preferably KRas G12C, KRas G12D, KRas G12V, KRasG12A, KRasG12R, KRasG12S or KRas G13D, most preferably KRas G12D mutations.
[0374] On the other hand, the present invention provides the use of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, in the preparation of a medicament for treating and / or preventing diseases mediated by Ras mutations, especially KRas mutations (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), preferably KRas G12D mutation.
[0375] For the various methods and use technical solutions provided by the present invention, the abnormal cell growth or the disease mediated by Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D, KRas G12V, KRasG12A, KRasG12R, KRasG12S or KRas G13D, most preferably KRas G12D mutation, especially refers to cancer or tumor. Exemplary such cancers or tumors include, but are not limited to, lung cancer, lung adenocarcinoma, bone cancer, pancreatic cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumor (CNS), primary CNS lymphoma, spinal tumor, brain stem glioma, or pituitary adenoma.
[0376] For the various methods and use technical solutions provided by the present invention, the abnormal cell growth or the disease mediated by Ras mutation, especially KRas mutation (such as G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation and G13D mutation), preferably KRas G12D, is preferably selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, lung cancer, bile duct cancer, endometrial cancer, ovarian cancer, and leukemia; most preferably selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, and bile duct cancer.
[0377] Therefore, in a preferred embodiment of this aspect, the present invention provides the above-mentioned methods and uses for treating or preventing cancer or tumors by inhibiting KRas G12V and / or KRas-G12D mutations. In a further preferred embodiment, the present invention provides the above-mentioned methods and uses for treating or preventing pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, and bile duct cancer by inhibiting KRas-G12D mutations.
[0378] The present invention also provides the use of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, as a KRas inhibitor (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation, and G13D mutation inhibitor) in research, in particular as a research tool compound for inhibiting KRas G12D. Therefore, the present invention relates to the in vitro use of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, as a KRas inhibitor, in particular a KRas G12D inhibitor, and in particular to the in vitro use of a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, as a research tool compound for the effectiveness of a KRas inhibitor, in particular a KRas G12D inhibitor. The present invention also relates to methods of inhibiting KRas (e.g., G12C mutation, G12D mutation, G12V mutation, G12A mutation, G12R mutation, G12S mutation, and G13D mutation), in particular KRas G12D, in particular in vitro methods, which comprise administering a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, to a sample (e.g., a biological sample). It should be understood that the term "in vitro" in this particular context is used in the sense of "outside a living human or animal body," which specifically includes experiments conducted with cells, cellular or subcellular extracts, and / or biomolecules in an artificial environment, such as aqueous solutions or culture media that can be provided in flasks, test tubes, culture dishes, microtiter plates, etc.
[0379] Drug combinations
[0380] The compounds of the present invention may be administered as the sole active ingredient or in combination with another drug or therapy.
[0381] Therefore, in another aspect, the present invention provides a drug combination comprising a compound of the present invention, preferably a pharmaceutically acceptable salt or solvate thereof, and another active agent, or consisting of both. The drug combination is used to inhibit abnormal cell growth in mammals, or to treat and / or prevent diseases mediated by Ras mutations, preferably KRas mutations (e.g., G12C mutations, G12D mutations, G12V mutations, G12A mutations, G12R mutations, G12S mutations, and G13D mutations), most preferably KRas-G12D mutations.
[0382] The other active agent may be one or more additional compounds of the present invention, or may be a second or additional (e.g., a third) compound that is compatible with the compounds of the present invention, i.e., does not adversely affect each other, or has complementary activities. For example, these active agents may be compounds that are known to regulate other biological activity pathways, or may be compounds that regulate different components in the biological activity pathways involved in the compounds of the present invention, or even compounds that overlap with the biological targets of the compounds of the present invention.
[0383] In a specific embodiment, other active agents that can be used in combination with the compounds of the present invention include, but are not limited to, chemotherapeutic agents, therapeutic antibodies, and radiotherapy, such as alkylating agents, antimetabolites, cell cycle inhibitors, mitotic inhibitors, topoisomerase inhibitors, antihormonal drugs, angiogenesis inhibitors, and cytotoxic agents.
[0384] Other active agents used in combination with the present invention can be administered simultaneously, separately or sequentially with the compounds of the present invention by the same or different routes of administration. The other active agents can be co-administered with the compounds of the present invention in a single pharmaceutical composition, or administered separately in different discrete units from the compounds of the present invention, such as a combination product, preferably in the form of a kit, which can be administered simultaneously or sequentially when administered separately, and the sequential administration can be close or distant in time. They can be prepared and / or formulated by the same or different manufacturers. Moreover, the compounds of the present invention and the other active agents can be (i) administered before the combination product is sent to the physician (e.g., in the case of a kit comprising the compounds of the present invention and another drug); (ii) administered by the physician himself (or under the guidance of a physician) before administration; (iii) administered by the patient himself, e.g., during the sequential administration of the compounds of the present invention and the other active agents, in a combination therapy.
[0385] The compounds of the present invention may also be combined with anti-tumor therapies including, but not limited to, surgery, radiation therapy, transplantation (eg, stem cell transplantation, bone marrow transplantation), tumor immunotherapy, chemotherapy, and the like.
[0386] Therefore, in another aspect, the present invention also provides a kit comprising two or more separate pharmaceutical compositions, at least one of which comprises a compound of the present invention or a pharmaceutically acceptable salt or solvate thereof, and a device for separately containing the compositions, such as a container, a sub-bottle, or a separate foil package, such as a blister pack for packaging tablets, capsules, etc., and instructions for use. The kit of the present invention is particularly suitable for administering different dosage forms, such as an oral dosage form and a parenteral dosage form, or for administering different compositions at different dosage intervals.
[0387] For the technical solutions of the above-mentioned pharmaceutical composition, drug combination or drug kit of the present invention, the abnormal cell growth involved or the disease mediated by Ras mutation, especially KRas mutation, preferably KRas G12C, KRas G12D, KRas G12V, KRas G12A, KRas G12R, KRas G12S or KRas G13D, most preferably KRas G12D mutation is as defined above for the method and use of the present invention.
[0388] For the above-mentioned compounds, pharmaceutical compositions, methods, uses, pharmaceutical combinations and kits of the present invention, the compounds of the Examples herein are preferred.
[0389] Preparation method of the compound of the present invention
[0390] In another aspect, the present invention also provides a method for preparing the compound defined in the present invention.
[0391] The compounds of the present invention can be prepared by a variety of methods, including the general methods given below, the methods disclosed in the Examples, or methods analogous thereto.
[0392] Standard synthetic methods and operations for preparing organic compounds and functional group conversions and operations are known in the art and can be found in standard textbooks, such as Smith MB, "March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure", 7th edition, Wiley, 2013). For each reaction step of each general synthetic scheme, appropriate reaction conditions are known to those skilled in the art or can be routinely determined. The method steps for synthesizing the compounds of the present invention can be under reaction conditions known per se (including those conditions specifically mentioned), in the absence or conventional presence of a solvent or diluent (including, for example, a solvent or diluent that is inert and soluble to the reagents used), in the absence or presence of a catalyst, a condensing agent or a neutralizing agent (such as an ion exchanger, such as a cation exchanger, such as H +The reaction is carried out at reduced, normal or elevated temperature (e.g., from about -100°C to about 190°C, including, for example, from about -78°C to about 150°C, such as from about 0°C to about 125°C, room temperature, -20 to 40°C or reflux temperature), under atmospheric pressure or in a closed vessel, under pressure when appropriate, and / or under an inert atmosphere, such as an argon or nitrogen atmosphere, depending on the nature of the reaction and / or the reactants.
[0393] Unless otherwise specified, the raw materials and reagents used in the preparation of the compounds are commercially available or known in the literature, or can be prepared by a person skilled in the art by the following methods, methods analogous to those given below, or standard methods known in the art. Unless otherwise specified in the process description, suitable solvents are those conventional solvents well known to a person skilled in the art for the specific type of reaction involved, such as water, esters, ethers, liquid aromatic hydrocarbons, alcohols, nitriles, halogenated hydrocarbons, amides, bases, carboxylic anhydrides, cyclic, linear or branched hydrocarbons, or mixtures of these solvents. Such solvent mixtures can also be used for post-processing, for example, post-processing by chromatography or partitioning.
[0394] If desired, the raw materials and intermediates in the synthetic reaction scheme can be separated and purified using conventional techniques, including but not limited to filtration, distillation, crystallization, chromatography, etc. If the intermediates and final products are obtained in solid form, purification can also be carried out by recrystallization or aging. The materials can be characterized using conventional methods including physical constants and spectral data. The reaction mixture is post-processed in a conventional manner, for example by mixing with water, separating the phases, and, if appropriate, purifying the crude product by chromatography.
[0395] Those skilled in the art will recognize the presence or absence of stereocenters in the compounds of the present invention. At all stages of the reaction, the mixture of isomers formed can be separated into individual isomers, such as diastereomers or enantiomers, or into any desired mixture of isomers, such as racemates or mixtures of diastereomers, see, for example, E.L. Eliel, S.H. Wilen and L.N. Mander, "Stereochemistry of Organic Compounds" (Wiley-Interscience, 1994).
[0396] Where a mixture of stereoisomers is produced during the preparation of the compounds of the present invention, the individual stereoisomers of the compounds of the present invention can be obtained by resolution, for example, by starting from the compounds of the present invention obtained as a mixture of stereoisomers using well-known methods, such as formation of diastereomeric pairs, by salt formation with an optically active acid, followed by fractional crystallization and regeneration of the free base, or by chiral preparative chromatography; alternatively, starting materials or intermediates with defined stereochemistry can be used, or any known chiral resolution method can be used to obtain optically pure or enantiomerically enriched synthetic intermediates, which can then be used as such in subsequent steps at various stages of the above-mentioned synthetic processes.
[0397] In certain specific cases, it may be necessary to protect a particular reactive group with an appropriate protecting group to avoid interference with the reaction of other reactive groups. Suitable protecting groups and methods of protection and deprotection using such suitable protecting groups are well known to those skilled in the art; examples thereof can be found in T. Greene and P. Wuts, Protective Groups in Organic Synthesis (3rd ed.), John Wiley & Sons, NY (1999).
[0398] The following is only an example of a general synthetic scheme for synthesizing the compounds of the present invention. Other routes and other reactants and intermediates known to those of ordinary skill in the art can also be used to obtain the compounds of the present invention.
[0399] For the sake of clarity, in the exemplary synthesis schemes described below, unless otherwise specified, R1 to R2 in the structural formula of each intermediate compound are 14 , X, Y, Z, M, G, W, k, n, m and t are as defined above for the compounds of the present invention, wherein PG represents a suitable protecting group that can be determined by those skilled in the art based on the knowledge of organic chemistry.
[0400] Synthesis Scheme A
[0401] The synthesis of some compounds of general formula IA and IB of the present invention can be prepared according to the following schemes or appropriate variations thereof, wherein the variables are as defined above unless otherwise stated.
[0402] Some representative compounds of the present invention can be synthesized according to the above scheme. Compound 1 is commercially available or can be obtained according to the methods used in the examples herein or methods analogous thereto. In step A, compound 1 undergoes an aromatic nucleophilic substitution reaction (when G is N) or a metal-catalyzed coupling reaction (when G is C) to obtain compound 2. Typical aromatic nucleophilic substitution conditions include DIEA / THF, NaH / THF, etc.; typical metal-catalyzed coupling reactions include Suzuki coupling reaction, Negishi coupling reaction, etc. In step B, compound 2 is fluorinated by a halogen exchange reaction under conditions such as KF / DMSO to obtain compound 3. In step C, compound 3 is introduced into a phenolic or aromatic amine compound by a metal-catalyzed coupling reaction to obtain compound 4 or 5. In step D, compound 4 or 5 undergoes an aromatic nucleophilic substitution reaction with an alcohol, thiol or selenium compound under conditions such as DIEA / dioxane, NaH / THF, DABCO / Cs2CO3 / ACN to obtain compound 6 or 7. In step E, the protective groups that may be present in compound 6 or 7 are removed to obtain a compound of formula IA or IB.
[0403] It should be noted that the removal of the protecting group in step E can be adjusted according to the protecting groups carried by the molecule, and can be a one-step reaction or a multi-step reaction. Conventional PG1 protecting groups such as Boc can be removed under conditions such as trifluoroacetic acid or hydrochloric acid; conventional PG2 protecting groups such as MOM can also be removed under conditions such as trifluoroacetic acid or hydrochloric acid; conventional PG2 protecting groups such as TIPS can be removed under conditions such as CsF / DMF; conventional PG2 protecting groups such as PMB can be removed under conditions such as trifluoroacetic acid; conventional PG2 protecting agents such as Me can be removed under conditions such as boron tribromide.
[0404] Synthesis Scheme B
[0405] Some compounds of the general formula IA and IB of the present invention can also be prepared according to the following schemes or appropriate variations thereof.
[0406] The synthesis of compound 2 in Step A can be carried out according to Synthesis Scheme A. In Step B, compound 2 undergoes an aromatic nucleophilic substitution reaction to provide compound 8, which is then subjected to a metal-catalyzed coupling reaction to introduce a phenolic or aromatic amine fragment to provide compound 6 or 7. In Step D, compound 6 or 7 is deprotected to provide a compound of Formula IA or IB. The typical conditions for the coupling reaction, nucleophilic substitution reaction, and deprotection reaction involved in this synthesis scheme are similar to those described in Synthesis Scheme A and can be used as a reference.
[0407] Synthesis Scheme C
[0408] Some representative compounds of the present invention (G=N) can be synthesized according to the above scheme. Compound 9 is commercially available or can be obtained according to the method used in the examples herein or a method analogous thereto. In step A, compound 9 undergoes an amination reaction under the conditions of a condensing agent (such as BOP, PyAOP, etc.) to obtain compound 10. Compound 10 is introduced into the corresponding B fragment through a metal-catalyzed coupling reaction in step B to obtain compound 11 or 12. In step C, compound 11 or 12 is oxidized (with an oxidizing agent such as mCPBA) to obtain compound 13a / 13b (or a mixture of 13a and 13b) or 14a / 14b (or a mixture of 14a and 14b), respectively. The obtained compound 13a / b or 14a / b is subjected to an aromatic nucleophilic substitution reaction to obtain compound 6 or 7, and the latter is removed from any protective agent in step E to obtain compound I-A' or I-B'.
[0409] It should be noted that the typical reaction conditions and reagents used for the metal-catalyzed coupling reaction, aromatic nucleophilic substitution reaction, and protecting agent removal reaction involved in the above synthesis scheme are well known in the art and fall within the routine experience of those skilled in the art, or can be determined by those skilled in the art by making appropriate changes based on the typical conditions of such reactions in the art, the characteristics of the raw materials used, and the target product.
[0410] Synthesis Example
[0411] The present invention will be further described below with reference to the following examples. It should be noted that the following examples are illustrative only and should not be considered as limiting the scope of protection of the present invention.
[0412] In describing the embodiments and the specific examples that follow, the following abbreviations are used herein:
[0413] ACN (acetonitrile); Boc (tert-butoxycarbonyl); BAST (bis(2-methoxyethyl)aminosulfur trifluoride); CDCl3 (deuterated chloroform); DAST (diethylaminosulfur trifluoride); DCM (dichloromethane); DIEA or DIPEA (N,N-diisopropylethylamine); DMF (N,N-dimethylformamide); DMSO (dimethyl sulfoxide); DMSO-d6 (hexadeuterated dimethyl sulfoxide); EA (ethyl acetate); EDTA-K2 (ethylenediaminetetraacetic acid dipotassium salt); EtOH (ethanol); FCC (flash column chromatography); g (gram); h (hour); H Cl (hydrogen chloride); HCl-MeOH or HCl / MeOH (hydrogen chloride methanol solution); HLM (human liver microsomes); H2O (water); H2SO4 (sulfuric acid); IV (intravenous administration); K2CO3 (potassium carbonate); LCMS (liquid chromatography-mass spectrometry); LC-MS / MS (liquid spectroscopy-mass spectrometry-mass spectrometry); MeOH (methanol); Methanol-d4 (tetradeuterated methanol); mg (milligrams); MHz (megahertz); min (minutes); mL (milliliters); mmol (millimoles); MOM (methoxymethyl ether); MTBE (methyl tert-butyl ether) m / z (mass-to-charge ratio); N2 (nitrogen); NaCl (sodium chloride); NaH (sodium hydride); NaHCO3 (sodium bicarbonate); Na2SO3 (sodium sulfite); Na2SO4 (sodium sulfate); NCS (chlorosuccinimide); NH4Cl (ammonium chloride); NMR (nuclear magnetic resonance); PdCl2(dtbpf) or Pd(dtbpf)Cl2 (1,1'-bis(di-tert-butylphosphino)ferrocenepalladium dichloride); PdCl2(dppf) or Pd(dppf)Cl2 (1,1'-bis(diphenylphosphino)ferrocenepalladium dichloride); Pd(OAc) 2 (palladium acetate); Pd(PPh3)4 (tetrakistriphenylphosphine palladium); PE (petroleum ether); PO (oral administration); POCl3 (phosphorus oxychloride); rt (room temperature); SFC (supercritical fluid chromatography); SiO2 (silica gel); TBAF (tetrabutylammonium fluoride); TEA (triethylamine); TFA (trifluoroacetic acid); THF (tetrahydrofuran); TIPS (triisopropylsilyl); TLC (thin layer chromatography); TsOH (p-toluenesulfonic acid); TsOH·H2O (p-toluenesulfonic acid monohydrate); μL (microliter); μM (micromolar); μmol (micromole).
[0414] In the following examples, the names and structures of the synthesized target compounds are given. Any discrepancies between the names and structures are not intentional; in such cases, the structures shall prevail.
[0415] In the following examples, experimental procedures, where specific conditions are not specified, generally follow conventional conditions for such reactions or those recommended by the manufacturer. Unless otherwise noted, percentages and parts are by weight. Liquid ratios are by volume unless otherwise noted.
[0416] Unless otherwise specified, the experimental materials and reagents used in the following examples can be obtained from commercial channels, prepared according to existing methods, or prepared according to methods similar to those disclosed in this application.
[0417] In the following examples, 1 H-NMR spectra were recorded using a Bruker (400 MHz), with chemical shifts expressed as δ (ppm) relative to the deuterated solvent peak (CDCl3: δ = 7.26 ppm; CD3OD: δ = 3.31 ppm; DMSO-d6: δ = 2.50 ppm). Mass spectra were recorded using an Aglient 1100 liquid chromatograph coupled with an Aglient G6100 LCMS / MS instrument.
[0418] Chiral analysis method:
[0419] SFC-1: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH (0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-0.5 min A / B = 95 / 5, 0.5-5.0 min A / B = 95 / 5-60 / 40, 5.0-8.0 min A / B = 60 / 40.
[0420] Chiral analysis method 2: Agilent 1260 Infinity, separation column: Daicel 4.6*100mm 5μm; Mobile phase A: n-hexane, Mobile phase B: ETOH / DCM = 9 / 1 (0.1% DEA); Flow rate: 1.0 mL / min; Column temperature: 35°C; Gradient: 0-20 min A / B = 60 / 40.
[0421] SFC-3: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH; flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 90 / 10.
[0422] SFC-4: Waters UPCC, analytical column: Daicel 100 x 4.6 mm, 5 μm; mobile phase A: CO2, mobile phase B: MeOH (0.1% DEA); flow rate: 2.0 mL / min; column temperature: 40°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 60 / 40.
[0423] Chiral analysis method 5: SHIMADZU LC-20AD, separation column: Daicel 150 x 4.6 mm, 5 μm; mobile phase A: n-hexane, mobile phase B: ETOH (+0.1% DEA); flow rate: 1.0 mL / min; column temperature: 35°C; gradient: 0-10 min, A / B = 90 / 10.
[0424] SFC-6: Waters UPCC, analytical column: Daicel 100*3mm 3μm; mobile phase A: CO2, mobile phase B: MeOH (0.1% DEA); flow rate: 1.5mL / min; column temperature: 35°C; back pressure: 1800psi; gradient: 0-8.0min A / B=70 / 30.
[0425] SFC-7: Waters UPCC, analytical column: Daicel 100*3mm 3μm; mobile phase A: CO2, mobile phase B: MeOH; flow rate: 2.0 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min A / B=60 / 40.
[0426] SFC-8: Waters UPCC, analytical column: Daicel 100*3mm 3μm; mobile phase A: CO2, mobile phase B: IPA (+0.1% 7.0 mol / l Ammonia); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min A / B = 55 / 45.
[0427] SFC-9: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: IPA (0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 70 / 30.
[0428] SFC-10: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH (0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 70 / 30.
[0429] SFC-11: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; Mobile phase A: CO2, Mobile phase B: MeOH (+0.1% 7.0 mol / l Ammonia); Flow rate: 1.5 mL / min; Column temperature: 35°C; Back pressure: 1800 psi; Gradient: 0-8.0 min, A / B = 60 / 40.
[0430] SFC-12: Waters UPCC, analytical column: REGIS (S,S) WHELK-O1, 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH (+0.1% 7.0 mol / l Ammonia); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-5.0 min, A / B = 80 / 20.
[0431] SFC-13: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: IPA (+0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-5.0 min, A / B = 70 / 30.
[0432] SFC-14: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: IPA (+0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 70 / 30.
[0433] SFC-15: Waters UPCC, analytical column: Daicel 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH (+0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-8.0 min, A / B = 85 / 15.
[0434] SFC-16: Waters UPCC, analytical column: (S,S) WHELK-O1, 100 x 3 mm, 3 μm; mobile phase A: CO2, mobile phase B: MeOH (+0.1% DEA); flow rate: 1.5 mL / min; column temperature: 35°C; back pressure: 1800 psi; gradient: 0-5.0 min, A / B = 70 / 30.
[0435] Intermediate A-1
[0436] 7-Bromo-2,4-dichloro-6,8-difluoroquinazoline
[0437] Step A: Methyl 4-bromo-3,5-difluoro-2-(3-(2,2,2-trichloroacetyl)ureido)benzoate
[0438] To a round-bottom flask equipped with a stirrer at room temperature, add methyl 2-amino-4-bromo-3,5-difluorobenzoate (34 g, 128 mmol) and THF (500 mL). Add 2,2,2-trichloroacetyl isocyanate (28.9 g, 153 mmol) dropwise with stirring at room temperature. The resulting mixture was stirred at room temperature for 2 hours and then concentrated under reduced pressure to afford methyl 4-bromo-3,5-difluoro-2-(3-(2,2,2-trichloroacetyl)ureido)benzoate (crude) as a brown solid, which was used directly in the next step. LCMS (m / z): 452.8 (M+H).
[0439] Step B: 7-Bromo-6,8-difluoroquinazoline-2,4-diol
[0440] At room temperature, methyl 4-bromo-3,5-difluoro-2-(3-(2,2,2-trichloroacetyl)ureido)benzoate, obtained in the previous step, was added to a round-bottom flask equipped with a stirrer, followed by the addition of NH3 (400 mL, 7 M MeOH solution). The resulting mixture was stirred at room temperature for 2 hours, and the reaction was monitored for completion by LCMS. The mixture was concentrated under reduced pressure, and the resulting solid was slurried with methyl tert-butyl ether and filtered to afford 7-bromo-6,8-difluoroquinazoline-2,4-diol (32 g, 90% yield for two steps) as a pale yellow solid. LCMS (m / z): 277.0 (M+H).
[0441] Step C: 7-Bromo-2,4-dichloro-6,8-difluoroquinazoline
[0442] To a round-bottom flask equipped with a stirrer, add 7-bromo-6,8-difluoroquinazoline-2,4-diol (6 g, 22 mmol) and POCl₃ (50 mL). DIEA (12 mL) was added dropwise with stirring at room temperature. After the addition was complete, the system was heated to 110°C and stirred overnight. The reaction solution was concentrated under reduced pressure to approximately 30 mL and poured into 500 mL of water. The precipitate was collected by filtration and dried to afford 7-bromo-2,4-dichloro-6,8-difluoroquinazoline (5 g, 74% yield) as a yellow solid. LCMS (m / z): 312.9 (M+H).
[0443] Intermediate B-1
[0444] 7-Bromo-2,4-dichloro-8-fluoroquinazoline
[0445] Step A: 7-Bromo-8-fluoroquinazoline-2,4(1H,3H)-dione
[0446] 2-Amino-4-bromo-3-fluorobenzoic acid (10.0 g, 42.7 mmol) and urea (25.7 g, 427.3 mmol) were mixed at room temperature, heated to 200°C, and stirred for 2 hours. The reaction gradually transitioned from a solid state to a liquid state, and then to a solid state again. After completion of the reaction, the solid was washed with hot water (250 mL) and filtered to obtain 7-bromo-8-fluoroquinazoline-2,4(1H,3H)-dione (12 g, crude product). LCMS (m / z): 258.9 (M+H).
[0447] Step B: 7-Bromo-2,4-dichloro-8-fluoroquinazoline
[0448] DIPEA (13.5 mL, 77.2 mmol) was added to a mixture of 7-bromo-8-fluoroquinazoline-2,4(1H,3H)-dione (4.0 g) and POCl3 (35.9 mL, 386.0 mmol) at room temperature. The mixture was heated to 100°C and stirred for 5 h. After the reaction was completed, the solvent and base were concentrated to remove most of the solvent and the base, and the mixture was diluted with ACN (10 mL). The resulting dilution was slowly added dropwise to water with stirring at room temperature. The precipitated solid was filtered and dried to obtain 7-bromo-2,4-dichloro-8-fluoroquinazoline (3.8 g, 83% yield) as a yellow solid. LCMS (m / z): 296.8 (M+H).
[0449] Intermediate C-1 and Intermediate C-1a
[0450] and
[0451] 7-Chloro-2,4-dichloro-8-fluoropyrido[4,3-d]pyrimidine and (1R,5S)-3-(7-chloro-2-chloro-8-fluoropyrido[4,3-d]pyrimidin-4-yl)-3,8-diazacyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
[0452] Intermediates C-1 and C-1a were prepared and characterized according to WO2021041671A1.
[0453] Intermediate A-1a
[0454] tert-Butyl (1R,5S)-3-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3,8-diazacyclo[3.2.1]octane-8-carboxylate
[0455] Step A: tert-Butyl (1R,5S)-3-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3,8-diazacyclo[3.2.1]octane-8-carboxylate
[0456] 7-Bromo-2,4-dichloro-6,8-difluoroquinazoline (8.0 g, 26 mmol), DIEA (8.0 mL), and THF (80 mL) were added to a round-bottom flask equipped with a stirrer. Under stirring at room temperature, (1R,5S)-tert-butyl 3,8-diazacyclo[3.2.1]octane-8-carboxylate (6.0 g, 28 mmol) was slowly added to the reaction system, and the resulting mixture was stirred for 1 hour. The reaction solution was concentrated, poured into water, and filtered. The filter cake was collected and dried to obtain (1R,5S)-3-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3,8-diazacyclo[3.2.1]octane-8-carboxylate (tert-butyl ester) as a yellow solid (9.0 g, 72% yield). LCMS (ESI, m / z): 499.0 (M+H).
[0457] Intermediate A-1b
[0458] tert-Butyl (1R,5S)-3-(7-bromo-2,6,8-trifluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0459] Step A: tert-Butyl (1R,5S)-3-(7-bromo-2,6,8-trifluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0460] A mixture of (1R,5S)-3-(7-bromo-2-chloro-6,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (9.0 g, 18.4 mmol), KF (21.4 g, 368 mmol), and DMSO (100 mL) was stirred at 100°C overnight. After completion of the reaction, monitored by LCMS, the reaction solution was cooled to room temperature. With stirring, the reaction solution was slowly poured into water (1 L), and a yellow solid precipitated. The solid was filtered, and the filter cake was washed with water (200 mL). The filter cake was collected and dried to yield a yellow solid, (1R,5S)-3-(7-bromo-2,6,8-trifluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (7.7 g, 88% yield). LCMS (m / z): 473.4 (M+H).
[0461] With reference to the above synthesis scheme, the present invention also synthesized the following intermediates:
[0462] Intermediate A-1b-I
[0463] tert-Butyl (1R,5S)-3-(2,6,8-trifluoro-7-(7-fluoro-8-(triisopropylsilyl)ethynyl)-3-(triisopropylsilyl)oxy)naphthalen-1-yl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0464] Step A: tert-Butyl (1R,5S)-3-(2,6,8-trifluoro-7-(7-fluoro-8-(triisopropylsilyl)ethynyl)-3-(triisopropylsilyl)oxy)naphthalen-1-yl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0465] At room temperature, tert-butyl (1R,5S)-3-(7-bromo-2,6,8-trifluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3.0 g, 6.34 mmol), (7-fluoro-8-(triisopropylsilyl)ethynyl)-3-(triisopropylsilyl)oxy)naphthalen-1-yl)boronic acid (4.13 g, 7.61 mmol), Pd(OAc)2 (71 mg, 0.32 mmol), BIDIME (209 mg, 0.63 mmol), and K3PO4 (4.04 g, 19.02 mmol) were dissolved in tert-amyl alcohol (30 mL), the atmosphere was replaced with N2 three times, and the mixture was heated to 110°C and stirred overnight. After the reaction was completed, the mixture was passed through celite and washed with EA (50 mL). The obtained organic phase was concentrated and purified by FCC (SiO2, EA / PE = 0-50%) to give a yellow solid (1R, 5S)-3-(2,6,8-trifluoro-7-(7-fluoro-8-(triisopropylsilyl)ethynyl)-3-(triisopropylsilyl)oxy)naphthalen-1-yl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (2.3 g, yield 41%). 1 H NMR(400MHz,Chloroform-d)δ7.74(dd,J=9.1,5.6Hz,1H),7.39(dd,J=9.8,1.7Hz,1H),7.34(d, J=2.6Hz,1H),7.31–7.28(m,1H),7.10(d,J=2.6Hz,1H),4.86–4.61(m,1H),4.54–4.26(m,2H),4 .20–4.01(m,1H),3.92–3.69(m,1H),3.58–3.36(m,1H),2.11–1.97(m,3H),1.53(s,9H),1.36–1 .23(m,4H),1.17–1.08(m,18H),0.95–0.79(m,18H),0.61–0.49(m,3H).LCMS(m / z):891.4(M+H).
[0466] Intermediates A-1b-I1 and A-1b-I2
[0467] The compound (1R,5S)-3-(2,6,8-trifluoro-7-(7-fluoro-8-(triisopropylsilyl)ethynyl)-3-(triisopropylsilyl)oxy)naphthalen-1-yl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (Intermediate A-1b-I, 10 g) was separated by SFC (SFC150, Waters) (Separation column: DAICEL HPLC elution method (250 x 25 mm, 10 μm; mobile phase: CO₂ / MeOH = 75 / 25; flow rate: 70 mL / min) yielded the first eluting isomer 1, intermediate A-1b-I1 (4.5 g, relatively short retention time). Chiral analysis method SFC-1, Rt = 3.855 min. LCMS (m / z): 891.4 (M+H). The second eluting isomer 2 was intermediate A-1b-I2 (4.9 g, relatively long retention time). Chiral analysis method SFC-1, Rt = 4.198 min. 1 H NMR(400MHz,Chloroform-d)δ7.74(dd,J=9.1,5.7Hz,1H),7.40(dd,J=9.7,1.7Hz,1H),7. 34(d,J=2.5Hz,1H),7.29(d,J=8.7Hz,1H),7.10(d,J=2.6Hz,1H),4.81–4.64(m,1H),4.51– 4.32(m,2H),4.18–4.03(m,1H),3.91–3.69(m,1H),3.52–3.32(m,1H),2.30–1.93(m,3H),1 .53(s,9H),1.37–1.21(m,4H),1.16–1.05(m,18H),0.94–0.80(m,18H),0.62–0.47(m,3H). 19 F NMR (376MHz, Chloroform-d) δ -47.14, -105.65, -112.24, -120.80. LCMS (m / z): 891.4 (M+H).
[0468] Intermediate C-2 and Intermediate C-2a
[0469] and
[0470] 7-Chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one and (1R,5S)-3-(7-chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
[0471] Step A: 4,6-dichloro-5-fluoronicotinoyl chloride
[0472] With stirring at room temperature, thionyl chloride (2.25 mL, 31 mmol) was slowly added to a solution of 4,6-dichloro-5-fluoronicotinic acid (5.0 g, 23.4 mmol) in DCM (100 mL), followed by DMF (175 mg, 2.4 mmol). The resulting reaction solution was stirred at 50°C for 2 h. After completion of the reaction as monitored by TLC, the mixture was concentrated and a small amount of toluene was added to obtain a yellow solid, 4,6-dichloro-5-fluoronicotinyl chloride (4.5 g, 83% yield), which was used directly in the subsequent reaction.
[0473] Step B: (4,6-Dichloro-5-fluoronicotinoyl)carbamidethiomethyl ester
[0474] A mixture of 4,6-dichloro-5-fluoronicotinoyl chloride (4.5 g, 19.8 mmol) and ethylene glycol dimethyl ether (20 ml) was slowly added dropwise to a mixture of 2-methylisothiourea sulfuric acid (15 g, 49.5 mmol) and 1M aqueous NaOH (70 ml) at 0°C with stirring. The mixture was stirred for 1 hour. The precipitated solid was filtered and dried to obtain (4,6-dichloro-5-fluoronicotinoyl)carbamide thiomethyl ester (5.0 g, 90% yield). LCMS (m / z): 282.1 (M+H).
[0475] Step C: 7-chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one
[0476] Dissolve (4,6-dichloro-5-fluoronicotinoyl)carbamoylthiomethyl ester (5.0 g, 17.8 mmol) in DMF (40 mL) and heat to 120°C with stirring for 3 h. After completion of the reaction as monitored by LCMS, cool to room temperature and add water (200 mL). The precipitated solid was filtered and dried to obtain (4,6-dichloro-5-fluoronicotinoyl)carbamoylthiomethyl ester (3.6 g, 82% yield). LCMS (m / z): 245.6 (M+H).
[0477] Step D: (1R,5S)-tert-butyl 3-(7-chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0478] To a solution of 7-chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (1.0 g, 4.0 mmol) in DMF (15 mL) was added tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.0 g, 4.9 mmol), BOP (2.3 g, 5.3 mmol), and DIEA (1.0 g, 8.1 mmol) at room temperature. The reaction mixture was stirred at 50°C for 2 h. After completion of the reaction, monitored by LCMS, the reaction mixture was poured into 100 mL of ice water to quench the reaction. Extraction was then performed with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The resulting crude product was purified by FCC (SiO2, EtOAc / PE = 0-20%) to afford tert-butyl (1R,5S)-3-(7-chloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (980 mg, 55% yield) as a yellow solid. LCMS (m / z): 440.1 (M+H).
[0479] Intermediates D-1, D-2, and D-2a
[0480] Step A: 2,6-Dichloro-3-fluoropyridin-4-amine
[0481] Selectfluor (68 g, 180 mmol) was added to a solution of 2,6-dichloropyridin-4-amine (25 g, 154 mmol) in methanol / water (V / V = 5:1, 300 mL) at room temperature. The resulting mixture was stirred at 50°C for 48 h, concentrated under reduced pressure, diluted with ethyl acetate, washed sequentially with water and saturated brine, and dried over anhydrous sodium sulfate. The residue was filtered and concentrated, and the crude product was purified by FCC (SiO2, EA / PE = 0-10%) to afford 2,6-dichloro-3-fluoropyridin-4-amine (10 g) as a white solid. LCMS (m / z): 180.9 (M+H).
[0482] Step B: tert-Butyl (tert-Butoxycarbonyl)(2,6-dichloro-3-fluoropyridin-4-yl)carbamate
[0483] 4-Dimethylaminopyridine (307 mg, 2.75 mmol) and di-tert-butyl dicarbonate (30 g, 138 mmol) were added to a solution of 2,6-dichloro-3-fluoropyridin-4-amine (10 g, 55 mmol) in tetrahydrofuran (100 mL) with stirring at room temperature. The resulting mixture was heated to 60°C and stirred for 16 h. The reaction was monitored for completion by TLC. The crude product was concentrated to afford the crude product, which was then slurried in methanol to afford tert-butyl (tert-butoxycarbonyl)(2,6-dichloro-3-fluoropyridin-4-yl)carbamate (16 g) as a white solid. LCMS (m / z): 381.2 (M+H).
[0484] Step C: tert-Butyl 4-((tert-Butoxycarbonyl)amino)-2,6-dichloro-5-fluoronicotinate
[0485] Under a dry ice-ethanol bath, LDA (2.0 M, 63 mL, 126 mmol) was slowly added to a solution of tert-butyl (tert-butoxycarbonyl)(2,6-dichloro-3-fluoropyridin-4-yl)carbamate (16 g, 42 mmol) in THF (200 mL). The resulting mixture was stirred at this temperature for 1 hour. TLC monitored the reaction completion. Acetic acid was added to quench the reaction, which was then diluted with EA, washed with water, and dried over anhydrous sodium sulfate. Filtration and concentration yielded the crude product, which was purified by FCC (SiO2, EA / PE = 0-20%) to afford tert-butyl 4-((tert-butoxycarbonyl)amino)-2,6-dichloro-5-fluoronicotinate (13 g).
[0486] Step D: 4-amino-2,6-dichloro-5-fluoronicotinic acid hydrochloride
[0487] Concentrated hydrochloric acid (30 ml) was added to a solution of tert-butyl 4-((tert-butoxycarbonyl)amino)-2,6-dichloro-5-fluoronicotinate (13 g, 34 mmol) in dioxane (90 mL) at room temperature. The resulting mixture was stirred at room temperature for 3 hours. After completion of the reaction, as monitored by LCMS, the reaction mixture was concentrated to yield 4-amino-2,6-dichloro-5-fluoronicotinic acid hydrochloride (8 g). LCMS (m / z): 224.9 (M+H).
[0488] Step E: 5,7-dichloro-8-fluoro-2-mercaptopyrido[4,3-d]pyrimidin-4(3H)-one
[0489] A mixed solution of 4-amino-2,6-dichloro-5-fluoronicotinic acid (8 g, 30.8 mmol) and thionyl chloride (200 mL) was stirred at 50°C for 3 h. The mixture was then concentrated, and the residue was dissolved in acetone (50 mL) to obtain Solution 1. A mixed solution of ammonium thiocyanate (7 g, 92 mmol) and acetone (160 mL) was added dropwise to Solution 1 at room temperature, and the resulting reaction solution was stirred for an additional 1 h at room temperature. After completion of the reaction, as monitored by LCMS, the reaction solution was poured into water, filtered, and the filter cake dried to yield 5,7-dichloro-8-fluoro-2-mercaptopyrido[4,3-d]pyrimidin-4(3H)-one (5 g). LCMS (m / z): 265.9 (M+H).
[0490] Step F: 5,7-dichloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (Intermediate D-1)
[0491] A mixture of 5,7-dichloro-8-fluoro-2-mercaptopyrido[4,3-d]pyrimidin-4(3H)-one (5 g, 18.8 mmol), methanol (380 mL), aqueous sodium hydroxide (0.1 M, 380 mL, 380 mmol), and iodomethane (5.3 g, 380 mmol) was stirred at room temperature for 2 h. After completion of the reaction, as monitored by LCMS, the reaction solution was poured into 1000 mL of water and acidified to pH ~6 with concentrated hydrochloric acid. The solution was filtered, and the filter cake was dried to yield the product, 5,7-dichloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (4 g). LCMS (m / z): 279.9 (M+H).
[0492] Step G: 7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (Intermediate D-2)
[0493] A mixture of 5,7-dichloro-8-fluoro-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (400 mg, 1.4 mmol), sodium methoxide (0.38 g, 7.5 mmol), DMA (10 mL), and methanol (2 mL) was stirred at 50°C for 16 h. After completion of the reaction, as monitored by LCMS, the mixture was diluted with water and adjusted to pH ~3 with concentrated hydrochloric acid. The filter cake was filtered and dried to yield 7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (250 mg). LCMS (m / z): 276.0 (M+H).
[0494] Step H: (1R,5S)-tert-butyl 3-(7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (Intermediate D-2a)
[0495] A mixed solution of 7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4(3H)-one (250 mg, 0.91 mmol), tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (290 mg, 1.4 mmol), BOP (620 mg, 1.4 mmol) and N,N-diisopropylethylamine (361 mg, 2.8 mmol) in DMF (5 mL) was stirred at 45 °C for 3 h. After the reaction was complete, as monitored by LCMS, the reaction solution was poured into water and filtered. The filter cake was collected and dried to obtain tert-butyl (1R,5S)-3-(7-chloro-8-fluoro-5-methoxy-2-(methylthio)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate as a yellow solid (300 mg). LCMS (m / z): 470.3 (M+H).
[0496] Intermediates D-3, D-3a, D-4, and D-4a
[0497] and
[0498] The syntheses of intermediates D-3, D-3a, D-4, and D-4a were carried out by referring to the syntheses of intermediates D-2 and D-2a described above.
[0499] Intermediates E-1, E-1a, and E-1b
[0500] and
[0501] 7-Bromo-2,4,6-trichloro-8-fluoroquinazoline (E-1)
[0502] ((1R,5S)-3-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (E-1a)
[0503] Tert-butyl ((1R,5S)-3-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (E-1b)
[0504] Step A: tert-Butyl ((1R,5S)-3-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0505] At room temperature, tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.77 g, 8.32 mmol) was added to a mixture of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline (CAS: 1698028-11-3, 2.50 g, 7.57 mmol), DIEA (1.96 g, 15.1 mmol), and THF (50 mL). The resulting mixture was stirred at room temperature for 1 hour. The reaction was monitored by LCMS. The product was concentrated under reduced pressure and further purified by FCC (SiO2, EA / PE = 0-30%) to give tert-butyl ((1R,5S)-3-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate) as a yellow solid (2.0 g, 52% yield). LCMS (m / z): 506.9.
[0506] Step B: tert-Butyl ((1R,5S)-3-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0507] At room temperature, KF (2.29 g, 39.5 mmol) was added to a mixture of tert-butyl ((1R,5S)-3-(7-bromo-2,6-dichloro-8-fluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (2.00 g, 3.95 mmol) and DMSO (50 mL). The resulting mixture was heated to 110°C and stirred for 16 h. After the reaction was completed as monitored by LCMS, the reaction solution was cooled to room temperature and water (200 mL) and EA (50 mL × 3) were added. Extraction. The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by FCC (SiO2, EA / PE = 0-25%) to give a yellow solid ((1R, 5S)-3-(7-bromo-6-chloro-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (1.6 g, yield 83%). LC-MS (m / z): 489.0 (M+H) and 491.0 (M+H).
[0508] Intermediate E-2b
[0509] tert-Butyl (1R,5S)-3-(6-chloro-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0510] The synthesis of intermediate E-2b was carried out according to the protocol described for intermediate E-1b, except that 2,4,6-trichloro-8-fluoroquinazoline (CAS: 2205387-69-3) was used instead of 7-bromo-2,4,6-trichloro-8-fluoroquinazoline in step A.
[0511] Intermediates F-1, F-1a, and F-1b
[0512] and
[0513] 7-Bromo-2,4-dichloro-8-fluoro-6-iodoquinazoline (F-1)
[0514] (1R,5S)-3-(7-bromo-2,8-difluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (F-1a)
[0515] Tert-butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-(trifluoromethyl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (F-1b)
[0516] Step A: 2-Amino-4-bromo-3-fluoro-5-iodobenzoic acid
[0517] At room temperature, NIS (50.6 g, 225 mmol) was added to a mixed solution of 2-amino-4-bromo-3-fluorobenzoic acid (50 g, 215 mmol) and DMF (500 mL). The resulting mixture was stirred at 80°C for 3 h. LCMS monitored the reaction after completion. The reaction solution was cooled, poured into water (2 L), and extracted with ethyl acetate (4 L). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-amino-4-bromo-3-fluoro-5-iodobenzoic acid (50 g, 65% yield) as a yellow solid. LCMS (m / z): 360.2 (M+H).
[0518] Step B: 7-Bromo-8-fluoro-6-iodoquinazoline-2,4-(1H,3H)-dione
[0519] A mixture of 2-amino-4-bromo-3-fluoro-5-iodobenzoic acid (50 g, 139 mmol) and urea (168 g) was stirred at 200°C for 2 hours. After completion of the reaction, the system was cooled to room temperature, slurried with water, and the solid was collected by filtration and dried to yield 7-bromo-8-fluoro-6-iodoquinazoline-2,4-(1H,3H)-dione (48 g, 90% yield) as a yellow solid. LCMS (m / z): 384.8 (M+H).
[0520] Step C: 7-Bromo-2,4-dichloro-8-fluoro-6-iodoquinazoline
[0521] At room temperature, DIEA (40 mL) was slowly added to a mixed solution of 7-bromo-8-fluoro-6-iodoquinazoline-2,4-(1H,3H)-dione (20 g, 52 mmol) and phosphorus oxychloride (160 mL). The resulting mixture was stirred at 100°C for 16 h. After TLC monitoring of the reaction completion, the reaction solution was concentrated and slowly poured into water. The filter cake was collected by filtration and dried to obtain 7-bromo-2,4-dichloro-8-fluoro-6-iodoquinazoline (18.5 g, 85% yield) as a yellow solid.
[0522] Step D: (1R,5S)-3-(7-bromo-2-chloro-8-fluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
[0523] The compound 7-bromo-2,4-dichloro-8-fluoro-6-iodoquinazoline (18.5 g, 44 mmol), (1R,5S)-tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (9.3 g, 44 mmol), DIEA (17 g, 132 mmol), and tetrahydrofuran (200 mL) were stirred at room temperature for 1 hour. After the reaction was complete as monitored by LCMS, the reaction solution was poured into water (2 L), filtered, and the solid collected. After drying, a yellow solid (1R,5S)-tert-butyl 3-(7-bromo-2-chloro-8-fluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (17.6 g, 67% yield) was obtained. LCMS (m / z): 596.6 (M+H).
[0524] Step E: tert-Butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0525] The compound (1R,5S)-3-(7-bromo-2-chloro-8-fluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (10 g, 16.8 mmol), potassium fluoride (8 g, 138 mmol), and DMSO (100 mL) were stirred at 110°C for 16 hours. After the reaction was complete as monitored by LCMS, the reaction solution was poured into water (2 L), filtered, and the solid was collected and dried to obtain (1R,5S)-3-(7-bromo-2,8-difluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (9 g, 92% yield) as a yellow solid. LCMS (m / z): 583.3 (M+H).
[0526] Step F: tert-Butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-(trifluoromethyl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0527] A mixture of tert-butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1 g, 1.7 mmol), methyl fluorosulfonyldifluoroacetate (660 mg, 0.44 mL, 3.4 mmol), cuprous iodide (1 g, 5.2 mmol), HMPA (2 mL), and DMF (10 mL) was heated to 110°C using microwave irradiation for 1 hour. After completion of the reaction, the reaction solution was filtered, extracted with ethyl acetate and water, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by FCC (SiO2, EA / PE = 0-20%) to give tert-butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-(trifluoromethyl)quinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate as a yellow solid (400 mg, 45% yield). LCMS (m / z): 523.6 (M+H).
[0528] Intermediate F-1c
[0529] tert-Butyl (1R,5S)-3-(7-bromo-6-cyano-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0530] Step A: (1R,5S)-3-(7-bromo-6-cyano-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester
[0531] Under nitrogen, a mixture of tert-butyl (1R,5S)-3-(7-bromo-2,8-difluoro-6-iodoquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (600 mg, 1.0 mmol), zinc cyanide (160 mg, 0.5 mmol), Pd(PPh3)4 (120 mg, 0.1 mmol), and DMF (10 mL) was stirred at 110°C for 16 h. After completion of the reaction, as monitored by LCMS, the reaction solution was filtered, extracted with ethyl acetate and water, and the organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by FCC (SiO2, EA / PE = 0-30%) to give a yellow solid product (1R,5S)-3-(7-bromo-6-cyano-2,8-difluoroquinazolin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid tert-butyl ester (280 mg, yield 58%). LCMS (m / z): 480.0 (M+H).
[0532] Intermediates G-1 and G-1a
[0533] 2,4,7-Trichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine (G-1)
[0534] (1R,5S)-3-(2,7-dichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane 8-carboxylic acid tert-butyl ester (G-1a)
[0535] Step A: 2-Chloro-3-fluoro-5-iodopyridin-4-amine
[0536] At room temperature, 2-chloro-3-fluoro-4-aminopyridine (25.0 g, 171 mmol) was dissolved in 250 mL of acetonitrile. NIS (35.4 g, 205 mmol) and p-toluenesulfonic acid monohydrate (3.24 g, 17.1 mmol) were then added separately. The resulting mixture was heated to 70°C and stirred overnight. The reaction was monitored by LCMS. After cooling to room temperature, the reaction mixture was quenched by pouring into water (500 mL) and extracted with ethyl acetate (800 mL x 3). The organic phases were combined, washed with saturated NaHCO₃, saturated Na₂S₂O₃, and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by FCC (SiO₂, EA / PE = 0-50%) to afford 2-chloro-3-fluoro-5-iodopyridin-4-amine (42 g, 90% yield) as a white solid. LCMS (m / z): 272.9 (M+H). 1H NMR (400MHz, DMSO-d6) δ8.10 (s, 1H), 6.69 (s, 2H). 19 F NMR (376MHz, DMSO-d6) δ-138.90.
[0537] Step B: Ethyl 4-amino-6-chloro-5-fluoronicotinate
[0538] At room temperature, 2-chloro-3-fluoro-5-iodopyridin-4-amine (40 g, 147 mmol) was dissolved in 400 mL of anhydrous ethanol. The system was purged with CO, repeated three times. Pd(PPh3)2Cl2 (10.3 g, 14.7 mmol) and TEA (95.0 g, 735 mmol) were then added to the reaction flask, and the CO atmosphere was purged three times. The resulting mixture was heated to 80°C under a CO atmosphere and allowed to react overnight. The reaction was monitored by LCMS, cooled to room temperature, and filtered through Celite. The filtrate was concentrated to dryness to obtain the crude product, which was purified by FCC (SiO2, EA / PE = 0-50%) to afford ethyl 4-amino-6-chloro-5-fluoronicotinate (30 g, 93% yield) as a white solid. LCMS (m / z): 219.0 (M+H).
[0539] Step C: Ethyl 4-(bis(tert-butoxycarbonyl)amino)-6-chloro-5-fluoronicotinate
[0540] Under stirring at room temperature, Boc2O (65.9 g, 302 mmol) was added dropwise to a solution of ethyl 4-amino-6-chloro-5-fluoronicotinate (30.0 g, 137 mmol) and DMAP (3.4 g, 27.5 mmol) in anhydrous dichloromethane (600 mL). After the addition was complete, the mixture was heated to 45°C and allowed to react overnight. Imidazole (9.33 g, 137 mmol) was added to the system and stirred for half an hour. The mixture was then washed with saturated ammonium chloride solution (300 mL x 3). The organic phase was separated and washed with saturated brine (300 mL x 2). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to obtain ethyl 4-(bis(tert-butoxycarbonyl)amino)-6-chloro-5-fluoronicotinate (45.9 g, 80% yield) as a yellow solid. LCMS (m / z): 419.1 (M+H).
[0541] Step D: Ethyl 4-(bis(tert-butoxycarbonyl)amino)-2-bromo-6-chloro-5-fluoronicotinate
[0542] A solution of ethyl 4-(bis(tert-butoxycarbonyl)amino)-6-chloro-5-fluoronicotinate (45.0 g, 107 mmol) in anhydrous THF (450 mL) was cooled to -40°C in a dry ice acetonitrile bath. A solution of TMPMgCl-LiCl in THF (161 mL, 161 mmol, 1 M) was added dropwise at this temperature with stirring. After the addition, stirring was continued at this temperature for 4 hours, followed by the dropwise addition of a solution of dibromotetrachloroethane (42.0 g, 129 mmol) in THF (100 mL). Stirring was continued at -40°C for 4 hours. The mixture was quenched by the addition of 500 mL of saturated ammonium chloride solution, followed by extraction with EtOAc (500 mL x 3). The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by FCC (SiO2, EA / DCM = 0-50%) to afford ethyl 4-(bis(tert-butoxycarbonyl)amino)-2-bromo-6-chloro-5-fluoronicotinate (17.0 g, 32% yield) as a white solid. LCMS (m / z): 497.0 (M+H).
[0543] Step E: 4-amino-2-bromo-6-chloro-5-fluoronicotinate
[0544] With stirring at room temperature, TFA (50 mL) was added in one portion to a solution of ethyl 4-(bis(tert-butoxycarbonyl)amino)-2-bromo-6-chloro-5-fluoronicotinate (9.5 g, 19.1 mmol) in dichloromethane (50 mL). The mixture was stirred at room temperature for 2 h, then concentrated to dryness. The residue was neutralized with 200 mL of saturated sodium bicarbonate solution and extracted with EtOAc (200 mL x 3). The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford ethyl 4-amino-2-bromo-6-chloro-5-fluoronicotinate (5.6 g, 99% yield) as a white solid. LCMS (m / z): 296.9 (M+H).
[0545] Step F: 4-Amino-6-chloro-5-fluoro-2-((triisopropylsilyl)ethynyl)nicotinate
[0546] At room temperature, ethyl 4-amino-2-bromo-6-chloro-5-fluoronicotinate (5.60 g, 18.8 mmol), Pd(PPh3)2Cl2 (1.32 g, 1.88 mmol), and CuI (717 mg, 3.76 mmol) were dissolved in anhydrous THF (150 mL). The reaction flask was evacuated and the atmosphere was replaced with nitrogen three times. Triisopropylsilyl acetylene (4.46 g, 24.5 mmol) and TEA (5.71 g, 56.5 mmol) were added, and the atmosphere was replaced with nitrogen three times. The resulting mixture was heated to 45°C for 2 h. The reaction was monitored by LCMS, cooled to room temperature, and filtered through celite. The filtrate was concentrated to dryness to give a crude product, which was purified by FCC (SiO2, EA / PE = 0-10%) to afford ethyl 4-amino-6-chloro-5-fluoro-2-((triisopropylsilyl)ethynyl)nicotinate (7 g, 93% yield) as a white solid. LCMS (m / z): 399.1 (M+H).
[0547] Step G: Ethyl 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)-2-((triisopropylsilyl)ethynyl)nicotinate
[0548] Under stirring at room temperature, 2,2,2-trichloroacetyl isocyanate (3.97 g, 21.1 mmol) was added to a solution of 4-amino-6-chloro-5-fluoro-2-((triisopropylsilyl)ethynyl)nicotinate (7.00 g, 17.5 mmol) in anhydrous THF (150 mL). The resulting mixture was stirred at room temperature for 1 h. It was then concentrated to dryness to give 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)-2-((triisopropylsilyl)ethynyl)nicotinate (11 g, crude) as a white solid. It was used directly in the next step without purification. LCMS (m / z): 586.0 (M+H).
[0549] Step H: 7-Chloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine-2,4-diol
[0550] At room temperature, ethyl 6-chloro-5-fluoro-4-(3-(2,2,2-trichloroacetyl)ureido)-2-((triisopropylsilyl)ethynyl)nicotinate (11 g, crude) was dissolved in ammonia-methanol solution (50 mL, 7 M, 350 mmol). The resulting mixture was stirred at room temperature for 2 h. The mixture was then concentrated to dryness, and the crude product was slurried with PE / EA (100 mL / 10 mL) and filtered to afford 7-chloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine-2,4-diol (5.8 g, 84% yield) as a white solid. LCMS (m / z): 396.1 (M+H).
[0551] Step I: 2,4,7-Trichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine
[0552] Phosphorus oxychloride (1.55 g, 10.1 mmol) and TEA (1.31 g, 10.1 mmol) were added to a solution of 7-chloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine-2,4-diol (1.00 g, 2.53 mmol) in anhydrous toluene (20 mL) at room temperature. The resulting mixture was heated to 100°C and stirred overnight before being concentrated to afford crude 2,4,7-trichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine, which was used directly in the next step.
[0553] Step J: (1R,5S)-tert-butyl 3-(2,7-dichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate
[0554] Under nitrogen, a solution of 2,4,7-trichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidine (crude product from Step 1) in anhydrous dichloromethane (20 mL) was cooled to -40°C, and DIPEA (976 mg, 7.56 mmol) was added, followed by a solution of tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylate (534 mg, 2.52 mmol) in DCM (2 mL). The resulting mixture was stirred at -40°C for 1 h. The reaction mixture was quenched by the addition of saturated ammonium chloride solution (30 mL), extracted with DCM (30 mL x 3), and the organic phases were combined, dried, and concentrated to give a crude product, which was then purified by FCC (SiO2, EA / PE = 0-10%) to afford tert-butyl (1R,5S)-3-(2,7-dichloro-8-fluoro-5-((triisopropylsilyl)ethynyl)pyrido[4,3-d]pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate as a white solid (960 mg, 63% yield over two steps). LCMS (m / z): 608.3 (M+H).
[0555] Intermediate k1
[0556] (7-Fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl)boronic acid
[0557] Step A: 7-Fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-ol
[0558] With stirring in an ice bath, TIPSCl (177 g, 920 mmol) was added dropwise to a solution of 7-fluoro-8-((triisopropylsilyl)ethynyl)naphthalene-1,3-diol (300 g, 837 mmol) and imidazole (119 g, 1.76 mol) in DCM (3 L). After the addition was complete, the system was slowly warmed to room temperature and stirred for 6 h. TLC monitored the reaction for completion. Water (900 mL) was added, stirred for 30 min, and the layers separated. The aqueous phase was extracted with DCM (900 mL), and the combined organic phases were dried over anhydrous sodium sulfate. The mixture was filtered, concentrated to dryness, and purified on a silica gel plug (PE / EA = 50:1) to yield 7-fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalene-1-ol (397 g, 92% yield).
[0559] Step B: 7-Fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl trifluoromethanesulfonate
[0560] Trifluoromethanesulfonic anhydride (326 g, 1.16 mol) was added dropwise to a solution of 7-fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-ol (397 g, 0.77 mol) and DIPEA (298 g, 2.31 mol) in DCM (4 L) at -45 to -35°C. After the addition was complete, stirring was continued at the same temperature for 0.5 h. The reaction was monitored for completion by TLC. The system was added to water (800 mL), the layers were separated, and the aqueous phase was extracted with DCM (1.2 L). The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The reaction mixture was purified by silica gel plug (PE / EA=50:1) to obtain 7-fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl trifluoromethanesulfonate (469 g, yield 94%).
[0561] Step C: (7-Fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl)boronic acid
[0562] Under nitrogen, Pd(dppf)Cl2 (13.2 g, 18.2 mmol) was added to a solution of 7-fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl trifluoromethanesulfonate (235 g, 0.36 mol), 5,5,5',5'-tetramethyl-2,2'-bis(1,3,2-dioxaborolane) (164 g, 0.73 mol), and potassium acetate (107 g, 1.1 mol) in dioxane (2.4 L). The temperature was raised to 85°C and stirred for 20 h. The reaction was monitored by TLC for completion. The mixture was cooled to room temperature, filtered through celite, rinsed with EA, concentrated, and purified on a silica gel column (EA / PE = 0-5%) to yield the crude compound.
[0563] The crude compound was dissolved in methanol (1.2 L), and 1N HCl (2.4 L) was added. The resulting mixture was stirred at room temperature for 30 minutes. EA (2.4 L) was added and stirring continued for 2 hours. The mixture was allowed to stand and separate. The organic phase was washed sequentially with water (2.4 L) and saturated brine (2.4 L x 2) and concentrated to yield (7-fluoro-8-((triisopropylsilyl)ethynyl)-3-((triisopropylsilyl)oxy)naphthalen-1-yl)boronic acid (183 g, 92% yield). 1 H NMR(400MHz,Chloroform-d)δ7.66–7.60(m,1H),7.34(d,J=2.5Hz,1H),7.24–7.19(m,1H),7.18(d,J=2.5Hz,1H),4.5 2(s,2H),1.35–1.29(m,3H),1.24–1.21(m,3H),1.20–1.17(m,18H),1.12(d,J=7.3Hz,18H).LCMS(m / z):543.3(M+H).
[0564] Intermediates k2 and k3
[0565] Tert-butyl (3-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (k3)
[0566] Step A: Ethyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate
[0567] To a solution of 2-(2,6-dibromophenyl)acetonitrile (5.0 g, 18 mmol) in DMF (50 mL) in an ice bath under nitrogen atmosphere was added sodium hydride (60%, 0.73 g, 22 mmol). The reaction system was stirred at 0°C for 10 min. Ethyl isothiocyanatoformate (2.14 mL, 18 mmol) was slowly added to the reaction system. After addition, the reaction was allowed to warm to room temperature and stirred for 1 h. The reaction system was then heated to 100°C and stirred for 1 h. The DMF was removed by concentration under reduced pressure, and water (100 mL) and ethyl acetate (10 mL) were added. The resulting mixture was stirred at room temperature for 15 min. After stirring, a large amount of yellow solid precipitated. This was filtered, washed with water, and dried to yield ethyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate (3.9 g) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ11.69(s,1H),7.93(dd,J=8.0,1.0Hz,1H),7.60(dd,J=7 .8,1.0Hz,1H),7.28–7.14(m,1H),4.24(q,J=7.1Hz,2H),1.29(t,J=7.1Hz,3H).
[0568] Step B: 2-Amino-4-bromobenzo[b]thiophene-3-carbonitrile
[0569] To a solution of ethyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate (3.9 g, 12 mmol) in DMSO (12 mL) and water (18 mL) was added sodium hydroxide (3.7 g, 93 mmol). The reaction was stirred at 125°C for 16 h. The reaction was cooled to room temperature, poured into 100 mL of ice water, filtered, washed with water, and dried to afford 2-amino-4-bromobenzo[b]thiophene-3-carbonitrile (2.2 g) as a pale yellow solid. 1 H NMR (400MHz, DMSO-d6) δ7.96(s,2H),7.70(dd,J=7.9,1.0Hz,1H),7.46(dd,J=7.9,1.0Hz,1H),7.14–6.96(m,1H).
[0570] Step C: tert-Butyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate
[0571] To a mixed solution of 2-amino-4-bromobenzo[b]thiophene-3-carbonitrile (2.2 g, 8.7 mmol) in DMF (29 mL) and THF (4.5 mL) were added 4-dimethylaminopyridine (104 mg, 0.85 mmol) and diisopropylethylamine (2.3 mL, 26 mmol) in sequence. Di-tert-butyl dicarbonate (2.2 mL, 9.5 mmol) was then slowly added dropwise. The reaction system was stirred at room temperature for 24 h. After completion of the reaction, water (100 mL) was added to the reaction system, causing a yellow solid to precipitate. The solid was collected by filtration, washed with water, and dried to yield tert-butyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate (1.4 g) as a pale yellow solid.
[0572] Step D: tert-Butyl (3-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate
[0573] To a 50 mL round-bottom flask, tert-butyl (4-bromo-3-cyanobenzo[b]thiophen-2-yl)carbamate (1.4 g, 3.9 mmol), pinacol diboron (1.5 g, 5.9 mmol), potassium acetate (0.77 g, 7.8 mmol), and 1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium dichloromethane complex (0.3 g, 0.35 mmol) were added. 1,4-dioxane (5 mL) was then added to the reaction flask. The reaction atmosphere was then replaced with nitrogen. The reaction mixture was heated to 105°C for 3 h. After the reaction, the filtrate was collected by filtration and concentrated to give the crude product, which was then purified by FCC (SiO2, petroleum ether / tetrahydrofuran ~0-30%) to afford tert-butyl (3-cyano-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (1.6 g) as a pale yellow solid. LCMS (m / z): 423.0 (M+Na).
[0574] Intermediates k4, k5 and k5-A
[0575] and
[0576] Tert-butyl (4-bromobenzo[b]thiophen-2-yl)carbamate (k4) and tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (k5)
[0577] Step A: Methyl 4-bromobenzo[b]thiophene-2-carboxylate
[0578] At room temperature, 2,6-dibromobenzaldehyde (15.7 g, 59.5 mmol), methyl thioglycolate (5.6 mL, 65.4 mmol), K2CO3 (15.7 g, 119.0 mmol), and DMF (200 mL) were added sequentially to a reaction flask containing a magnetic separator. The resulting mixture was heated to 110°C and stirred for 10 hours. TLC monitored the reaction completion. The reaction solution was poured into 300 mL of water, whereupon a large amount of yellow solid precipitated. The solid was filtered, washed with water, and dried at 50°C to yield crude methyl 4-bromobenzo[b]thiophene-2-carboxylate (18 g). LCMS (m / z): 270.9 (M+H).
[0579] Step B: 4-Bromobenzo[b]thiophene-2-carboxylic acid
[0580] LiOH·H₂O (5.4 mL, 129.7 mmol) and methyl 4-bromobenzo[b]thiophene-2-carboxylate (7.0 g, 25.9 mmol) were added sequentially to a mixture of THF (10 mL) and H₂O (2 mL). The resulting mixture was stirred at room temperature for 16 h. After completion of the reaction, the pH was adjusted to 3 with 1 M hydrochloric acid, followed by extraction with EA (60 mL × 3), drying over anhydrous Na₂SO₄, filtration, and concentration under reduced pressure to afford crude 1-benzothiophene-2-carboxylic acid (8.0 g). LCMS (m / z): 256.9 (M+H).
[0581] Step C: tert-Butyl (4-bromobenzo[b]thiophen-2-yl)carbamate
[0582] 4-Bromobenzo[b]thiophene-2-carboxylic acid (2.5 g), DPPA (3.2 mL, 14.7 mmol), DIEA (2.0 mL, 19.5 mmol), toluene (25 mL), and tert-butanol (1.4 mL, 14.7 mmol) were added sequentially to a reaction flask, and the resulting mixture was stirred at 100°C for 16 h. After completion of the reaction, the mixture was concentrated under reduced pressure, monitored by LCMS, and the crude product was purified by FCC (SiO2, EA / PE = 0-30%) to afford tert-butyl (4-bromo-1-benzothiophen-2-yl)carbamate (3.0 g). LCMS (m / z): 271.9 (M-56).
[0583] Step D: tert-Butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate
[0584] tert-Butyl (4-bromobenzo[b]thiophen-2-yl)carbamate (2.9 g, 8.9 mmol), 5,5,5',5'-tetramethyl-2,2'-bis(1,3,2-dioxaborolane) (5.0 g, 22.3 mmol), DephosPdCl2 (0.64 g, 0.9 mmol), KOAc (2.6 g, 26.7 mmol), and 1,4-dioxane (30 mL) were added sequentially to a reaction flask. The atmosphere was purged with nitrogen three times, and the reaction mixture was stirred at 95°C for 1 h. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the crude product was purified by FCC (SiO2, EA / PE = 0-30%) to afford tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (3.1 g, 98% yield).
[0585] Synthesis of Intermediate k5-A Referring to the synthesis of Intermediate k5, in step D, pinacol diboronate was used instead of 5,5,5',5'-tetramethyl-2,2'-bis(1,3,2-dioxaborolane).
[0586] Intermediates k6 and k7
[0587] Tert-butyl (4-bromo-5-fluorobenzo[b]thiophen-2-yl)carbamate (k6) and tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5-fluorobenzo[b]thiophen-2-yl)carbamate (k7)
[0588] Step A: Methyl 4-bromo-5-fluoro-1-benzothiophene-2-carboxylate
[0589] Under nitrogen at room temperature, potassium carbonate (37.5 g, 271.4 mmol) and methyl thioglycolate (17.3 g, 169.2 mmol) were added to a solution of 2-bromo-3,6-difluorobenzaldehyde (30 g, 135.7 mmol) in THF (500 mL). The reaction mixture was heated to 45°C and stirred for 4 hours, then heated to 90°C and stirred for 16 hours. After completion of the reaction, the reaction mixture was concentrated to dryness, water was added to the concentrate, and extraction was performed with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC (SiO2, DCM / PE = 0-8%) to yield methyl 4-bromo-5-fluoro-1-benzothiophene-2-carboxylate (24.3 g, 62% yield) as an off-white solid. LCMS (m / z): 288.9 (M+H).
[0590] Step B: 4-Bromo-5-fluoro-1-benzothiophene-2-carboxylic acid
[0591] Under nitrogen, lithium hydroxide monohydrate (10.6 g, 252.2 mmol) was added to a solution of methyl 4-bromo-5-fluoro-1-benzothiophene-2-carboxylate (24.3 g, 84.1 mmol) in THF (170 mL) and water (57 mL). The resulting mixture was stirred at room temperature for 3 hours. After completion of the reaction, as monitored by LCMS, the reaction solution was concentrated to dryness. Dilute aqueous hydrochloric acid (1N) was added to the concentrated residue until the pH reached ≈ 5, causing solid precipitation. Stirring was continued at room temperature for 0.5 hour, and the mixture was filtered. The filter cake was rinsed with water and dried under vacuum to yield 4-bromo-5-fluoro-1-benzothiophene-2-carboxylic acid (22.5 g, 98% yield) as an off-white solid. LCMS (m / z): 274.9 (M+H).
[0592] Step C: tert-Butyl (4-bromo-5-fluorobenzo[b]thiophen-2-yl)carbamate
[0593] Under nitrogen, triethylamine (11.6 g, 115.4 mmol) and diphenylphosphoryl azide (27.2 g, 98.9 mmol) were added to a solution of 4-bromo-5-fluoro-1-benzothiophene-2-carboxylic acid (22.5 g, 82.4 mmol) in anhydrous toluene (135 mL) and anhydrous tert-butyl alcohol (45 mL). The resulting mixture was stirred at 100°C for 16 h. After completion of the reaction, monitored by LCMS, the reaction solution was poured into 100 mL of saturated sodium bicarbonate solution and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by slurrying with EA / PE = 1 / 10 (80 mL) to obtain tert-butyl (4-bromo-5-fluorobenzo[b]thiophen-2-yl)carbamate (28 g, 98% yield) as a yellow solid. LCMS (m / z): 289.9 (M+H).
[0594] Step D: tert-Butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5-fluorobenzo[b]thiophen-2-yl)carbamate
[0595] Under nitrogen protection at room temperature, to a solution of tert-butyl (4-bromo-5-fluorobenzo[b]thiophen-2-yl)carbamate (5 g, 14.5 mmol) in 1,4-dioxane (80 mL) was added neopentyl glycol diborate (4.88 g, 21.7 mmol), potassium acetate (2.83 g, 28.9 mmol), and DPEphosPdCl2 (1.04 g, 1.45 mmol). The resulting reaction mixture was heated to 90°C and stirred for 16 h. After completion of the reaction, as monitored by LCMS, the reaction mixture was filtered through celite, the filter cake was rinsed with ethyl acetate, and the filtrate was concentrated to dryness. The crude product was purified by FCC (SiO2, EA / PE = 0-10%) to give tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5-fluorobenzo[b]thiophen-2-yl)carbamate (3.2 g, 58% yield) as a white solid. LCMS (m / z): 256.0 (M+H-68-56). 1 H NMR (400MHz, DMSO-d6) δ10.73(s,1H),7.86–7.77(m,1H),7.14(d,J=0.7Hz,1H),6.90(dd,J=9.8,8.6Hz,1H),3.81(s,4H),1.49(s,9H),1.02(s,6H).
[0596] Intermediates k8 and k9
[0597] Tert-butyl (4-bromo-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate (k8) and tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborol-2-yl)-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate (k9)
[0598] Step A: 1-(2-Bromo-4-fluoro-6-methylphenyl)diazonium fluoroborate
[0599] Under nitrogen at 0-5°C, a solution of 2-bromo-4-fluoro-6-toluidine (23.5 g, 115.2 mmol) in aqueous fluoroboric acid (140 mL, 50 wt%) was slowly added dropwise to a solution of sodium nitrite (9.5 g, 138.2 mmol) in water (20 mL). The resulting reaction mixture was stirred at 0°C for 1 h. After completion of the reaction, monitored by LCMS, the reaction mixture was filtered, and the filter cake was rinsed with aqueous fluoroboric acid (50 mL, 50 wt%) and ethyl acetate (50 mL). The filter cake was dried under vacuum to afford 1-(2-bromo-4-fluoro-6-methylphenyl)diazoniumfluoroborate (31 g, 89% yield) as an off-white solid. LCMS (m / z): 216.9 (M+H).
[0600] Step B: 1-Bromo-2,5-difluoro-3-methylbenzene
[0601] Under nitrogen, 1-(2-bromo-4-fluoro-6-methylphenyl)diazonium fluoroborate was added to a single-necked flask containing a magnetic rod. The resulting system was heated to 170°C and stirred for 7 hours. After completion of the reaction, monitored by LCMS, the crude product was purified by FCC (SiO2, PE) to yield 1-bromo-2,5-difluoro-3-methylbenzene (16 g, 76% yield) as a colorless liquid. GCMS (m / z): 206.0 (M). 1 H NMR (400MHz, DMSO-d6) δ7.55–7.48(m,1H),7.29–7.22(m,1H),2.28(s,3H).
[0602] Step C: 2-Bromo-3,6-difluoro-4-methylbenzaldehyde
[0603] To a solution of 1-bromo-2,5-difluoro-3-methylbenzene (16 g, 77.3 mmol) in anhydrous THF (150 mL) at -70°C under nitrogen was slowly added dropwise LDA (46 mL, 2 M THF solution, 92.7 mmol). The reaction was stirred at the same temperature for 40 minutes, followed by the addition of anhydrous DMF (17 g, 231.9 mmol). The resulting mixture was stirred at -70°C for 1 hour. After completion of the reaction, monitored by LCMS, the reaction solution was poured into 100 mL of saturated ammonium chloride and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC (SiO2, EA / PE = 0-4%) to afford 2-bromo-3,6-difluoro-4-methylbenzaldehyde (15.5 g, 85% yield) as a pale yellow solid. LCMS (m / z): 236.9 (M+H).
[0604] Step D: Methyl 4-bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylate
[0605] To a solution of 2-bromo-3,6-difluoro-4-methylbenzaldehyde (15.5 g, 66.0 mmol) in tetrahydrofuran (200 mL) at room temperature under nitrogen was added potassium carbonate (18.2 g, 131.9 mmol) and methyl thioglycolate (8.4 g, 79.1 mmol). The resulting reaction solution was heated to 45°C and stirred for 4 hours, then heated to 90°C and stirred for 16 hours. After completion of the reaction, as monitored by LCMS, the reaction solution was concentrated to dryness, water was added to the concentrate, and extraction was performed with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by slurrying with EA (100 mL) to obtain methyl 4-bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylate (7.5 g, 37% yield) as a pale yellow solid. LCMS (m / z): 302.9 (M+H).
[0606] Step E: 4-Bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylic acid
[0607] Under nitrogen, lithium hydroxide monohydrate (3.1 g, 74.3 mmol) was added to a solution of methyl 4-bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylate (7.5 g, 24.7 mmol) in tetrahydrofuran (60 mL) and water (20 mL). The resulting mixture was stirred at room temperature for 3 hours. After completion of the reaction, as monitored by LCMS, the reaction solution was concentrated to dryness. Dilute aqueous hydrochloric acid (1 N) was added to the concentrate until the pH reached ≈ 5, causing solid precipitation. Stirring was continued at room temperature for 0.5 hour, and the mixture was filtered. The filter cake was rinsed with water and dried under vacuum to afford 4-bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylic acid (6.7 g, 94% yield) as an off-white solid. LCMS (m / z): 288.9 (M+H).
[0608] Step F: tert-Butyl (4-bromo-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate
[0609] Under nitrogen, triethylamine (3.3 g, 32.6 mmol) and diphenylphosphoryl azide (7.7 g, 27.9 mmol) were added to a solution of 4-bromo-5-fluoro-6-methylbenzo[b]thiophene-2-carboxylic acid (6.7 g, 23.3 mmol) in anhydrous toluene (40 mL) and anhydrous tert-butyl alcohol (13 mL). The resulting mixture was stirred at 100°C for 16 h. After completion of the reaction, monitored by LCMS, the reaction solution was poured into 100 mL of saturated sodium bicarbonate solution and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by slurrying with EA / PE = 1 / 10 (30 mL) to obtain tert-butyl (4-bromo-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate (7.1 g, 85% yield) as a yellow solid. LCMS (m / z): 303.9 (M+H-56).
[0610] Step G: tert-Butyl (4-(5,5-dimethyl-1,3,2-dioxaborol-2-yl)-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate
[0611] To a solution of tert-butyl (4-bromo-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate (3.0 g, 8.3 mmol) in 1,4-dioxane (48 mL) at room temperature was added neopentyl glycol diborate (2.8 g, 12.5 mmol), potassium acetate (1.63 g, 16.6 mmol), and DPEphosPdCl2 (594 mg, 0.83 mmol). The resulting reaction mixture was heated to 90°C and stirred for 16 hours. After completion of the reaction, monitored by LCMS, the reaction mixture was filtered through celite, the filter cake was rinsed with ethyl acetate, and the filtrate was concentrated to dryness. The crude product was purified by FCC (SiO2, EA / PE = 0-10%) to give tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborol-2-yl)-5-fluoro-6-methylbenzo[b]thiophen-2-yl)carbamate (1.5 g, 46% yield) as a white solid. LCMS (m / z): 270.0 (M+H-68-56). 1 H NMR (400MHz, DMSO-d6) δ10.65(s,1H),7.68(d,J=7.1Hz,1H),7.06(s,1H),3.80(s,4H),2.24(d,3H),1.48(s,9H),1.02(s,6H).
[0612] Intermediates k10 and k11
[0613] Tert-butyl (4-bromo-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (k10) and tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (k11)
[0614] Step A: 2-Bromo-3,6-difluoro-5-nitrobenzaldehyde
[0615] To a three-necked flask containing fuming nitric acid (42.7 g, 678.7 mmol) was slowly added dropwise concentrated sulfuric acid (90 mL) at 0°C. The mixture was stirred at this temperature for 10 minutes. 2-Bromo-3,6-difluorobenzaldehyde (30 g, 135.7 mmol) was then added portionwise to the reaction mixture. The mixture was stirred at 0°C for 10 minutes. The resulting mixture was stirred at room temperature for 1 hour. After completion of the reaction, as monitored by LCMS, the mixture was slowly added to ice water and extracted with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness. The crude product was purified by FCC (SiO2, EA / PE = 0-10%) to afford 2-bromo-3,6-difluoro-5-nitrobenzaldehyde as a pale yellow solid (31.3 g, 87% yield). 1 H NMR (400MHz, DMSO-d6) δ10.18 (s, 1H), 8.61 (dd, J = 8.0, 6.5Hz, 1H)
[0616] Step B: Methyl 4-bromo-5-fluoro-7-nitrobenzo[b]thiophene-2-carboxylate
[0617] To a solution of 2-bromo-3,6-difluoro-5-nitrobenzaldehyde (30.0 g, 113 mmol) in DMF (300 mL) at 0°C were added potassium carbonate (23.4 g, 169 mmol) and methyl thioglycolate (14.4 g, 135 mmol). The resulting reaction mixture was stirred at room temperature for 12 hours. After completion of the reaction, monitored by LCMS, the reaction mixture was slowly added to ice water and filtered. The filter cake was purified by slurrying (EA / PE = 2 / 1) to obtain methyl 4-bromo-5-fluoro-7-nitrobenzo[b]thiophene-2-carboxylate (15 g, 40% yield) as a yellow solid. LCMS (m / z): 333.9 (M+H).
[0618] Step C: 7-amino-4-bromo-5-fluorobenzo[b]thiophene-2-carboxylic acid methyl ester
[0619] To a solution of methyl 4-bromo-5-fluoro-7-nitrobenzo[b]thiophene-2-carboxylate (15.0 g, 44.9 mmol) in ethanol (130 mL) and acetic acid (20 mL) at 0°C was added reduced iron powder (12.0 g, 224 mmol). The mixture was stirred at room temperature for 2 hours. After completion of the reaction, as monitored by LCMS, the reaction solution was filtered through celite and the filtrate was washed with water, saturated sodium bicarbonate, and saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to yield the desired product, methyl 7-amino-4-bromo-5-fluorobenzo[b]thiophene-2-carboxylate (10.0 g, 74% yield). LCMS (m / z): 303.9 (M+H).
[0620] Step D: Methyl 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylate
[0621] To a solution of methyl 7-amino-4-bromo-5-fluorobenzo[b]thiophene-2-carboxylate (9.5 g, 31.2 mmol) in tetrafluoroboric acid (80 mL, 40 wt% aqueous solution) at 0°C was added sodium nitrite (4.1 g, 46.9 mmol). The reaction was stirred at this temperature for 1 hour. After complete conversion of the starting material to the diazonium salt as monitored by LCMS, the reaction mixture was filtered and the filter cake collected to yield a yellow solid. The resulting yellow solid was stirred at 200°C for 20 minutes. After completion of the reaction as monitored by LCMS, the crude product was purified by FCC (SiO2, EA / PE = 0-45%) to yield methyl 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylate (1.6 g, 17% yield) as a yellow solid. 1 H NMR (400MHz, DMSO-d6) δ8.03 (d, J=3.3Hz, 1H), 7.81 (dd, J=9.8, 9.2Hz, 1H), 3.93 (s, 3H). 19 F NMR (376 MHz, DMSO-d6) δ -106.95 to -106.97, -112.37 to -112.40 and 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylic acid (1.4 g, yield 15%). 1 H NMR (400MHz, DMSO-d6) δ14.11 (s, 1H), 8.01 (d, J = 3.3Hz, 1H), 7.83–7.75 (m, 1H). 19 F NMR (376MHz, DMSO-d6) δ-107.30~-107.32,-112.50~-112.52.
[0622] Step E: 4-Bromo-5,7-difluorobenzo[b]thiophene-2-carboxylic acid
[0623] To a solution of methyl 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylate (1.6 g, 5.2 mmol) in tetrahydrofuran (10 mL), methanol (3 mL), and water (3 mL) was added lithium hydroxide monohydrate (656 mg, 15.6 mmol) at room temperature. The reaction was stirred at room temperature for 2 hours. After completion of the reaction, as monitored by LCMS, water (30 mL) and 1N hydrochloric acid solution (5 mL) were added to the reaction solution, which was then extracted with ethyl acetate. The organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to yield the crude product 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylic acid (1.4 g, 92% yield).
[0624] Step F: tert-Butyl (4-bromo-5,7-difluorobenzo[b]thiophen-2-yl)carbamate
[0625] To a solution of 4-bromo-5,7-difluorobenzo[b]thiophene-2-carboxylic acid (2.8 g, 9.5 mmol) in toluene (40 mL) and tert-butanol (10 mL) at room temperature were added triethylamine (2.9 g, 28.4 mmol) and diphenylphosphoryl azide (3.7 g, 14.3 mmol). The resulting reaction mixture was heated to 100°C and stirred for 12 hours. After completion of the reaction, the mixture was concentrated to dryness, and the crude product was purified by FCC (SiO2, EA / PE = 0-15%) to afford tert-butyl (4-bromo-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (3.0 g, 86% yield) as a yellow solid. LCMS (m / z): 307.8 (M-56).
[0626] Step G: tert-Butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate
[0627] To a solution of tert-butyl (4-bromo-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (2.5 g, 6.8 mmol) in 1,4-dioxane (40 mL) at room temperature under nitrogen was added neopentyl glycol diborate (2.0 g, 8.9 mmol), potassium acetate (2.0 g, 20.6 mmol), and DPEphosPdCl2 (501 mg, 0.7 mmol). The reaction mixture was heated to 90°C and stirred for 5 h. After completion of the reaction, monitored by GCMS, the reaction mixture was concentrated to dryness, and the crude product was purified by FCC (SiO2, EA / PE = 0-10%) to afford tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5,7-difluorobenzo[b]thiophen-2-yl)carbamate (1.4 g, 51% yield) as a yellow solid. 1H NMR (400MHz, DMSO-d6) δ10.98 (s, 1H), 7.24 (d, J = 3.8Hz, 1H), 7.00–6.91 (m, 1H), 3.80 (s, 4H), 1.01 (s, 6H). 19 F NMR(376MHz,DMSO-d6)δ-103.69–-103.85,-111.30–-111.46.
[0628] Intermediates k12 and k13
[0629] Tert-butyl (4-bromo-7-fluorobenzo[b]thiophen-2-yl)carbamate (k12) and tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (k13)
[0630] Step A: Methyl 4-bromo-7-fluorobenzo[b]thiophene-2-carboxylate
[0631] At room temperature, compound 6-bromo-2,3-difluorobenzaldehyde (15 g, 68.2 mmol), methyl thioglycolate (6.7 mL, 75 mmol), K2CO3 (18.8 g, 13.6 mmol), and DMF (150 mL) were added sequentially to a reaction flask equipped with a magnetic bar. The resulting mixture was heated to 110°C and stirred for 10 h. The reaction was monitored by TLC. The reaction solution was poured into 300 mL of water, and a large amount of yellow solid precipitated. The solid was filtered, the filter cake was washed with water, and dried at 50°C to obtain compound 4-bromo-7-fluorobenzo[b]thiophene-2-carboxylic acid methyl ester (13 g, yield 66%). GCMS (m / z): 288 / 290 (M ·+ ). 1 H NMR (400MHz, Chloroform-d) δ8.16–8.13(m,1H),7.55–7.47(m,1H),7.08–6.98(m,1H),3.98(s,3H). 19 F NMR(376MHz,Chloroform-d)δ-116.23.
[0632] Step B: 4-Bromo-7-fluorobenzo[b]thiophene-2-carboxylic acid
[0633] LiOH·H₂O (7.3 g, 173.6 mmol) and methyl 4-bromo-7-fluorobenzo[b]thiophene-2-carboxylate (10 g, 34.7 mmol) were added sequentially to a mixture of THF (100 mL) and H₂O (20 mL). The resulting mixture was stirred at room temperature for 16 h. After completion of the reaction, the pH was adjusted to 3 with 1 M hydrochloric acid and extracted with EA (80 mL x 3). The combined organic phases were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford 4-bromo-7-fluorobenzo[b]thiophene-2-carboxylic acid (9.3 g, 98% yield).
[0634] Step C: tert-Butyl (4-bromo-7-fluorobenzo[b]thiophen-2-yl)carbamate
[0635] 4-Bromo-7-fluorobenzo[b]thiophene-2-carboxylic acid (9.3 g), DPPA (11 mL, 51 mmol), DIPEA (8.8 mL, 51 mmol), toluene (100 mL), and tert-butyl alcohol (4.8 mL, 51 mmol) were added sequentially to a reaction flask, and the resulting mixture was stirred at 100°C for 16 h. After completion of the reaction, monitored by LCMS, the mixture was concentrated under reduced pressure, and the crude product was purified by FCC (SiO2, EA / PE = 0-30%) to afford tert-butyl (4-bromo-7-fluorobenzo[b]thiophen-2-yl)carbamate (10 g, 85% yield). 1 H NMR (400MHz, Chloroform-d) δ7.40–7.34(m,2H),6.84–6.73(m,2H),1.56(s,9H). 19 F NMR(376MHz,Chloroform-d)δ-118.33.
[0636] Step D: tert-Butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate
[0637] tert-Butyl (4-bromo-7-fluorobenzo[b]thiophen-2-yl)carbamate (10 g, 29 mmol), 5,5,5',5'-tetramethyl-2,2'-bis(1,3,2-dioxaborolane) (24.9 g, 110 mmol), DPEpHosPdCl2 (2.1 g, 2.9 mmol), KOAc (8.5 g, 87 mmol), and 1,4-dioxane (150 mL) were added sequentially to a reaction flask. The atmosphere was replaced with nitrogen three times, and the resulting reaction solution was stirred at 95°C for 1 h. After completion of the reaction, the reaction was concentrated under reduced pressure, and the crude product was purified by FCC (SiO2, EA / PE = 0-30%) to afford tert-butyl (4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate (12 g). LCMS (m / z): 255.9 (M+H-68-56).
[0638] Intermediate k14
[0639] tert-Butyl (3-cyano-4-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-7-fluorobenzo[b]thiophen-2-yl)carbamate
[0640] The synthesis and characterization of intermediate k14 were carried out according to the method described in WO2021118877A1.
[0641] Intermediate a1
[0642] (3-Fluoro-1-methylpiperidin-3-yl)methanol
[0643] Step A: (3-Fluoro-1-methylpiperidin-3-yl)methanol
[0644] Under N2, 2-methyltetrahydrofuran (5 mL) was added to the compound 3-fluoro-1-methylpiperidine-3-carboxylic acid methyl ester (200 mg, 0.76 mmol). Then, lithium aluminum tetrahydride (1.5 mL, 1.5 mmol, 1.0 mol / L tetrahydrofuran solution) was slowly added dropwise at 0°C. The resulting reaction solution was stirred at 70°C for 5 hours. After the reaction was completed as monitored by LCMS, 1 mL of water and 30 mL of ethyl acetate were added to the reaction solution to quench the reaction. The resulting reaction mixture was filtered through celite, and the filtrate was concentrated to dryness to give a colorless oily crude product (3-fluoro-1-methylpiperidin-3-yl)methanol (130 mg, yield 77%). 1H NMR (400MHz, DMSO-d6) δ4.89(s,1H),3.53–3.27(m,3H),2.48–2.22(m,2H),2.21–2.04(m,4H),1.65–1.42(m,4H). 19 F NMR(376MHz,DMSO-d6)δ-165.75.
[0645] Intermediate a2
[0646] (1,3-Dimethylpiperidin-3-yl)methanol
[0647] Step A: (1,3-Dimethylpiperidin-3-yl)methanol
[0648] Under N₂, 2-methyltetrahydrofuran (2 mL) was added to methyl 3-fluoro-1-methylpiperidine-3-carboxylate (300 mg, 1.23 mmol). Lithium aluminum tetrahydride (2.5 mL, 2.5 mmol, 1.0 mol / L tetrahydrofuran solution) was then slowly added dropwise at 0°C. The resulting reaction solution was stirred at 70°C for 4 hours. After completion of the reaction, 1 mL of water and 30 mL of ethyl acetate were added to the reaction solution to quench the reaction. The resulting reaction mixture was filtered through celite, and the filtrate was concentrated to dryness to obtain the crude product (3-fluoro-1-methylpiperidin-3-yl)methanol (150 mg, 85% yield) as a colorless oil. LCMS (m / z): 144.0 (M+H).
[0649] Intermediate a3
[0650] (1-(2-Methoxyethyl)-3-methylpiperidin-3-yl)methanol
[0651] Step A: 3-Methylpiperidine-3-carboxylic acid trifluoroacetate
[0652] To 1-(tert-butoxycarbonyl)-3-methylpiperidine-3-carboxylic acid (700 mg, 2.88 mmol) was added dichloromethane (2 mL) and trifluoroacetic acid (2 mL) at room temperature. The resulting reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated to dryness to obtain a crude yellow solid, 3-methylpiperidine-3-carboxylic acid trifluoroacetate (500 mg, crude product), which was used directly in the subsequent reaction.
[0653] Step B: 2-Methoxyethyl 1-(2-methoxyethyl)-3-methylpiperidine-3-carboxylate
[0654] To 3-methylpiperidine-3-carboxylic acid (300 mg) was added DMF (5 mL) at room temperature. Potassium carbonate (1.45 g, 10.5 mmol) and 1-bromo-2-methoxyethane (728 mg, 21.1 mmol) were then added sequentially. The resulting reaction solution was stirred at room temperature for 12 hours. After completion of the reaction, monitored by TLC (100% EtOAc), the reaction solution was filtered and concentrated to dryness. The crude product was purified by FCC (SiO2, EtOAc / PE = 50-100%) to afford 2-methoxyethyl 1-(2-methoxyethyl)-3-methylpiperidine-3-carboxylate (290 mg) as a colorless oil. 1 H NMR(400MHz,Chloroform-d)δ4.28–4.18(m,2H),3.59(t,J=4.8Hz,2H),3.49(t,J=6.1Hz,2H),3.38(s,3H ),3.33(s,3H),3.14–3.02(m,1H),2.66–2.43(m,3H),2.26–1.87(m,4H),1.72–1.55(m,2H),1.15(s,3H).
[0655] Step C: (1-(2-methoxyethyl)-3-methylpiperidin-3-yl)methanol
[0656] Under N₂, anhydrous tetrahydrofuran (2 mL) was added to 2-methoxyethyl 1-(2-methoxyethyl)-3-methylpiperidine-3-carboxylate (230 mg, 0.09 mmol). Lithium aluminum tetrahydride (2.2 mL, 2.2 mmol, 1.0 mol / L tetrahydrofuran solution) was then slowly added dropwise at 0°C. The resulting reaction solution was stirred at 0°C for half an hour. After completion of the reaction, as monitored by LCMS, 1 mL of water and 30 mL of ethyl acetate were added to quench the reaction. The resulting reaction mixture was filtered through celite, and the filtrate was concentrated to dryness to obtain the crude product (1-(2-methoxyethyl)-3-methylpiperidin-3-yl)methanol (110 mg, 66% yield) as a yellow oil. LCMS (m / z): 188.1 (M+H).
[0657] Intermediate a4
[0658] (1-(2-Fluoroethyl)-3-methylpiperidin-3-yl)methanol
[0659] Step A: 2-Fluoroethyl 1-(2-Fluoroethyl)-3-methylpiperidine-3-carboxylate
[0660] To 3-methylpiperidine-3-carboxylic acid (200 mg, 1.4 mmol) was added DMF (5 mL) at room temperature. Potassium carbonate (965 mg, 6.9 mmol) and 1-fluoro-2-iodoethane (607 mg, 3.5 mmol) were then added sequentially. The resulting reaction solution was stirred at room temperature for 12 hours. After completion of the reaction, monitored by TLC (100% EtOAc), the reaction solution was filtered and concentrated to dryness. The crude product was purified by FCC (SiO2, EtOAc / PE = 50-100%) to afford 2-fluoroethyl 1-(2-fluoroethyl)-3-methylpiperidine-3-carboxylate (180 mg, 55% yield) as a colorless oil. 1 H NMR(400MHz,Chloroform-d)δ4.69–4.63(m,1H),4.62–4.57(m,1H),4.56–4.51(m,1H),4.49–4.44(m,1H),4.4 1–4.28(m,2H),2.74–2.59(m,2H),2.22–1.97(m,4H),1.75–1.53(m,4H),1.17(s,3H).LCMS(m / z):236.0(M+H).
[0661] Step B: (1-(2-Fluoroethyl)-3-methylpiperidin-3-yl)methanol
[0662] Under N₂, anhydrous tetrahydrofuran (2 mL) was added to 2-fluoroethyl 1-(2-fluoroethyl)-3-methylpiperidine-3-carboxylate (180 mg, 0.76 mmol). Lithium aluminum tetrahydride (2.3 mL, 2.3 mmol, 1.0 mol / L tetrahydrofuran solution) was then slowly added dropwise at 0°C. The resulting reaction solution was stirred at 0°C for half an hour. After completion of the reaction, 1 mL of water and 30 mL of ethyl acetate were added to the reaction solution to quench the reaction. The resulting reaction mixture was filtered through celite, and the filtrate was concentrated to dryness to obtain the crude product (1-(2-fluoroethyl)-3-methylpiperidin-3-yl)methanol (100 mg, 74% yield) as a yellow oil. LCMS (m / z): 176.1 (M+H).
[0663] Intermediate a5
[0664] (4-Methoxy-1,3-dimethylpiperidin-3-yl)methanol
[0665] Step A: 3-Methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester
[0666] At room temperature, CH₃I (13.79 g, 97.17 mmol) was added dropwise to a stirred mixture of 1-(tert-butyl)-3-methyl 4-oxopiperidine-1,3-dicarboxylate (5.0 g, 19.43 mmol), K₂CO₃ (8.06 g, 58.30 mmol), and anhydrous acetonitrile (50 mL). The mixture was allowed to react overnight at room temperature. After TLC analysis, the reaction mixture was poured into NH₄Cl (100 mL) and extracted with EA (100 mL x 3). The collected organic phase was washed with saturated NaCl (50 mL). The organic phase was concentrated to obtain the crude product, which was purified by FCC (SiO₂, EA / PE = 0-20%) to afford 1-(tert-butyl)-3-methyl 4-oxopiperidine-1,3-dicarboxylate (4.85 g, 92% yield) as a colorless oil. LCMS (m / z): 216.0 (M+H-56). 1 H NMR (400MHz, Methanol-d4) δ4.51 (d, J= 13.7Hz,1H),4.23–4.05(m,1H),3.73(s,3H),3.47–3.27(m,1H),3.17(d, J=13.7Hz,1H),2.75(s,1H),2.57–2.41(m,1H),1.50(s,9H),1.28(s,3H).
[0667] Step B: 4-Hydroxy-3-methylpiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester
[0668] Under ice-cooling conditions, NaBH₄ (230 mg, 6.08 mmol) was added portionwise to a mixture of 3-methyl-1-(tert-butyl)-4-oxopiperidine-1,3-dicarboxylate (1.5 g, 5.53 mmol) and MeOH (15 mL). The mixture was stirred at room temperature for 15 minutes. TLC indicated the disappearance of the starting material. The reaction mixture was poured into NH₄Cl (50 mL) and extracted with EA (50 mL x 3). The collected organic phase was washed with saturated NaCl (30 mL). The organic solution was concentrated to obtain the crude product, which was purified by FCC (SiO₂, EA / PE = 0-60%) to afford 3-methyl-1-(tert-butyl)-4-hydroxy-3-methylpiperidine-1,3-dicarboxylate (800 mg, 53% yield) as a colorless oil. LCMS (m / z): 218.0 (M+H-56). 1 H NMR (400MHz, Methanol-d4) δ3.91–3.83(m,1H),3.71–3.66(m,3H),3.64–3.47(m,3H),1.90–1.78(m,1H),1.73–1.56(m,1H),1.45(s,9H),1.14(s,3H).
[0669] Step C: 4-methoxy-3-methylpiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester
[0670] NaH (219 mg, 5.49 mmol, 60%) was added to a mixture of 1-(tert-butyl)-3-methyl-4-hydroxy-3-methylpiperidine-1,3-dicarboxylate (500 mg, 1.83 mmol) and DMF (12 mL) under ice-cooling conditions. The mixture was stirred for 20 minutes. CHI (1.3 g, 9.15 mmol) was then added to the reaction mixture, and the mixture was stirred for 3 hours under ice-cooling conditions. After TLC analysis, the reaction mixture was poured into NH4Cl (80 mL) and extracted with EA (50 mL × 3). The collected organic phase was washed with saturated NaCl (20 mL). The organic phase was concentrated and the crude product was purified by FCC (SiO2, EA / PE = 0-20%) to afford 1-(tert-butyl)-3-methyl-4-methoxy-3-methylpiperidine-1,3-dicarboxylate (350 mg, 67% yield) as a colorless oil. LCMS (m / z): 232.0 (M+H-56).
[0671] Step D: (4-methoxy-1,3-dimethylpiperidin-3-yl)methanol
[0672] At room temperature, LiAH4 (5.39 mL, 5.39 mmol, 1 M in THF) was added to 3-methyl-1-(tert-butyl)-4-methoxy-3-methylpiperidin-1,3-dicarboxylate (310 mg, 1.08 mmol) and stirred at 70°C for 2 hours. After completion of the reaction, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAH4 until gas production ceased. The mixture was then dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated to afford (4-methoxy-1,3-dimethylpiperidin-3-yl)methanol (170 mg, 91% yield) as a colorless liquid. LCMS (m / z): 174.0 (M+H). 1 H NMR (400MHz, Methanol-d4) δ3.69–3.52(m,2H),3.34(s,3H),3.22–3.03(m,1H) ),2.80–2.42(m,2H),2.33–2.17(m,4H),2.13–1.50(m,4H),1.08–0.88(m,3H).
[0673] Intermediate a5A
[0674] The compound 3-methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) ester 3-methyl ester (120 g) was separated by SFC (SFC150, Waters) (separation column: DAICEL 250 x 50 mm, 10 μm; mobile phase: CO2 / MeOH = 90 / 10; flow rate: 120 mL / min) to obtain the first eluting isomer 1, compound a5A (52.8 g, relatively short retention time). Chiral analysis method SFC-3, Rt = 0.682 min. 1 H NMR (400 MHz, Chloroform-d) δ 4.59–4.42 (m, 1H), 4.26–3.98 (m, 1H), 3.73 (s, 3H), 3.42–3.24 (m, 1H), 3.16–3.01 (m, 1H), 2.93–2.63 (m, 1H), 2.58–2.40 (m, 1H), 1.49 (s, 9H), 1.31 (s, 3H). LCMS (m / z): 216.1 (M-56+H). The subsequently eluted isomer 2 was compound a5B (52.4 g, relatively long retention time). Chiral analysis by SFC-3: Rt = 1.035 min. 1 H NMR(400MHz,Chloroform-d)δ4.60–4.41(m,1H),4.24–3.94(m,1H),3.73(s,3H),3.42–3.24 (m,1H),3.17–3.00(m,1H),2.93–2.64(m,1H),2.56–2.40(m,1H),1.49(s,9H),1.31(s,3H).
[0675] Intermediate a5A-1
[0676] (3S)-(4-Methoxy-1,3-dimethylpiperidin-3-yl)methanol
[0677] Step A: (3R)-4-Hydroxy-3-methylpiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester
[0678] Under ice-cooling conditions, NaBH₄ (279 mg, 7.37 mmol) was added portionwise to a mixture of (R)-tert-butyl 3-methyl-4-oxopiperidine-1-carboxylate-3-carboxylate (Intermediate a5A, 2.0 g, 7.37 mmol) and MeOH (50 mL). The mixture was stirred under ice-cooling conditions for 10 min. TLC indicated the disappearance of the starting material. The reaction mixture was then poured into NH₄Cl (100 mL) and extracted with EA (100 mL × 3). The collected organic phases were washed with saturated aqueous NaCl (30 mL). The organic phases were concentrated to obtain a crude product which was purified by FCC (SiO₂, EA / PE = 0% to 40%) to afford 3-methyl (3R)-1-(tert-butyl)4-hydroxy-3-methylpiperidine-1,3-dicarboxylate as a colorless oil (1.7 g, 85% yield). LCMS (m / z): 218.1 (M+H-56). 1 H NMR(400MHz,Chloroform-d)δ4.05–3.93(m,1H),3.78–3.70(m,3H),3.69–3.59(m,2H),3.35–3.22(m ,1H),3.20–3.10(m,1H),1.97–1.82(m,1H),1.77–1.63(m,1H),1.54–1.40(m,9H),1.29–1.18(m,3H).
[0679] Step B: (3R)-4-methoxy-3-methylpiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester
[0680] Under ice-cooling conditions, NaH (439 mg, 10.94 mmol, 60%) was added to a mixture of 3-methyl (3R)-4-hydroxy-3-methylpiperidine-1,3-dicarboxylate (1.0 g, 3.66 mmol) and DMF (10 mL) and stirred for 20 minutes. CHI (1.56 g, 10.94 mmol) was then added to the reaction mixture, and stirring continued for 3 hours under ice-cooling conditions. After completion of the reaction, monitored by TLC, the reaction solution was poured into saturated aqueous NH4Cl (80 mL) and extracted with EA (50 mL x 3). The collected organic phase was washed with saturated aqueous NaCl (20 mL). The concentrated crude product was purified by FCC (SiO2, EA / PE = 0-40%) to afford 3-methyl (3R)-4-methoxy-3-methylpiperidine-1,3-dicarboxylate (tert-butyl) as a white solid (1.0 g, 95% yield). LCMS (m / z): 232.1 (M+H-56). 1H NMR(400MHz,Chloroform-d3)δ3.98–3.78(m,1H),3.75–3.61(m,4H),3.56–3.47(m,1H),3.46–3.36 (m,1H),3.34(s,1H),3.30(s,2H),3.19–2.86(m,1H),1.89–1.56(m,2H),1.45(s,9H),1.16(s,3H).
[0681] Step C: (3S)-(4-methoxy-1,3-dimethylpiperidin-3-yl)methanol
[0682] At room temperature, LiAH4 (2.04 mL, 2.04 mmol, 1 M in THF) was added to 3-methyl (3R)-4-methoxy-3-methylpiperidin-1,3-dicarboxylate (200 mg, 0.696 mmol) and the mixture was heated to 70°C and stirred for 2 h. After the reaction, as monitored by LCMS, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAH4 until gas production ceased. The mixture was then diluted with a small amount of EA and dried over anhydrous sodium sulfate. The mixture was filtered, and the mother liquor was concentrated to afford a colorless liquid (3S)-(4-methoxy-1,3-dimethylpiperidin-3-yl)methanol (120 mg, 99% yield). LCMS (m / z): 174.1 (M+H). 1 H NMR(400MHz,Chloroform-d3)δ3.95–3.53(m,4H),3.30(s,2H),3.27(s,1H),3.13–2 .55(m,2H),2.16(s,1H),2.13(s,2H),2.04–1.81(m,3H),0.89(s,1H),0.83(s,2H).
[0683] Intermediate a5A-2
[0684] ((3S)-1-Ethyl-4-methoxy-3-methylpiperidin-3-yl)methanol
[0685] The synthesis of intermediate a5A-2 was carried out according to the method described for intermediate a6A-2.
[0686] Intermediate a6
[0687] (4,4-Difluoro-1,3-dimethylpiperidin-3-yl)methanol
[0688] Step A: 1-(tert-Butyl)3-methyl-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylate
[0689] At room temperature, DAST (4.87 mL, 5.94 g, 36.86 mmol) was added to a mixture of 3-methyl-1-(tert-butyl)-4-oxopiperidine-1,3-dicarboxylate (1.0 g, 3.69 mmol) and DCM (10 mL). The mixture was heated to 50°C and allowed to react overnight. After the reaction was complete, the reaction mixture was returned to room temperature and slowly added to saturated aqueous NaHCO₃. Extraction was performed with EA (100 mL x 3). The collected organic phase was washed with saturated NaCl (50 mL). The organic phase was concentrated to obtain a crude product, which was purified by FCC (SiO₂, EA / PE = 0-10%) to afford 3-methyl-1-(tert-butyl)-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylate (290 mg, 27% yield) as a colorless oil. LCMS (m / z): 238.0 (M+H-56).
[0690] Step B: (4,4-difluoro-1,3-dimethylpiperidin-3-yl)methanol
[0691] At room temperature, LiAH4 (4.94 mL, 4.94 mmol, 1 M in THF) was added to 3-methyl 1-(tert-butyl)-4,4-difluoro-3-methylpiperidin-1,3-dicarboxylate (290 mg, 989 umol) and stirred at 70°C for 2.5 hours. After completion of the reaction, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAH4 until gas production ceased. The solution was diluted with EA and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated to yield (4-methoxy-1,3-dimethylpiperidin-3-yl)methanol (170 mg, 96% yield) as a colorless liquid. LCMS (m / z): 180.0 (M+H).
[0692] Intermediate a6A-1
[0693] (S)-(4,4-Difluoro-1,3-dimethylpiperidin-3-yl)methanol
[0694] Step A: (S)-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylic acid-1-(tert-butyl) 3-methyl ester
[0695] Under ice-cooling conditions, BAST (19.57 g, 16.3 mL, 88.46 mmol) was added dropwise to a mixture of (R)-3-methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester (Intermediate a5A, 8.0 g, 29.49 mmol) and DCM (40 mL). After the addition was complete, the mixture was stirred at room temperature overnight. After completion of the reaction, monitored by TLC, the reaction mixture was slowly poured into a semi-saturated NaHCO solution (100 mL) and extracted with DCM (100 mL x 3). The combined organic phases were concentrated and purified by FCC (SiO, EA / PE = 0-10%) to afford (S)-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester (3.2 g, 37% yield) as a colorless oil. LCMS (m / z): 238.1 (M-56+H).
[0696] Step B: (S)-(4,4-difluoro-1,3-dimethylpiperidin-3-yl)methanol
[0697] At room temperature, LiAH4 (18.62 mL, 18.62 mmol, 1 M in THF) was added to 3-methyl (S)-4,4-difluoro-3-methylpiperidin-1,3-dicarboxylate (1.82 g, 6.21 mmol) and the mixture was heated to 70°C and stirred for 2 h. After completion of the reaction, monitored by LCMS, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAH4 until no further gas was generated. The mixture was then dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated to afford (S)-(4,4-difluoro-1,3-dimethylpiperidin-3-yl)methanol (1 g, 91% yield) as a colorless oil. LCMS (m / z): 180.1 (M+H).
[0698] Intermediate a6A-2
[0699] (S)-(4,4-Difluoro-1,3-dimethylpiperidin-3-yl)methanol
[0700] Step A: (S)-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylic acid-1-(tert-butyl) 3-methyl ester
[0701] Dissolve (R)-3-methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) ester (a5A, 10 g, 36.86 mmol) in 100 mL of anhydrous tetrahydrofuran and replace the atmosphere with nitrogen three times. Cool the reaction mixture to 0°C in an ice bath. Then, add [bis(2-methoxyethyl)amine]sulfur trifluoride (24.46 g, 20.39 mL, 110.57 mmol) dropwise to the reaction system. Return the mixture to room temperature and stir overnight. After TLC monitoring of the reaction, slowly pour the mixture into 500 mL of semi-saturated sodium bicarbonate solution and stir for 10 minutes until no bubbles form. Extract the mixture three times with dichloromethane. Combine the organic phases, wash with saturated brine, dry over anhydrous sodium sulfate, filter, and concentrate to obtain the crude product. The crude product was purified by FCC (SiO2, EA / PE = 0-17%) to afford (S)-3-methyl-1-(tert-butyl)-4,4-difluoro-3-methylpiperidine-1,3-dicarboxylate as a colorless oil (4.88 g, 43% yield). LCMS (m / z): 187.9 (M-56+H). 1H NMR (400 MHz, Chloroform-d) δ 4.09–3.79 (m, 1H), 3.74 (s, 3H), 3.70–3.15 (m, 3H), 2.60–2.18 (m, 1H), 2.07–1.91 (m, 1H), 1.45 (s, 9H), 1.33 (s, 3H).
[0702] Step B: (S)-(4,4-difluoro-3-methylpiperidine-3-carboxylic acid methyl ester) hydrochloride
[0703] At room temperature, 4M HCl-dioxane (30 mL) was added to (S)-3-methyl 4,4-difluoro-3-methylpiperidine-1,3-dicarboxylate (3.1 g, 10.57 mmol) and stirred for 1 hour. The mixture was concentrated under reduced pressure and then evaporated twice with EA (20 mL) to obtain (S)-(methyl 4,4-difluoro-3-methylpiperidine-3-carboxylate) hydrochloride (2.3 g, 95% yield) as a white solid.
[0704] Step C: (S)-1-ethyl-4,4-difluoro-3-methylpiperidine-3-carboxylic acid methyl ester
[0705] Potassium carbonate (429.22 mg, 3.11 mmol) and iodoethane (484.38 mg, 3.11 mmol) were added sequentially to a solution of (S)-(methyl 4,4-difluoro-3-methylpiperidine-3-carboxylate) hydrochloride (200 mg, 1.04 mmol) in acetonitrile (2 mL) at room temperature. The resulting mixture was stirred at 90°C overnight. After completion of the reaction, monitored by TLC, the reaction solution was filtered through celite, and the filter cake was washed twice with acetonitrile. The filtrate was collected and concentrated to dryness to afford (S)-methyl 1-ethyl-4,4-difluoro-3-methylpiperidine-3-carboxylate (110 mg, 48% yield) as a colorless oil, which was used directly in the next step without purification. LCMS (m / z): 222.1 (M+H).
[0706] Step D: (S)-(4,4-difluoro-1-(ethyl)-3-methylpiperidin-3-yl)methanol
[0707] Under ice-cooling conditions, a 1 M solution of LiAlH₄-THF (0.95 mL, 0.95 mmol) was added dropwise to a solution of (S)-1-ethyl-4,4-difluoro-3-methylpiperidine-3-carboxylic acid methyl ester (110 mg, 0.474 mmol) in anhydrous tetrahydrofuran (5 mL). The resulting mixture was stirred at room temperature for 20 minutes. After completion of the reaction, the mixture was quenched by adding Na₂SO₄·10H₂O until no bubbles formed. The mixture was then dried over approximately 5 g of anhydrous sodium sulfate. The reaction mixture was filtered through celite, and the filter cake was washed three times with anhydrous tetrahydrofuran. The filtrate was collected and concentrated to dryness to afford (S)-(4,4-difluoro-1-(ethyl)-3-methylpiperidin-3-yl)methanol (90 mg, 98% yield) as a colorless oil. This product was used directly in the next step without purification. LCMS (m / z): 194.1 (M+H).
[0708] Intermediate a6A-3
[0709] (S)-(4,4-Difluoro-1-(2-fluoroethyl)-3-methylpiperidin-3-yl)methanol
[0710] Step A: (S)-methyl 4,4-difluoro-1-(2-fluoroethyl)-3-methylpiperidine-3-carboxylate
[0711] Potassium carbonate (429 mg, 3.11 mmol) and 1-fluoro-2-iodoethane (540 mg, 3.11 mmol) were added sequentially to a solution of (S)-(methyl 4,4-difluoro-3-methylpiperidine-3-carboxylate) hydrochloride (200 mg, 1.04 mmol) in acetonitrile (2 mL) at room temperature. The resulting mixture was stirred at 90°C overnight. After completion of the reaction, monitored by TLC, the reaction solution was filtered through celite, and the filter cake was washed twice with acetonitrile. The filtrate was collected and concentrated to dryness to afford the product, (S)-methyl 4,4-difluoro-1-(2-fluoroethyl)-3-methylpiperidine-3-carboxylate (180 mg, 73% yield), as a colorless oil, which was used directly in the next step without purification. LCMS (m / z): 240.1 (M+H).
[0712] Step B: (S)-(4,4-difluoro-1-(2-fluoroethyl)-3-methylpiperidin-3-yl)methanol
[0713] Under ice-cooling conditions, a 1M LiAlH₄-THF solution (1.5 mL, 1.50 mmol) was added dropwise to a solution of (S)-(methyl 4,4-difluoro-1-(2-fluoroethyl)-3-methylpiperidin-3-carboxylate) (180 mg, 0.752 mmol) in anhydrous tetrahydrofuran (5 mL). The mixture was stirred at room temperature for 20 min. After completion of the reaction, the mixture was quenched by TLC, followed by addition of Na₂SO₄·10H₂O until bubbling ceased. The mixture was then dried over approximately 5 g of anhydrous sodium sulfate. The reaction mixture was filtered through celite, and the filter cake was washed three times with anhydrous tetrahydrofuran. The filtrate was collected and concentrated to dryness to afford (S)-(4,4-difluoro-1-(2-fluoroethyl)-3-methylpiperidin-3-yl)methanol (155 mg, 98% yield) as a colorless oil. This product was used directly in the next step without purification. LCMS (m / z): 212.1 (M+H).
[0714] Intermediate a6A-4
[0715] (S)-(4,4-Difluoro-1-allyl-3-methylpiperidin-3-yl)methanol
[0716] Step A: (S)-1-allyl-4,4-difluoro-3-methylpiperidine-3-carboxylic acid methyl ester
[0717] At room temperature, 3-bromoprop-1-ene (316 mg, 2.61 mmol) was added to a mixture of (S)-methyl 4,4-difluoro-3-methylpiperidine-3-carboxylate hydrochloride (200 mg, 0.871 mmol), K2CO3 (463 mg, 2.61 mmol), and ACN (5 mL). The mixture was heated to 90°C and stirred overnight. After completion of the reaction, the reaction solution was filtered through celite. The filtrate was concentrated and purified by FCC (SiO2, EA / PE = 0-20%) to give (S)-methyl 1-allyl-4,4-difluoro-3-methylpiperidine-3-carboxylate (160 mg, 79% yield) as a colorless oil. LCMS (m / z): 234.1 (M+H).
[0718] Step B: (S)-(1-allyl-4,4-difluoro-3-methylpiperidin-3-yl)methanol
[0719] LiAH₄ (1.37 mL, 1.37 mmol, 1 M THF solution) was added to (S)-methyl 1-allyl-4,4-difluoro-3-methylpiperidine-3-carboxylate (160 mg, 0.686 mmol) at room temperature and stirred for 10 min. After completion of the reaction, monitored by TLC, Na₂SO₄·10H₂O was slowly added to the reaction mixture in an ice bath to quench the LiAH₄ until gas production ceased. The mixture was then dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated to afford (S)-(1-allyl-4,4-difluoro-3-methylpiperidin-3-yl)methanol (140 mg, 99% yield) as a colorless oil. LCMS (m / z): 206.1 (M+H).
[0720] Intermediate a6A-5
[0721] (S)-(4,4-Difluoro-1-cyclopropyl-3-methylpiperidin-3-yl)methanol
[0722] Step A: (S)-1-cyclopropyl-4,4-difluoro-3-methylpiperidine-3-carboxylic acid methyl ester
[0723] A mixture of (S)-methyl 4,4-difluoro-3-methylpiperidine-3-carboxylate hydrochloride (300 mg, 1.31 mmol), cyclopropylboronic acid (449 mg, 5.23 mmol), K2CO3 (542 mg, 3.92 mmol), Cu(OAc)2 (23.73 mg, 0.131 mmol), and DCM (20 mL) was stirred at 40°C for 3 days under air. After product formation was monitored by LCMS, the reaction solution was poured into H2O (20 mL) and extracted with DCM (30 mL x 3). The combined organic phases were concentrated and purified by FCC (SiO2, EA / PE = 0-15%) to afford (S)-methyl 1-cyclopropyl-4,4-difluoro-3-methylpiperidine-3-carboxylate (67 mg, 22% yield) as a colorless oil. LCMS (m / z): 234.1 (M+H). 1 H NMR (400MHz, CDCl3) δ3.63 (s, 3H), 3.04 (d, J = 11.7Hz, 1H), 2.82–2.63 (m, 1H), 2.61–2.37 (m, 2H), 2.35– 2.12(m,1H),1.96–1.79(m,1H),1.64–1.53(m,1H),1.23(s,3H),0.44–0.32(m,2H),0.30–0.13(m,2H). 19 F NMR (376MHz, CDCl3) δ-106.32,-106.96.
[0724] Step B: (S)-(4,4-difluoro-1-cyclopropyl-3-methylpiperidin-3-yl)methanol
[0725] At room temperature, LiAH4 (0.18 mL, 0.18 mmol, 1 M THF solution) was added to a mixture of (S)-methyl 1-cyclopropyl-4,4-difluoro-3-methylpiperidine-3-carboxylate (42 mg, 0.18 mmol) and anhydrous THF (3 mL) and stirred at room temperature for 10 min. After completion of the reaction, monitored by TLC, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAlH4 until gas production ceased. The mixture was diluted with a small amount of EA and dried over anhydrous sodium sulfate. The mixture was filtered, and the mother liquor was concentrated to afford (S)-(4,4-difluoro-1-cyclopropyl-3-methylpiperidin-3-yl)methanol (32 mg, 87% yield) as a colorless oil. LCMS (m / z): 206.1 (M+H).
[0726] Intermediate a7
[0727] (3-Methyl-3-azabicyclo[4.1.0]heptan-1-yl)methanol
[0728] Step A: 7,7-Dichloro-3-methyl-3-azabicyclo[4.1.0]heptane-1-carboxylic acid methyl ester
[0729] Polyethylene glycol (1.0 g) was added to a mixed solution of 1-methyl-1,2,5,6-tetrahydropyridine-3-carboxylic acid methyl ester, hydrogen bromide (1.3 g, 5.5 mmol), sodium hydroxide (45 mL, 50% wt), and CHCl₃ (150 mL) at room temperature. After complete addition, the mixture was heated to 80°C and stirred overnight. After completion of the reaction, LCMS analysis confirmed the addition of water (50 mL) and extraction with DCM (50 mL x 3). The organic phase was washed with saturated brine, concentrated, and further subjected to FCC (SiO₂, EA / PE = 0-25%) to afford methyl 7,7-dichloro-3-methyl-3-azabicyclo[4.1.0]heptane-1-carboxylate (150 mg, 11% yield) as a colorless liquid. LC-MS (m / z): 238.0 (M+H).
[0730] Step B: (3-Methyl-3-azabicyclo[4.1.0]heptan-1-yl)methanol
[0731] LiAlH₄ (3.16 mL, 1 M THF solution, 3.16 mmol) was added dropwise to a mixture of methyl 7,7-dichloro-3-methyl-3-azabicyclo[4.1.0]heptane-1-carboxylate (150 mg, 0.63 mmol) and THF (2 mL) at room temperature. After complete addition, the mixture was heated to 70°C and stirred overnight. After completion of the reaction, the mixture was quenched with Na₂SO₄·10H₂O until gas evolution ceased. The reaction mixture was filtered through celite, and the filtrate was concentrated at low temperature (35°C) to afford a colorless liquid (3-methyl-3-azabicyclo[4.1.0]heptane-1-yl)methanol (40 mg, 45% yield), which was used directly in the subsequent reaction. LC-MS (m / z): 142.0 (M+H).
[0732] Intermediate a8
[0733] (4-Fluoro-1,3-dimethylpiperidin-3-yl)methanol
[0734] Intermediate a8A-1
[0735] (3S)-(4-Fluoro-1,3-dimethylpiperidin-3-yl)methanol
[0736] Step A: (S)-4-Fluoro-3-methyl-3,6-dihydropyridine-1,3(2H)-dicarboxylic acid-1-(tert-butyl) ester-3-methyl ester
[0737] Under ice-cooling conditions, BAST (19.57 g, 16.3 mL, 88.46 mmol) was added dropwise to a mixture of (R)-3-methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) 3-methyl ester (Intermediate a5A, 8.0 g, 29.49 mmol) and DCM (40 mL). After the addition was complete, the mixture was stirred at room temperature overnight. After completion of the reaction, monitored by TLC, the reaction mixture was slowly poured into a semi-saturated NaHCO solution (100 mL) and extracted with DCM (100 mL x 3). The combined organic phases were concentrated and purified by FCC (SiO, EA / PE = 0-10%) to afford (S)-3-methyl-4-fluoro-3-methyl-3,6-dihydropyridine-1,3(2H)-dicarboxylate (tert-butyl) 1-methyl ester (1.0 g, 12% yield) as a colorless oil. LCMS (m / z): 218.1 (M-56+H).
[0738] Step B: (S)-(4-Fluoro-1,3-dimethyl-1,2,3,6-tetrahydropyridin-3-yl)methanol
[0739] At room temperature, LiAH4 (4.02 mL, 4.02 mmol, in 1M THF) was added to (S)-3-methyl-1-(tert-butyl)-4-fluoro-3-methyl-3,6-dihydropyridine-1,3(2H)-dicarboxylate (500 mg, 1.83 mmol) and stirred at 70°C for 1 hour. After completion of the reaction, monitored by LCMS, Na2SO4·10H2O was slowly added to the reaction mixture in an ice bath to quench the LiAH4 until gas production ceased. The mixture was then dried over anhydrous sodium sulfate, filtered, and the mother liquor was concentrated to afford (S)-(4-fluoro-1,3-dimethyl-1,2,3,6-tetrahydropyridin-3-yl)methanol (284 mg, 98% yield) as a colorless oil. LCMS (m / z): 160.1 (M+H).
[0740] Step C: (3S)-(4-Fluoro-1,3-dimethylpiperidin-3-yl)methanol
[0741] Under nitrogen at room temperature, Pd / C (5% wt, 374 mg, 0.176 mmol) was added to a mixture of (S)-(4-fluoro-1,3-dimethyl-1,2,3,6-tetrahydropyridin-3-yl)methanol (280 mg, 1.76 mmol) and EA:MeOH = 1:1 (20 mL). The mixture was purged with hydrogen and then reacted under 60 psi H₂ pressure at room temperature for 2 h. After completion of the reaction, the reaction solution was filtered through Celite and washed with EA (50 mL). The organic phase was concentrated to afford (3S)-(4-fluoro-1,3-dimethylpiperidin-3-yl)methanol (220 mg, 78% yield) as a colorless oil. LCMS (m / z): 162 (M+H).
[0742] Intermediate a8A-2
[0743] ((3S)-1-Ethyl-4-fluoro-3-methylpiperidin-3-yl)methanol
[0744] Step A: (S)-4-Fluoro-3-methyl-1,2,3,6-tetrahydropyridine-3-carboxylic acid methyl ester hydrochloride
[0745] At room temperature, 4M HCl-dioxane (15 mL) was added to (S)-3-methyl-1-(tert-butyl)-4-fluoro-3-methyl-3,6-dihydropyridine-1,3(2H)-dicarboxylate (1 g, 3.66 mmol) and stirred for 1 hour. The reaction was monitored by LCMS. The solution was concentrated under reduced pressure to remove the acid, affording a pale yellow solid (S)-methyl-1,2,3,6-tetrahydropyridine-3-carboxylate hydrochloride (760 mg, 99% yield). LCMS (m / z): 174.1 (M+H).
[0746] Step B: (S)-1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridine-3-carboxylic acid methyl ester
[0747] At room temperature, iodoethane (1.7 g, 10.88 mmol) was added to a mixture of (S)-methyl 4-fluoro-3-methyl-1,2,3,6-tetrahydropyridine-3-carboxylate hydrochloride (760 mg, 3.63 mmol), K2CO3 (1.5 g, 10.88 mmol), and ACN (10 mL). The mixture was heated to 90°C and stirred for 5 h. After completion of the reaction, the mixture was filtered through Celite, and the filtrate was concentrated and purified by FCC (SiO2, EA / PE = 0-20%) to afford (S)-methyl 1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridine-3-carboxylate (317 mg, 43% yield) as a colorless oil. LCMS (m / z): 202.1 (M+H).
[0748] Step C: (S)-(1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridin-3-yl)methanol
[0749] At room temperature, LiAlH₄ (1.58 mL, 1.58 mmol, 1 M THF solution) was added to a solution of (S)-methyl 1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridine-3-carboxylate (317 mg, 1.58 mmol) in THF (3 mL) and stirred at room temperature for 10 min. After completion of the reaction, monitored by TLC, Na₂SO₄·10H₂O was slowly added to the reaction mixture in an ice bath to quench the LiAlH₄ until gas production ceased. The mixture was diluted with an appropriate amount of EA and dried over anhydrous sodium sulfate. The mixture was filtered, the mother liquor was collected, and concentrated to afford (S)-(1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridin-3-yl)methanol (250 mg, 92% yield) as a colorless oil. LCMS (m / z): 174.1 (M+H).
[0750] Step D: ((3S)-1-Ethyl-4-fluoro-3-methylpiperidin-3-yl)methanol
[0751] Under nitrogen at room temperature, Pd / C (10% wt, 154 mg, 144 umol) was added to a solution of (S)-(1-ethyl-4-fluoro-3-methyl-1,2,3,6-tetrahydropyridin-3-yl)methanol (250 mg, 1.44 mmol) in MeOH (50 mL). The mixture was replaced with H2 twice, and the reaction was stirred at 25°C under a hydrogen balloon for 2 h. After completion of the reaction, monitored by LCMS, the reaction mixture was filtered through Celite, washed with EA (50 mL), and the combined filtrates were concentrated to afford ((3S)-1-ethyl-4-fluoro-3-methylpiperidin-3-yl)methanol (200 mg, 79% yield) as a colorless oil. LCMS (m / z): 176.1 (M+H).
[0752] Intermediate a9A-1
[0753] (3S)-(1,3,4-Trimethylpiperidin-3-yl)methanol
[0754] Step A: (S)-3-Methyl-4-methylenepiperidin-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester
[0755] Under ice-cooling conditions, a solution of potassium tert-butoxide in THF (5.25 mL, 1 M, 5.25 mmol) was added dropwise to a solution of methyltriphenylphosphonium bromide (1.89 g, 5.25 mmol) in toluene (10 mL). The resulting mixture was stirred under ice-cooling for 0.5 h. A solution of (R)-3-methyl-4-oxopiperidine-1,3-dicarboxylic acid 1-(tert-butyl) ester (Intermediate a5A, 1.00 g, 3.50 mmol) in toluene (5 mL) was added dropwise to the reaction mixture. The reaction temperature was maintained for 1 h. The temperature was then slowly raised to 110°C and maintained with stirring overnight. The reaction was monitored for completion by TLC, and the mixture was cooled to room temperature and concentrated to dryness under reduced pressure to give a crude product. This was then purified by FCC (SiO2, EA / PE = 0-100%) to afford (S)-3-methyl-4-methylenepiperidine-1,3-dicarboxylate (tert-butyl)-3-methyl ester (750 mg, 75% yield) as a colorless oil. LCMS (m / z): 214.1 (M-56+H), 292.1 (M+Na).
[0756] Step B: (3S)-3,4-dimethylpiperidine-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester
[0757] Under nitrogen at room temperature, Pd / C (500 mg, 10% w / w, 0.47 mmol) was added to a solution of (S)-3-methyl-4-methylenepiperidin-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester (750 mg, 2.78 mmol) in methanol (20 mL). The system was purged with a hydrogen balloon, and the reaction was stirred under a hydrogen atmosphere overnight. After completion of the reaction, the mixture was filtered through Celite and the filtrate was concentrated to obtain the crude product. Purification by FCC (SiO2, EA / PE = 0-50%) afforded (3S)-3,4-dimethylpiperidin-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester (600 mg, 79% yield) as a colorless oil. LCMS (m / z): 216.1 (M-56+H), 294.1 (M+Na). 1H NMR(400MHz, Methanol-d4)δ4.08–4.02(m,0.23H),3.98(dd,J=13.7,1.5Hz,1H),3.91–3.78(m,1.23H),3.72(s,0.69H),3.67(s,3H),3.21– 2.76(m,2.46H),2.20–2.06(m,0.23H),1.81–1.29(m,14.9H),1.20(s, 3H), 1.07 (s, 0.69H), 1.02 (d, J = 6.6Hz, 3H), 0.86 (d, J = 6.8Hz, 0.69H).
[0758] Step C: (3S)-(1,3,4-trimethylpiperidin-3-yl)methanol
[0759] At room temperature, LiAlH₄-THF (1 M, 5.26 mmol, 5.26 mL) was added dropwise to a solution of (3S)-3,4-dimethylpiperidin-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester (500 mg, 1.75 mmol) in THF (5 mL). The resulting mixture was heated to 70°C and stirred for 3 h. After completion of the reaction, as monitored by LCMS, the reaction was quenched by the addition of Na₂SO₄·10H₂O until gas evolution ceased. The reaction solution was filtered through celite, and the filtrate was concentrated under reduced pressure at 35°C to afford a colorless liquid (3S)-(1,3,4-trimethylpiperidin-3-yl)methanol (250 mg, 91% yield). LC-MS (m / z): 158.2 (M+H).
[0760] Intermediate a9A-2
[0761] ((3S,4S)-1-Ethyl-3,4-dimethylpiperidin-3-yl)methanol
[0762] Step A: (S)-3-Methyl-4-methylenepiperidine-3-carboxylic acid methyl ester hydrochloride
[0763] (S)-3-Methyl-4-methylenepiperidin-1,3-dicarboxylic acid-1-(tert-butyl)-3-methyl ester (400 mg, 1.48 mmol) was added to HCl / Dioxane (4 M) (5 mL) at room temperature and stirred for 1 hour. After completion of the reaction, the reaction solution was concentrated to afford (S)-3-methyl-4-methylenepiperidin-3-carboxylic acid methyl ester hydrochloride (304 mg, 100% yield) as a white solid. LC-MS (m / z): 170.1 (M+H).
[0764] Step B: (S)-1-ethyl-3-methyl-4-methylenepiperidine-3-carboxylic acid methyl ester
[0765] Potassium carbonate (1.02 g, 7.43 mmol) was added to a mixture of (S)-3-methyl-4-methylenepiperidine-3-carboxylic acid methyl ester hydrochloride (304 mg, 1.49 mmol), iodoethane (695 mg, 4.45 mmol), and anhydrous acetonitrile (10 mL) at room temperature. The resulting mixture was heated to 90°C and stirred overnight. After completion of the reaction, the mixture was filtered and rinsed with EA (20 mL). The filtrate was collected, concentrated, and further subjected to FCC (EA / PE = 0-80%) to afford (S)-1-ethyl-3-methyl-4-methylenepiperidine-3-carboxylic acid methyl ester (120 mg, 48% yield) as a colorless liquid. LC-MS (m / z): 198.1 (M+H).
[0766] Step C: Methyl (3S,4S)-1-ethyl-3,4-dimethylpiperidine-3-carboxylate
[0767] Pd / C (18 mg, 10% wt) was added to a mixture of (S)-1-ethyl-3-methyl-4-methylenepiperidine-3-carboxylic acid methyl ester (180 mg, 0.910 mmol) and MeOH (5 mL) at room temperature. After complete addition, the mixture was stirred at room temperature under H2 (60 psi) overnight. After completion of the reaction, the mixture was filtered and rinsed with MeOH (20 mL), monitored by LCMS. The filtrate was collected and concentrated to afford (3S)-1-ethyl-3,4-dimethylpiperidine-3-carboxylic acid methyl ester (150 mg, 82% yield) as a colorless liquid. LC-MS (m / z): 200.1 (M+H).
[0768] Step D: ((3S,4S)-1-ethyl-3,4-dimethylpiperidin-3-yl)methanol
[0769] LiAlH₄ (1 M, 0.75 mmol, 0.75 mL) was added dropwise to a mixture of (3S)-1-ethyl-3,4-dimethylpiperidin-3-carboxylic acid methyl ester (150 mg, 0.75 mmol) and THF (5 mL) under ice-cooling. The mixture was stirred in an ice-cooling bath for 0.5 hours. After completion of the reaction, as monitored by LCMS, the reaction was quenched by the addition of Na₂SO₄·10H₂O until gas evolution ceased. The reaction solution was filtered through celite, and the filtrate was concentrated at low temperature (35°C) to afford ((3S)-1-ethyl-3,4-dimethylpiperidin-3-yl)methanol (100 mg, 78% yield) as a colorless liquid. LC-MS (m / z): 172.1 (M+H).
[0770] Intermediate a10A-1
[0771] (S)-(1,3-Dimethyl-4-methylenepiperidin-3-yl)methanol
[0772] Step A: (S)-(1,3-Dimethyl-4-methylenepiperidin-3-yl)methanol
[0773] LiAlH₄ (0.7 mL, 2.5 M THF solution, 1.75 mmol) was added dropwise to a mixture of (S)-3-methyl-1-(tert-butyl)-4-methylenepiperidin-1,3-dicarboxylate (150 mg, 0.56 mmol) and THF (2 mL) at room temperature. After complete addition, the mixture was heated to 70°C and stirred for 3 h. After completion of the reaction, monitored by TLC, the reaction was quenched by the addition of Na₂SO₄·10H₂O, dried over anhydrous sodium sulfate, and diluted with ethyl acetate. The reaction mixture was filtered through Celite to remove solids. The filtrate was concentrated to afford (S)-(1,3-dimethyl-4-methylenepiperidin-3-yl)methanol (120 mg, 80% yield) as a colorless oil, which was used directly in the subsequent reaction.
[0774] Intermediate a10A-2
[0775] ((S)-1-Ethyl-3-methyl-4-methylenepiperidin-3-yl)methanol
[0776] Step A: ((S)-1-Ethyl-3-methyl-4-methylenepiperidin-3-yl)methanol
[0777] LiAlH₄ (1 M, 0.66 mmol, 0.66 mL) was added dropwise to a mixture of (S)-1-ethyl-3-methyl-4-methylenepiperidin-3-carboxylic acid methyl ester (130 mg, 0.66 mmol) and THF (5 mL) under ice-cooling. The mixture was stirred in an ice-cooling bath for 0.5 h. After completion of the reaction, as monitored by LCMS, the reaction was quenched by the addition of Na₂SO₄·10H₂O until gas evolution ceased. The reaction mixture was filtered through celite, and the filtrate was concentrated at low temperature (35°C) to afford ((S)-1-ethyl-3-methyl-4-methylenepiperidin-3-yl)methanol (90 mg, 81% yield) as a colorless liquid. LC-MS (m / z): 170.1 (M+H).
[0778] Intermediate a11A-1
[0779] (S,E)–(4-(Fluoromethylene)-1,3-dimethylpiperidin-3-yl)methanol
[0780] Step A: (S,E)-4-(Fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester and (S,Z)-4-(Fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester
[0781] Dissolve (fluoromethylene)triphenylphosphine tetrafluoroborate (10.56 g, 27.64 mmol) in anhydrous THF (50 mL) and replace the atmosphere with nitrogen three times. Under dry ice and ethanol, cool the reaction mixture to -70°C and add a solution of potassium tert-butoxide in tetrahydrofuran (27.64 mL, 1 M, 27.64 mmol) dropwise to the reaction system. Maintain the temperature and continue stirring for 1 hour. Then, add a solution of (R)-3-methyl-1-(tert-butyl)-3-methyl-4-oxopiperidine-1,3-dicarboxylate (Intermediate a5A, 5.0 g, 18.43 mmol) in anhydrous tetrahydrofuran (15 mL) dropwise to the reaction system. After the addition is complete, slowly warm the resulting mixture to room temperature and stir overnight. After completion of the reaction, monitor the reaction by TLC. Pour the reaction mixture slowly into water (100 mL) and extract three times with ethyl acetate. The combined organic phases were washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to yield the crude product. The crude product was purified by FCC (SiO2, EA / PE = 0-15%) to afford (S,E)-3-methyl-1-tert-butyl-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylate as a colorless oil (1.98 g, 37% yield). LCMS (m / z): 232.1 (M-56+H). 1 H NMR (400 MHz, Chloroform-d) δ 6.55 (d, J = 84.7, 1H), 4.35 (d, J = 13.2 Hz, 1H), 4.10–3.82 (m, 1H), 3.69 (s, 3H), 3.00–2.85 (m, 1H), 2.76 (d, J = 13.1 Hz, 1H), 2.71–2.60 (m, 1H), 2.31–2.08 (m, 1H), 1.46 (s, 9H), 1.29 (s, 3H); the double bond configuration of compound a11A-1-1 was confirmed by the NOE signals of H1 and H2; and the product, (S,Z)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester (600 mg, yield 11%), was obtained as a colorless oily product. LCMS (m / z): 232.1 (M-56+H). 1H NMR (400 MHz, Chloroform-d) δ 6.43 (d, J = 83.7, 1H), 3.86–3.75 (m, 1H), 3.71 (s, 3H), 3.62–3.47 (m, 1H), 3.42–3.29 (m, 2H), 2.24–2.06 (m, 2H), 1.46 (s, 9H), 1.43–1.39 (m, 3H); the double bond configuration of compound a11A-2-1 was determined by the NOE signals of H1 and H3.
[0782] Step B: (S,E)-4-(Fluoromethylene)-3-methylpiperidine-3-carboxylic acid methyl ester hydrochloride
[0783] At room temperature, add 4M HCl-dioxane (10 mL) to 1-tert-butyl (S,E)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylate-3-methyl ester (600 mg, 2.09 mmol) and stir at room temperature for 1 hour. Concentrate to remove the acid solution to obtain (S,E)-4-(fluoromethylene)-3-methylpiperidine-3-carboxylate hydrochloride (572 mg, 100% yield) as a white solid. LCMS (m / z): 188.1 (M+H).
[0784] Step C: Methyl (S,E)-4-(fluoromethylene)-1,3-dimethylpiperidine-3-carboxylate
[0785] At room temperature, (S,E)-4-(fluoromethylene)-3-methylpiperidine-3-carboxylic acid methyl ester hydrochloride (370 mg, 1.98 mmol) was dissolved in methanol (5 mL). Triethylamine was added dropwise until the reaction solution had a pH of ~10 and stirred for 10 minutes. Glacial acetic acid was then added dropwise until the reaction solution had a pH of ~4. Aqueous formaldehyde solution (481.15 mg, 5.93 mmol) was added to the reaction solution and stirred at room temperature for 30 minutes. Sodium cyanoborohydride (136.62 mg, 2.17 mmol) was added to the reaction solution and stirred at room temperature for 2 hours. After completion of the reaction, the solvent was removed by concentration under reduced pressure and the solution was evaporated twice from anhydrous tetrahydrofuran to obtain (S,E)-4-(fluoromethylene)-1,3-dimethylpiperidine-3-carboxylic acid methyl ester (380 mg, 96% yield) as a white solid. LCMS (m / z): 202.1 (M+H).
[0786] Step D: (S,E)-(4-(Fluoromethylene)-1,3-dimethylpiperidin-3-yl)methanol
[0787] Under ice-cooling conditions, a 1 M solution of LiAlH₄-THF (2.83 mL, 107.5 mg, 2.83 mmol) was added dropwise to a solution of (E)-methyl 4-(fluoromethylene)-1,3-dimethylpiperidine-3-carboxylate (380 mg, 1.89 mmol) in anhydrous tetrahydrofuran (5 mL). The resulting mixture was stirred at room temperature for 20 min. After completion of the reaction, monitored by LCMS, the reaction solution was quenched with sodium sulfate decahydrate until no bubbles formed. Approximately 5 g of anhydrous sodium sulfate was added to remove water. The reaction solution was filtered through celite, and the filter cake was washed three times with anhydrous tetrahydrofuran. The filtrate was collected and concentrated to dryness to afford (S,E)-(4-(fluoromethylene)-1,3-dimethylpiperidin-3-yl)methanol (300 mg, 92% yield) as a colorless oil. LCMS (m / z): 174.1 (M+H).
[0788] Intermediate a11A-2
[0789] (S,Z)-(4-(Fluoromethylene)-1,3-dimethylpiperidin-3-yl)methanol
[0790] The synthesis of intermediate a11A-2 was carried out according to the scheme described for intermediate a11A-1, except that (S,Z)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester (compound a11A-2-1) was used in step B instead of (S,E)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester (compound a11A-1-1).
[0791] Intermediate a11A-3
[0792] (S,E)-(1-Ethyl-4-(fluoromethylene)-3-methylpiperidin-3-yl)methanol
[0793] Step A: (S,E)-1-ethyl-4-(fluoromethylene)-3-methylpiperidine-3-carboxylic acid methyl ester
[0794] Potassium carbonate (370.73 mg, 2.68 mmol) and iodoethane (278.92 mg, 1.79 mmol) were added sequentially to a solution of (S,E)-methyl 4-(fluoromethylene)-3-methylpiperidine-3-carboxylate hydrochloride (200 mg, 0.894 mmol) in acetonitrile (6 mL) at room temperature. The resulting mixture was heated to 90°C and stirred overnight. After completion of the reaction, monitored by LCMS, the reaction mixture was filtered through celite, and the filter cake was washed twice with acetonitrile. The filtrate was collected and concentrated to dryness to obtain the crude product. The crude product was purified by FCC (SiO2, EA / PE = 0-90%) to afford (S,E)-methyl 1-ethyl-4-(fluoromethylene)-3-methylpiperidine-3-carboxylate (100 mg, 69% yield) as a colorless oil. LCMS (m / z): 216.1 (M+H).
[0795] Step B: (S,E)-(1-ethyl-4-(fluoromethylene)-3-methylpiperidin-3-yl)methanol
[0796] Under ice-cooling conditions, a 1M solution of LiAlH₄-THF (0.7 mL, 0.7 mmol) was added dropwise to a solution of (S,E)-1-ethyl-4-(fluoromethylene)-3-methylpiperidine-3-carboxylic acid methyl ester (100 mg, 0.46 mmol) in anhydrous tetrahydrofuran (5 mL). The resulting mixture was stirred at room temperature for 20 min. After completion of the reaction, sodium sulfate decahydrate was added to quench the reaction until no bubbles formed, as monitored by LCMS. The mixture was then dried over approximately 5 g of anhydrous sodium sulfate. The reaction mixture was filtered through celite, and the filter cake was washed three times with anhydrous tetrahydrofuran. The filtrate was collected and concentrated to dryness to afford (S,E)-(1-ethyl-4-(fluoromethylene)-3-methylpiperidin-3-yl)methanol (80 mg, 92% yield) as a colorless oil. LCMS (m / z): 188.1 (M+H).
[0797] Intermediate a12A-1
[0798] ((3S,4S)-4-(Fluoromethyl)-1,3-dimethylpiperidin-3-yl)methanol
[0799] Step A: (S,E)-4-(Fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester and (S,Z)-4-(Fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl ester-3-methyl ester
[0800] The synthesis of step A was carried out by referring to the synthesis of intermediate a11A-1, step A.
[0801] Step B: (3S,4S)-4-(Fluoromethyl)-3-methylpiperidine-1,3-dicarboxylate-1-(tert-butyl)-3-methyl ester
[0802] Under nitrogen at room temperature, wet Pd / C (400 mg, 10% w / w) was added to a mixture of (S,E)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl-3-methyl ester and (S,Z)-4-(fluoromethylene)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl-3-methyl ester (850 mg, 2.96 mmol) in methanol (10 mL). The system was purged with a hydrogen balloon, and the reaction was stirred under a hydrogen atmosphere overnight. After completion of the reaction, monitored by TLC, the mixture was filtered through celite, and the filtrate was concentrated to dryness to obtain the crude product. Purification by FCC (SiO2, EA / PE = 0-10%) afforded the product (3S,4S)-4-(fluoromethyl)-3-methylpiperidine-1,3-dicarboxylic acid-1-tert-butyl-3-methyl ester (600 mg, 70% yield) as a colorless oil. LCMS (m / z): 234.1 (M-56+H), 312.1 (M+Na). 1 H NMR(400MHz, Methanol-d4)δ4.76–4.70(m,0.5H),4.64–4.52(m,1H),4.46–4.41(m,0.5H),4.23(d,J=13.7Hz,1H),4.08–3.9 9(m,1H),3.67(s,3H),3.06–2.86(m,1H),2.86–2.70(m,1H),1.95–1.81(m,1H),1.80–1.68(m,2H),1.46(s,9H),1.27(s,3H). 19 F NMR (376MHz, Methanol-d4) δ221.80.
[0803] Step C: (3S,4S)-4-(Fluoromethyl)-3-methylpiperidine-3-carboxylic acid methyl ester hydrochloride
[0804] At room temperature, 3M hydrochloric acid-dioxane (10 mL, 30 mmol) was added dropwise to a solution of (3S,4S)-4-(fluoromethyl)-3-methylpiperidine-1,3-dicarboxylate-1-(tert-butyl)-3-methyl ester (600 mg, 2.07 mmol) in ethyl acetate (10 mL). The resulting mixture was stirred at room temperature for 1 hour. LCMS monitored the reaction completion, and the mixture was concentrated under reduced pressure to afford (3S,4S)-4-(fluoromethyl)-3-methylpiperidine-3-carboxylate hydrochloride (500 mg, crude) as a white solid. LCMS (m / z): 190.1 (M+H).
[0805] Step D: Methyl (3S,4S)-4-(fluoromethyl)-1,3-dimethylpiperidine-3-carboxylate
[0806] Methyl (3S,4S)-4-(fluoromethyl)-3-methylpiperidine-3-carboxylate hydrochloride (500 mg, crude product from the previous step) was dissolved in methanol (10 mL) at room temperature. Aqueous formaldehyde (2 mL, 35-40% w / w, ~24 mmol) was added and stirred at room temperature for 2 h. Sodium cyanoborohydride (696 mg, 11.1 mmol) was added portionwise, and the resulting mixture was stirred at room temperature for 2 h. LCMS monitored the reaction completion. Saturated aqueous NH4Cl was added to the reaction solution, and the product was extracted three times with ethyl acetate. The combined organic phases were concentrated to give the crude product, which was purified by FCC (SiO2, EA / PE = 0-100%) to afford methyl (3S,4S)-4-(fluoromethyl)-1,3-dimethylpiperidine-3-carboxylate (200 mg, 44% yield) as a colorless oil. LCMS (m / z): 204.1 (M+H).
[0807] Step E: ((3S,4S)-4-(Fluoromethyl)-1,3-dimethylpiperidin-3-yl)methanol
[0808] LiAlH4-THF (1.7 mL, 1 M, 1.7 mmol) was slowly added dropwise to a solution of (3S,4S)-4-(fluoromethyl)-1,3-dimethylpiperidine-3-carboxylic acid methyl ester (200 mg, 0.869 mmol) in anhydrous THF (2 mL) at room temperature. The resulting mixture was stirred at room temperature for 0.5 hours. The reaction was monitored by TLC, cooled in an ice bath, and quenched by the addition of sodium sulfate decahydrate until no bubbles formed. An appropriate amount of ethyl acetate was added, the mixture was dried over anhydrous sodium sulfate, filtered, and concentrated to dryness to afford the crude product ((3S,4S)-4-(fluoromethyl)-1,3-dimethylpiperidin-3-yl)methanol (100 mg, 58% yield) as a colorless oil. LCMS (m...
Claims
1. A compound of formula (I), a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, in: R1 and R1' together form an intracyclic bridge -(CH2) t - or -CH2=CH2-; R2 and R3 are each independently selected from H, halogen, -C 1-6 Alkyl, optionally substituted by halogen -C 2- 6 alkynyl and -OC optionally substituted by halogen 1-6 alkyl; G is selected from CH and N; Y is selected from O, S and Se; M is selected from N or C-R4; Z is selected from N, C, O, S and Se; B is selected from X is selected from C and S, and p is selected from 0 and 1, provided that when p is 0, X is S, and when p is 1, X is C; W is selected from H, halogen, -C 1-6 Alkyl, OH and NH2; R4 is selected from H, halogen, CN, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or CN; R5 is selected from H, halogen and NH2; R6 is selected from H, halogen, CN, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -Se-C 1-6 Alkyl and -C 2-6 Alkynyl, Among them -C 1-6 Alkyl and -C 2-6 each alkynyl group is independently optionally substituted with halogen; R7 and R8 are each independently selected from H, halogen, -NO2, CN, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 replaced; R9 is selected from -Si(R b )3, CN, NO2, -C 1-6 Alkyl, -OC 1-6 Alkyl, -SC 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl, -(CH2) n -C 3-6 Cycloalkyl, -(CH2) n -5-6 membered heteroaryl and -(CH2) n -phenyl, where -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 3-6 Cycloalkyl, 5-6 membered heteroaryl and phenyl are each independently optionally selected from halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1- 6 alkyl group substitution; R a selected from H and -C optionally substituted by halogen 1-6 alkyl; R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl, each optionally substituted with halogen; R 10 Selected from H, halogen, CN, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or CN; R 11 Selected from H, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl and -(CH2) n -C 3-6 Cycloalkyl, where C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl or C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, CN, -OC 1-6 Alkyl or -O-CON(R a )2 replaced; R 12 Selected from H, halogen, -CN, -OH, N(R a )2. -OC 1-6 Alkyl, -OC 3-6 Cycloalkyl, -C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl and -(CH2) n -C 3-6 Cycloalkyl, where each occurrence of C 1-6 Alkyl, -C 2-6 Alkenyl, -C 2-6 Alkynyl or C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, CN or -OC 1-6 Alkyl substitution, or two R attached to the same carbon atom 12 Formation = C (R c )2. Spiral C 3-6 Cycloalkyl or spiro 4-7 membered heterocycloalkyl, wherein R c are each independently selected from H, halogen and -C 1-6 Alkyl, and the spiro C 3-6 Cycloalkyl or spiro 4-7 membered heterocycloalkyl optionally substituted with halogen and -C 1-6 Alkyl substitution, or two R attached to adjacent ring carbon atoms 12 Together with the carbon atom to which they are attached, they form a C3-4 cycloalkyl group, or two R attached to non-adjacent ring carbon atoms 12 together to form a bridged methylene or ethylene group; R 13 Selected from H, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or -OC 1-6 Alkyl substitution; Or when R 12 and R 13 When attached to adjacent ring carbon atoms, together with the carbon atoms to which they are attached, they form a C3-4 cycloalkyl group; R 14 Selected from H, -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, where C 1-6 Alkyl and C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen or -OC 1-6 Alkyl substituted, or two R attached to the same carbon atom 14 Together with the carbon atom to which they are attached, they form C 3-4 Cycloalkyl; k is selected from 0 or 1; m and n are each independently selected from integers from 0 to 2; and t is selected from an integer of 1 to 2.
2. The compound of formula (I) according to claim 1, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, wherein B is Wherein R5 is halogen, R6 is selected from halogen, C 1-6 Alkyl or C 2-6 Alkynyl, R7 and R8 are each independently selected from H, and W is -OH.
3. The compound of formula (I) according to claim 1, its stereoisomer, tautomer, stable isotope variant, pharmaceutically acceptable salt or solvate, wherein B is R5 is H or halogen, R6 is selected from halogen, -C 2-6 Alkynyl and -C 1-6 alkyl, R7 and R8 are each independently selected from H, halogen, CN and NO2, and W is -OH; or R5 is -NH2, R6 is -CN, R7 and R8 are each independently selected from H or halogen, and W is H.
4. The compound of formula (I) according to claim 1, its stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate, wherein B is Wherein R7 is H; R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 Alkyl; R9 is selected from -Si(R b )3, NO2, CN, -C 1-6 Alkyl, -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 Cycloalkyl groups are each independently optionally selected from halogen, -Se-C 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl radical substitution; R 10 Selected from halogen and -C 1-6 alkyl; and W is -OH or -NH2.
5. A compound of formula (I) according to any one of claims 1 to 4, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein G is N, and R1 and R1 ’ Together they form -CH2-, -CH2CH2- or -CH2=CH2-, preferably -CH2CH2-.
6. A compound of formula (I) according to any one of claims 1 to 5, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein R2 is H and R3 is halogen, preferably F.
7. A compound of formula (I) according to any one of claims 1 to 6, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, wherein M is N or C-R4, and R4 is selected from halogen, CN and C-R4 substituted by halogen. 1-6 Alkyl, preferably M is selected from N, CF, C-Cl, C-CN and C-CF3.
8. The compound of formula (I) according to any one of claims 1 to 7, wherein Y is O, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof.
9. The compound of formula (I) according to any one of claims 1 to 8, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, wherein R 14 Each is independently H or D.
10. The compound of formula (I) according to any one of claims 1 to 9, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, wherein the structural fragment for Preferred where R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2; and / or R 14 are each independently selected from H and D; and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 alkyl.
11. The compound of formula (I) according to claim 1, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, which have the following sub-formula: in: Y is O; G is CH or N; M is C-R4; Z is selected from C, Se and O; W is -OH or -NH2; R1 and R1' together form -(CH2) t -; R2 is H; R3 is halogen; R4 is halogen; R5 is selected from H and halogen; R6 is selected from halogen, -C 1-6 Alkyl and -C 2-6 Alkynyl; R7 and R8 are each independently selected from H, halogen, CN and NO2; R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 alkyl; R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 alkyl; R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl; R 14 is H; m and n are each independently selected from integers from 0 to 2; and t is selected from 1 or 2.
12. The compound of formula (I) according to claim 11, its stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate, wherein R 11 -C substituted by one or more hydrogen isotopes 1-6 Alkyl, preferably -CD3, and / or R 14 It is D.
13. The compound of formula (I) according to claim 1, its stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate, which is Wherein R2 is selected from H, -C 2-6 Alkynyl, optionally substituted by halogen or D- 1-6 Alkyl and -OC optionally substituted by halogen or D 1- 6 alkyl; R5 is halogen, preferably F; and / or R6 is -C 2-6 Alkynyl, preferably ethynyl; and / or R4 is halogen, preferably F; and / or R 14 are each independently selected from H and D; and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 alkyl, and m is selected from 1 or 2.
14. The compound of formula (I) according to claim 1, its stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate, which is Wherein R2 is selected from H, -C 2-6 Alkynyl, optionally substituted by halogen or D- 1-6 Alkyl and -OC optionally substituted by halogen or D 1- 6 alkyl; and / or R4 is selected from halogen (preferably F or Cl), CN and -C substituted by halogen (preferably F) 1-6 and / or R7 and R8 are both H, or both are halogen (preferably F), or one of them is H and the other is halogen (preferably F), or one of them is H and the other is halogen (preferably F) substituted C 1-6 Alkyl; and / or R 11 For optional -OC 1-6 Alkyl or halogen or D substituted -C 1-6 Alkyl, preferably -C optionally substituted with one or more D 1-3 Alkyl; and / or R 12 is selected from halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2 or spiral C 3-6 Cycloalkyl, where R c are each independently selected from H, halogen and -C 1-6 Alkyl, and / or R 13 -C 1-6 Alkyl, preferably -C 1-3 Alkyl; and / or R 14 are each independently H or D; and / or W is selected from H; and m is selected from 1 or 2.
15. The compound of formula (I) according to claim 1, its stereoisomers, tautomers, stable isotopic variants, pharmaceutically acceptable salts or solvates, which have the following sub-formula: in: Y is O; G is CH or N; M is C-R4; Z is selected from C, Se and O; W is -OH or -NH2; R1 and R1' together form -(CH2) t -; R2 is H; R3 is halogen; R4 is halogen; R7 is H; R8 is selected from H, CN, halogen, NO2, -C 1-6 Alkyl, -N(R a )2、-C(O)N(R a )2 and -C(O)OR a , where -C 1-6 The alkyl group is optionally substituted with halogen or -N(R a )2 substituted, wherein R a selected from H and -C optionally substituted by halogen 1-6 alkyl; R9 is selected from -Si(R b )3. -C 1-6 Alkyl and -(CH2) n -C 3-6 Cycloalkyl, wherein -C 1-6 Alkyl and -C 3-6 The cycloalkyl groups are each independently optionally substituted with halogen, -Se- 1-6 Alkyl and optionally halogen-substituted C 1-6 Alkyl substituted, and R b Selected from -C 1-6 Alkyl and -C 2-6 alkenyl, each optionally substituted with halogen; R 10 Selected from halogen and -C 1-6 alkyl; R 11 For optional -OC 1-6 Alkyl or halogen-substituted -C 1-6 alkyl; R 12 is selected from H, halogen, CN, -C optionally substituted by halogen 1-6 Alkyl, optionally substituted by halogen -C 2-6 Alkynyl and -OC optionally substituted by halogen 1-6 Alkyl, or two R attached to the same carbon atom 12 Formation = C (R c )2, where R c are each independently selected from H, halogen and -C 1-6 alkyl; R 13 is selected from H, halogen and -C optionally substituted by halogen 1-6 alkyl; R 14 is H; k is selected from 0 or 1; m and n are each independently selected from integers from 0 to 2; and t is selected from 1 or 2.
16. A compound which is a compound of the Examples or a stereoisomer, tautomer, stable isotopic variant, pharmaceutically acceptable salt or solvate thereof.
17. A pharmaceutical composition comprising a compound according to any one of claims 1 to 16, a stereoisomer, a tautomer, a stable isotopic variant, a pharmaceutically acceptable salt or a solvate thereof, and a pharmaceutically acceptable excipient.
18. A compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 17, for use as a medicament for the treatment and / or prevention of diseases mediated by KRas mutations, preferably KRas G12V and / or KRas G12D mutations.
19. Use of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 17, in the preparation of a medicament for preventing or treating a disease mediated by a KRas mutation, preferably a KRas G12V and / or KRas G12D mutation.
20. The method of claim 19, wherein the disease mediated by a KRas mutation, preferably a KRas G12V and / or KRas G12D mutation, is selected from the group consisting of pancreatic cancer, lung cancer, lung adenocarcinoma, bone cancer, skin cancer, head and neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, cancer of the endocrine system, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney or ureter cancer, renal cell carcinoma, renal pelvis cancer, central nervous system tumors (CNS), primary CNS lymphomas, spinal tumors, brain stem gliomas or pituitary adenomas.
21. The use according to claim 20, wherein the disease mediated by KRas mutation, preferably KRas G12V and / or KRas G12D mutation, is selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, lung cancer, bile duct cancer, endometrial cancer, ovarian cancer, leukemia; most preferably selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, bile duct cancer.
22. A method for treating and / or preventing diseases mediated by Ras mutant proteins, in particular KRas mutant proteins, preferably KRas G12V and / or KRas G12D mutant proteins, comprising administering to a subject in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 16 or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 17.
23. The method of claim 22, wherein the disease mediated by KRas mutations, preferably KRas G12V and / or KRas G12D mutations, is selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, lung cancer, bile duct cancer, endometrial cancer, ovarian cancer, leukemia; most preferably selected from pancreatic cancer, colon cancer, rectal cancer, lung adenocarcinoma, bile duct cancer.
